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Scheme 1 Dynamic kinetic resolution of 5(4H)-oxazolones 
The dynamic kinetic resolution of 2-phenyl-4-substituted-5(411)-oxazolones 89a-g 
has been investigated as a method for the synthesis of optically active a-amino acid 
derivatives. The effects of lipase, [either Novozyme ® (Candida antarctica lipase B), 
or Lipozyme® (Rhizomucor miehei lipase)], solvent, nucleophile, and the addition of 
external triethylamine to the reaction is described. When R'= Ph, an 88% yield and 
98% enantiomeric excess (e.e.) of a-amino acid ester 96a was obtained with 
Novozyme® in acetonitrile as solvent. The synthesis of novel 5(411)-oxazolones 
129a-e, which are identified as key intermediates in the synthesis of a series of 
matrix metalloproteinase inhibitors 94, is described. Application of the lipase 
catalysed dynamic kinetic resolution conditions to 129a-e, afforded high yields 
(96%) and diastereomeric excesses (d.e.'s), (86%) of the resulting pseudodipeptides 
(2R,2'5)-127a-e and 130-132, by careful selection of the reaction conditions. 
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CLEC cross linked enzyme crystals 
d doublet 
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hydrochloride 
e.e. enantiomeric excess 
ESMS electrospray mass spectrometry 
Et ethyl 
Et3N triethylamine 
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FAB fast atom bombardment 
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HPLC high performance liquid chromatography 
h hour(s) 
IPA iso-propyl alcohol 
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Me methyl 
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Mp melting point 
MS mass spectrometry 
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nmr nuclear magnetic resonance 





SAR structure activity relationship 
t triplet 
Tf triflate 
TFA trifluoroacetic acid 
THF tetrahydrofuran 
Ts tosylate 
TBTU 2-( 1H-benzotriazole- 1 -yl)- 1,1,3 ,3-tetramethyluronium 
tetrafluoroborate 
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1.1.0. Lipases and their role in nature 
1.1.1. Role of lipases in nature 
In nature, lipases, or triacyiglycerol hydrolases (E.C. 3.1.1.3) as they are 
systematically known, are classified as hydrolases that catalyse the hydrolysis of 
fatty acids and glycerol at the lipid/water interface. In contrast to proteases and 
esterases, lipases generally exhibit little or no catalytic activity at low substrate 
concentrations, and therefore do not follow normal Michaelis-Menten kinetics. 
Hydrolysis is only realised once the substrate concentration has reached its saturation 










'N CM C 
[S) 
CMC: Critical micellar concentration 
Figure 1 Activity of lipases and esterases 1 
In the early 1990's when the first X-ray crystal structures of lipases began to emerge, 
it became evident that the mechanism of interfacial activation was due, in part, to the 
presence of an amphiphilic peptidic loop, or lid, covering the active site of the 
enzyme.' ,' The analysis of X-ray co-crystals between lipase and substrate analogues 
suggested that once CMC is reached, a conformational change occurs at the 
lipid/water interface, and the lid 'flips', thus allowing access to the previously buried 
Introduction 
active site. 4 It should be noted however that not all lipases have a lid present in their 
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Scheme 2 Catalytic mechanism of lipases 
acyl enzyme 
All of the lipases whose structures have been elucidated, (12 based on data up to 
1998) contain a common architecture. Catalytic activity is realised by a triad 
consisting of a nucleophilic serine residue, a histidine residue, and an aspartate or 
glutamate residue (Scheme 2) similar to that found in the serine proteases. Also, in 
2 
Introduction 
over thirty cases of cloned lipases, a consensus sequence of -Gly/Ala-X-Ser-X-Glu-
has been identified at the active site serine. 5 
Recently there has been some degree of confusion in the literature with regards to the 
naming of some lipases. For example, Candida rugosa was previously classified as 
Candida cylindracea, and Pseudomonas cepacia was previously classified as 
Pseudomonas fluorescens. To avoid any confusion, the name given in the cited 
article is used here. 
1.1.2. The introduction of organic solvent 
There are several advantages to using an organic solvent as opposed to an aqueous 
system for enzymatic transformations, these include, (a) water insoluble substrates, 
and substrates and products that may be unstable in aqueous media can be 
investigated, (b) a broader range of nucleophiles can be used including e.g. alcohols, 
amines, ammonia, oximes, and hydrazines, (c) separation of reagents from the 
enzymes is greatly simplified as the enzymes are insoluble in organic solvents 
therefore only require filtration, and (d) the enzyme can be recovered and reused. 
The use of organic media in enzymatic catalysis was first documented by Pottevin 6 
in 1906 when he used a pancreatic extract in methanol to catalyse the formation of 
methyl oleate. It was not until the pioneering work of Klibanov and co-workers 
almost eighty years later in the mid 1980's, that biocatalysis in organic solvent was 
implemented in the synthetic chemistry laboratory. Initial perception was that 
enzymes would exhibit only low catalytic activity as the concentration of organic 
solvent was increased, due to denaturation of the enzyme. 
To circumvent this problem, Klibanov and co-workers 7 encapsulated aqueous 
solutions of hog liver carboxylesterase and lipase from Candida cylindracea inside 
the porous supports Sepharose or Chromosorb. The resulting beads were suspended 
in a water-immiscible organic solvent, methyl propionate in the case of hog liver 
carboxylesterase, and tributyrin for lipase from Candida cylindracea. In both cases 
the solvent also served as substrate (Scheme 3a and b respectively). A number of 
3 
Introduction 
primary and secondary alcohols were tested as nucleophiles and both enzymes 
exhibited high transesterification activity and stereoselectivity. 
0 	 hog liver 	0 
a) 	Ii + HO 	R* 	carboxylesterase 	 + HO 	R' 
	
(RS) 	 (S) 	 (R) 
R 1 
b) Tributyrin + HO—( 	
Candida cylindracia 	 0 	R 1 	 OH 
R2 
lipase 	 I + 







Expanding on these promising initial results, Klibanov and co-workers' utilised 
lyophilised Candida cylindracea and porcine pancreatic lipases in hexane in the 
esterification and transesterification of racemic carboxylic acids and esters 
respectively. Klibanov et al.,9 were also the first to implement lipases in organic 
solvent for amide bond formation and peptide synthesis (see Section (1.2.2.) below). 
A major problem with using lyophilised enzyme preparations in organic solvents 
is that the observed activity is often 10,000 fold less than that observed in aqueous 
systems due to denaturation.'° Immobilisation of enzymes onto solid supports, via 
covalent attachment, or electrostatic interactions, and more recently the introduction 
of cross-linked enzyme crystals,' 2 (CLECs, prepared by cross-linking the enzyme 
with glyceraldehyde), heralded a new approach to enzyme preparation and provided 
enzymes with increased stability and activity in organic solvents. The introduction of 
surfactants, 13 hydrophobic sol-gel materials, 14 solid state acid-base buffers 15 and 
control of the hydration level of enzymes' 6 have all added to a greater understanding 
of the processes of enzyme activation in organic solvents. The advances in 
techniques for using biocatalysts in organic media have been reviewed in two 
informative articles. 17,18 
4 
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1.2.0. Resolution processes 
1.2.1. Kinetic resolution 
The general reaction is outlined in Figure 2. The success of a kinetic resolution 
relies on the fact that in the presence of a chiral environment, e.g. an enzyme, the 
rate of reaction, (k (R) and k) for each enantiomer, ((R) and (5)) of a racemic mixture 
differ significantly. In the ideal case, the rate of reaction of the slower reacting 
enantiomer would be 0, resulting in the reaction of a single enantiomer. As a result, a 






Substrate (S) 	 Product (S) 
(fast) 
Figure 2 
Kinetic resolution of alcohols and carboxylic acids are carried out routinely in the 
laboratory and are far too wide ranging to be covered in the required detail in this 
thesis. Kazlauskas and co-workers 19-2 ' have published an empirical rule predicting 
the chiral preference of lipases for the resolution of secondary alcohols. In all cases, 
the preferred enantiomer, drawn with the hydroxyl group pointing forward out of the 
plane of the paper, was as depicted in Figure 3a. Kazlauskas 22 also published a 
similar rule for the resolution of primary alcohols (with no oxygen substituent at the 
adjacent stereocentre) using lipase from Pseudomonas cepacia. Although the 
opposite enantiopreference is predicted, it is hypothesised that the substrate 
interacted with the lipase in a similar manner to secondary alcohols, with the 
substituents on the adjacent chiral carbon functioning as the large, L, and medium, 
M, sized groups. The addition of the methylene group allows the primary alcohol 








M L Mj ~D 
Figure 3 a) Enantiopreference of a) lipases towards secondary alcohols, and b) Pseudomonas 
cepacia towards primary alcohols 
Similar rules have been predicted for the enantioselectivity of Candida rugosa 
lipase23 towards carboxylic acids (Figure 4a), and Aspergillus niger lipase20 for L-a-
amino acids (Figure 4b). The predicative rules for carboxylic acids, however, are less 
reliable than those for secondary alcohols, and are best applied to reactions carried 
out with purified lipase instead of the crude commercial preparation which often 
contain contaminating enzymes. 24 
a) 
HCO2H 	 )HOCH 
XNH + 
Figure 4 a) Proposed enantiomer preference of a) Candida rugosa lipase towards carboxylic acids, 
and b) charged L- a-amino acids preferred by Aspergillus niger lipase 
A large number of excellent articles already exist in the literature documenting 
kinetic resolutions in both non-aqueous and aqueous media. 25-27 A number of unusual 
cases merit closer inspection. 
1.2.2. Kinetic resolution with nitrogen nucleophiles 
Although there are far fewer examples documenting the use of nitrogen 
nucleophiles in enzymatic processes in the literature, the area is growing rapidly. As 
indicated above, Klibanov was the first to document the use of amines of amino acid 
esters, as nucleophiles for lipase mediated biotransformations in organic solvent. 
However, Gotor and co-workers" were the first to implement the use of primary 
amines as nucleophiles in the aminolysis of ethyl (±)-2-halopropionate, 1 (X= C128 










X= Cl 40-90% e.e. 
X= Br 5-90 % e.e. 
Scheme 4 
Greater enantioselectivity was obtained for the Novozyme+,  (Candida antarctica 
lipase B), mediated resolution of ethyl 3-substituted-3-hydroxypropionates 3 in 
dioxan with benzylamine as the nucleophile (Scheme 5).3031  The resulting (R)-
benzylamides 4 were obtained in >99% and 98% e.e. at 45% and 50% conversion 
when R= methyl and chloromethyl respectively. Also, in the case where R= 
chloromethyl the corresponding (5)-ethyl ester 3 was recovered in optically pure 
form. Both chiral 3-hydroxy amides and esters are of interest as they serve as 
intermediates in the synthesis of 3-aminoalcohols, which are themselves 
intermediates in the synthesis of a number of antibiotics and antidepressants. 
0 	 0 	 0 
Novozyme® RJL .-. 
OEt 	 N 	Ph + R LL.OEt 





Gotor et al.32 also introduced the transamidation reaction illustrated in Scheme 6. 
The activated racemic trifluoroethylamide 5 was reacted with n-butylamine in the 
presence of Candida cylindracea lipase (CCL) to give the (S)-n-butylamide 6 in 49% 
yield and 78% e.e. 
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0 	 0 	 0 
CF3 BU-NH2 	 NHBu + 	NCF3 *L CCL 
CI 	 CI 
rac-5 	 (S')-6 78% e.e. 
Scheme 6 
An excellent example of amide bond formation was achieved by Conde et al.33 
Separate exposure of each enantiomer of diethyl Cbz-glutamate 7 to Novozyme®  in 
the presence of a variety of amines, afforded aminolysis predominantly at the a-
position for the L-eflantiOmer, and predominantly at the 7-position for the D-
enantiomer (Scheme 7). Best results were obtained at an elevated temperature of 45-
60 °C. 











Scheme 7 reagents and conditions: i. L-7, Novozyme®, DIPE, pentylamine, lh, 60 °C, ii. D-7, 
Novozyme®, DIPE, pentylamine, 4 days, 45 °C. 
Greater success has been achieved in the resolution of amines, although a number of 
issues must be addressed before carrying out such reactions. Amines, being more 
nucleophilic than alcohols, are prone to react non-enzymatically with activated esters 
resulting in low e.e.'s. The use of enol esters must also be avoided as the aldehydes 
or ketones liberated in these processes undergo Schiff-base reactions with the amine 
substrates to form imines. The synthesis of chiral (R)-propiolamides 12, using 3-
substituted-propylate methyl esters 10 as acyl donors, proceeded in good yield with 
e.e.'s ranging from 63-97% (Scheme 8). 3 ' 35 The best results, collected in Table 1, 
were achieved with 1 -phenylethylamine in diisopropylether. Lower e.e. 's were 
obtained (63-84%) when 2-propyl and 2-hexylamine were used. 
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0 	 R2 	 0 R 	 R2 
R1 	
+ 	 Novozyme® R  
_________ 	1 N CH3 	H2N'CH3 OCH3 H2N CH3  H 
10 	 rac-11 	 (R)-12 
Scheme 8 
Entry 10 R' 11 R2 12 Yield! % e.e.I % 
1 CH2=CH C5H 11 20 95 
2 CH2=C(CH3) C2H5 27 95 
3 
00 1 
Ph 83 >95 
4 Ph- Ph 84 >95 
5 Ph 79 >95 
6 Ph Ph 78 >95 
Table 1 
Gotor et al.36 expanded on these results publishing the resolution of 1-
(heteroaryl)ethylamines 13 with Novozyme ®, to furnish the desired (R)-amides 14 
with excellent e.e.'s (Scheme 9) Hedenstr6m 37 also used Novozyme®  for the 
resolution of amines. Using a variety of organic solvents and temperatures, 
diastereomeric 2-methyloctanoic phenylethylamide was prepared from racemic 
phenylethylamine and racemic ethyl 2-methyloctanoate with moderate selectivity. 
R 	Novozyme®,  EtOAc R 	 R 
,>-.--NH2 	solvent 	
)-_NH2 + ) 
rac-13 	 (R)-14 89-99% e.e. 
R= a) fuiyl, b) thienyl, c) pyridyl, 
Scheme 9 
BASF AG (Germany) introduced the resolution of 1-phenylethylamine 15 as a 
commercial process utilising lipase from Burkholderia plantarii with ethyl 
9 
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methoxyacetate 16 as acyl donor (Scheme 1O).38  Yields in excess of 45% of pure (S)-
1-phenylethylamine 15 are reported. 
0 
	





rac-15 	16 	 (5)-15 >99% e.e. (R)-17 93% e.e. 
Scheme 10 
The use 3-methyl-3-pentanol as solvent has proved successful in suppressing non-
enzymatic amidation. In the resolution of 1 -(1 -naphthyl)ethylamine 18 with 
cyanomethyl pent-4-enoate 19 as acyl donor, the use of THF, CH 2C12 , DMF and tert-
butyl alcohol as solvent resulted in a degree of non-enzymatic amidation. On 
switching to 3-methyl-3-pentanol, (5)-amide 20 was isolated in 43% yield and 97% 
e.e. as depicted in Scheme 11.39 
3-methyl-3-pentanol +  




rac-18 	 19 	 (S)-20 
43% yield, 97% e.e. 
Scheme 11 Enantioselective acylation of 1-(1-naphthyl)ethylamine 
A recent advance in enzymatic amidation reactions has been the introduction of 
symmetrical40 '4 ' and unsymmetrical 39 '4244 carbonates as acyl donors. The reactions are 
irreversible as the carbamates formed are not substrates for lipases or proteases. 
Carbamates also have the advantage of simple removal under mild conditions to 
furnish the valuable chiral amine. 
10 
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Gotor and co-workers were the first to implement unsymmetrical vinyl carbonates 
in the resolution of amines (Scheme 12). The best results obtained were for the 
resolution of 1-phenylethylamine 22 with n-octyl vinyl carbonate in the presence of 
Novozyme®. The resulting (R)-carbamate 23 was obtained in 98% e.e. at 39% 
conversion. Lower e.e.'s were observed when n-butyl vinyl carbonate was used as 
acyl donor. Lower e.e.'s were also obtained in the resolution of 2-heptyl and 2-butyl 
amine. 
Ph 
R 0A0 + ~_NH2 





hexane 	/ H 
(R)-23 
Wong and co-workers45 carried out a systematic study of amine protecting groups 
and categorised their utility. By investigating the amount of non-enzymatic 
background reaction in non-reaction suppressing solvents, such as toluene, or 
reaction suppressing solvent (3-methyl-3-pentanol) against the IR absorption of the 
carbonyl groups, it is possible to obtain an accurate estimation of reactivity of similar 
and dissimilar esters and carbonates. This is possible because the frequency of the 
carbonyl stretch reflects the bond length, and therefore the reactivity of the carbonyl 
group. A larger wavenumber indicates a shorter C=O bond, thus a more reactive 
carbonyl group. The study identified novel enzymatic protecting groups, namely 24, 
and carbonate 25, and the known dibenzyl carbonate 26.41  which were utilised in 
amine resolutions with yields of 33-46% and e.e. of 81-99% (Table 2). 
0 0
Y
0 ( CL00O 
0 	 0 
24 	 25 	 26 
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Entry 	Product' 	Acyl Donor 	Yield 	e.e. % 
Ph 0 	 (R) 
1 	 24 	 43 	 99 
01:111? (R) 
HN 	0 
2 	 24 46 	 99 
(S,5) 3 aOH NHCbz 26 36 	 82 
(R) 
26 9".NHCbz 41 	 8 1 
a) Reaction conditions: toluene (high concentration), N ovozyme® 
Table 2 
The use of ammonia as the nucleophile was simultaneously reported by the 
groups of Sheldon46 and Gotor. 47 Sheldon reported that by bubbling ammonia gas 
through a solution of the 2-chloroethyl ester of ibuprofen 27, and adding 
Novozyme®, the resulting (R)-amide 28 was formed (Scheme 13).48  At 56% 
conversion, the (5)-ester 27 was recovered in 93% e.e. The corresponding hydrolysis 
reaction in water furnished ester (S)-27 in only 58% e.e. at 63% conversion. 
Similarly, in the ammoniolysis of a-methylbenzyl n-butyrate 29, a-methylbenzyl 
alcohol 30 was recovered at 45% conversion in 98% ex (Scheme 14). Enzymatic 
ammoniolysis has also been employed in a one pot, double resolution process for the 
















0+0 OH + H2N 
(R)-30 98% e.e. 
Scheme 14 Ammoniolysis of cs-methylbenzy n-butyrate 
1.2.3. Kinetic resolution of organometallic substrates 
Lipases have proved to be robust enzymes and their use in the kinetic resolution 
of organometallic compounds such as ferrocenes, (i6-arene)-chromium  and 
(4 
diene)-iron tricarbonyl complexes is known. Chiral 1 -hydroxymethyl-2-substituted 
ferrocenes, possessing planar chirality, are useful in asymmetric catalysis and 
therefore routes to optically pure ferrocenes are of great interest. 1 -Hydroxymethyl-
2-substituted ferrocenes have been resolved using a number of lipases with excellent 
selectivity, as depicted in Scheme 15, with a summary of the results presented in 
Table 3 •50-54  The results lead to a preferred enantiomer model (with regard to the size 
of the ortho substituent to the hydroxymethyl group) similar to that proposed by 




— CH2OH lipase, solvent "t — CH2OAc ZFICCH2011 
4:t~ -~~ OAc 4& 
+ 
4:5~ 
rac-31 32 33 
Scheme 15 
Entry Lipase Solvent 31 R cony. 32 e.e. 33 e.e. 
1 Pseudomonas benzene CH20H 80 100(15) 20 
cepacia5 t 
2 CCL52 tBuOMe CH2N(CH3)2 65 - >95 
(32a,  1R)) 
3 CCL52 tBuOMe CH2N(CH3) 42 92(15) - 
4 Novozyme"11 DIPE SCH3 32 90(1R) 48 
5 Lipozyme Ob54 DIPE StBu 55 
- 95(43 a) 
6 Novozyme0154 DCM SPh 40 90(1R) 60 
7 Novozyme® ° DCM I 52 89 96 
(JS,2S) 
a) Isolated yield, b) Rhizomucor miehei lipase, c) Vinyl propionate used as acyl donor, product was 
corresponding propionate ester. 
Table 3 
Ferrocenes containing central chirality have also been resolved enzymatically. 
Boaz55 resolved 1-ferrocenylethanol 34 into the (R)-acetate 35 and recovered (5)-
alcohol 34 with a high degree of selectivity (Scheme 16). Similarly, Kim et al.56 
prepared the (R)-acetates 37 and recovered (5)-alcohols 36 of ferrocenylpropanol and 
ferrocenylbutanol (Scheme 17). 
Pseudomonas fluorescens 
'te' Y,,, 	lipase, tBuOMe 	 + OH 
OAc 	
OAc 	 Fe OH 
4~> 	 4& 4& 










R= a) Me, b) Et 
Scheme 17 
OAc 
":Fy~ R + 
6 
(R)-37 >98% e.e. 
OH 
6 
(S)-36 98% e.e. 
The (R)-(+)-cyanohydrin acetate 38, was prepared in 84% e.e. from the 






Nakamura et al.58 and Yamazaki 59 independently reported the resolution of (±)-
tricarbonyl ( 6-2-methylbenzyl alcohol)-chromium 39 in isoproprenyl acetate and 
vinyl palmitate in toluene respectively. Excellent selectivity was observed, 
furnishing both the unreacted (R)-39 and acetylated (S) -40 products in optically pure 
form (Scheme 18). The 2-methoxy, 3-methyl 59 and 2-trimethylsily 58 derivatives were 
also prepared with equally impressive results. 
	
C
CH 	lipase P, solvent 	 cH3 
(CH20H 	OyR 	aCH20H 
Cr(CO)3 	 0 Cr(CO)3 
(RS)-39 	 (R)-39 
R= CH3 	47% yield, 100% e.e. 





48% yield, 98% e.e. 58 
49% yield, > 98% e.e. 59 
Scheme 18 Resolution of(-tricarbonyl (rf-2-methylbenzyl alcohol) -chromium 39 
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The resolution of (arene)Cr(CO) 3 complexes with central chirality has also been 
achieved. When 41 was exposed to lipase Toyobo A from Pseudomonas aeruginosa, 
acetate 43 and unreacted alcohol 42 were obtained in optically pure form in >40% 
yield (Scheme 19).60 
OH 	 OH 	 OAc 
- ToyoboA 
	
yOAc 	 + 
OMe 	 -OMe 
r(CO)3 	 Cr(CO)3 	 Cr(CO)3 
41 	 (Ar1R2S, aS)-42 (Ar1S2R, aR)-43 
Scheme 19 
The resolution of hydroxymethyl substituted (diene)Fe(CO) 3 complexes 44, has also 
been realised (Table 4).60  By careful choice of the lipase, it was also possible to 




Entry Lipase R 1 R2 yield! % e.e./ % (config.) 
1 AmanoPS H CH3 22 97(5) 
2 AmanoPS H Ph 36 96(5) 
3 Amano AY H Ph 18 99 (R) 
4 Amano PS CH3 Ph 48 99(s) 
5 Amano PS CH3 "Bu 47 92(S) 
Table 4 
The resolution of a number of a-hydroxystannanes was achieved via formation of 
the corresponding butyl esters (Scheme 20). At 50% conversion, the butyl acetate 
IRI 
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(S)-46 was obtained in 38% yield, 98% e.e., and the unreacted alcohol (R)-45 in 41% 
yield, 97% e.e. 6 ' 
0 
OH 	PPL, Et20, 25 °C 	0 B 	 OH 
MeSn(CH3)3 BuCO2CH2CF3 MeSn(CH3)3 + MeSn(CH3)3 
45 	 (S)-46 	(R)-45 
98% e.e. 	97% e.e. 
Scheme 20 
Optically active silane62 47 and germane63 48 compounds have also been prepared. 
Both enantiomers of silane 47 were prepared by correct choice of lipase, CCL 





R= Ph, n-octyl 47 





57% yield, 50% e.e. 
1.2.4. The desymmetrisation of meso or prochiral substrates 
Although kinetic resolution processes have proved very successful, they 
suffer from the limitation of a maximum yield of 50%. Close monitoring of the 
progress of the reaction is often required so as to maximise the e.e. of the desired 
compound. In general, if the product is required in optically pure form, the reaction 
is stopped at low conversion, 20-30%, whereas if the substrate is required, the 
reaction is stopped at high conversion, 70-80%. The end result in both instances is a 
reduction in yield to significantly less than the theoretical 50%. The use of meso or 
prochiral substrates is one method of overcoming this limitation (Scheme 21). As in 
a normal kinetic resolution, the enzyme will react with one alcohol group faster than 
the other, thereby creating a chiral product, in this case (R)-50 with a theoretical 
yield and e.e. of 100%. 
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HO OH 	 HO OAc 
49 (R)-50 
Scheme 21 Desymmetrisation ofprochiral 2-substituted-1, 3-diols 
Through the desymmetrisation of meso or prochiral compounds a large number of 
acyclic and cyclic, mono and unsymmetrical diacetates and diacids have been 
prepared. A number of excellent reviews summarising the compounds prepared 
utilising meso or prochiral substrates exist in the literature. 25 ' -66 
Johnson has carried out an extensive programme in the enzymatic preparation of 5, 
6, 7, and 8 membered ring unsaturated diols, represented in Figure 5. These chiral 
cyclic intermediates have been used in the synthesis of a number of biologically 
important compounds, such as C-glycosides, several (deoxy)norjirimycins, 
conduritol derivatives, 3-deoxy-D-arabino-heptulosonic acid derivatives, and the 
tropane alkaloid calystegine A3 •67 
AcO .OH 
OTBS 





AcO 	 OH 
x 
AcO 	 OH 
Figure 5 
A comprehensive study on the effect of solvent, acyl donor, enzyme, temperature 
and concentration was carried out in the desymmetrisation of the 2-substituted-1,3-
propanediol 51, an intermediate in the synthesis of a potential antifungal agent 
SCH5 1408 developed by Schering-Plough. 68 Of the 205 commercial enzyme 
preparations tested, four furnished the desired (5)-acetate 52 with an acceptable e.e. 
18 
Introduction 
of >97%. Novozyme®  was chosen for further examination and the optimised 
conditions (Scheme 22) were operated on pilot plant scale to furnish the product in 








(S)-52 97% e.e. 
Scheme 22 Resolution of 2-substituted-I, 3-propanediol 
Chiral phosphonate derivatives have recently been prepared from prochiral 
phosphonates (Scheme 23).69  Best results were obtained with Lipase PS in a range of 
ether solvents at 25 °C. The results were found to be in agreement with those 
predicted for the enantiopreference of chiral primary alcohols with lipases from 
Pseudomonas cepacia reported by Kazlauskas. 22 
HO 	0 	lipase PS, solvent 11 
R—P(OEt) 
HO—' 	 25°C 	OAc 





83-99% yield, 91-98% e.e. 
The desymmetrisation of mono-substituted malonates 54 was achieved under 
transesterification conditions by Gutman et al.70 ' 7 ' By the correct choice of 
nucleophile and substrate ester, both enantiomers of the unsymmetrical diester 53 
were obtained with the same lipase. Although excellent e.e. 's were obtained, the 
reactions were stopped at moderate conversions (48-53%) to minimise the formation 
of diester by-product. 
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53 90-95% e.e. 	 54 ent-53 98% e.e. 
Scheme 24 
1.2.5. Dynamic kinetic resolution 
Another method of maximising the obtainable yield is through a dynamic kinetic 
resolution process (Figure 6) which involves a classical kinetic resolution coupled 
with in situ substrate racemisation. 72-76 Substrate racemisation enables complete 
conversion to the desired product, resulting in a theoretical yield and e.e. of 100%. 
For a dynamic kinetic resolution to be effective, the rate of racemisation, kC)  must 
be greater than (or at least equal to) the rate of enzymatic reaction k u,, for the faster 
reacting enantiomer (5). Also, the initial kinetic resolution must be selective in that 










Figure 6 Dynamic kinetic resolution 
Zwanenburg and co-workers 77 utilised a dynamic kinetic resolution in the 
synthesis of the 5-acetyloxy-2(5H)-furanones 56 (Scheme 25). The stereogenic 
centre at C-S of the substrate hydroxy-2(5H)-furanones 55 is labile due to 
mutarotation. Acylation of the faster reacting (5) enantiomer with lipase PS-30 




Rcl 	 R2 	R1 






(S)-56 78-86% e.e. 
Scheme 25 Dynamic resolution of5-hydroxy-2(5H)-furanones 
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In a subsequent report, the synthesis of 6-acetyloxy-2H-pyran-3(611)-one 57 under 
identical conditions was achieved. 78 
O 	 OAc 
(S)-57 76% e.e. 
Kellog and Feringa79 reported the synthesis of 5-acetyloxy-2(5H)-furanone 58, and 
the corresponding pyrrolinone 60, in optically pure form using Lipase R or 
Novozyme® respectively (Scheme 26). 
X= 0 X=NAc Ac 
AcO,O 0 	Lipase R HO. 0 Novozyme® AcO,r0 
OAc - OAc 




60 100% conversion 
>99% e.e. 	 >99% e.e. 
Scheme 26 
Oda and co-workers 8 employed cyanohydrins in the enzymatic synthesis of 
optically active aryl cyanohydrin acetates 62 (Scheme 27). Cyanohydrins are ideal 
substrates for dynamic kinetic resolution as they readily equilibrate under basic 
conditions to the corresponding aldehyde and cyanide. The racemic cyanohydrins 61 
were prepared in situ through reversible transhydrocyanation with aryl aldehydes and 
acetone cyanohydrin as a mild source of HCN, catalysed by basic ion exchange 
resin. The subsequent transesterification catalysed by immobilised Pseudomonas 
species lipase furnished the stable aryl cyanohydrin acetates 62 in high yields and 












Scheme 27 Synthesis of optically active cyanohydrin acetates 
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Rayner and co-workers 80 exploited reversible hemithioacetal formation and their 
conversion to stable thioacetates catalysed by Pseudomonas fluorescens lipase was 
achieved (Scheme 28). The racemic hemithioacetals 63 were prepared in situ by 
mixing an aldehyde and thiol, with dissociation of the hemithioacetals promoted by 







RS...R2 	 lipase 	 RS.R2 
OH 	 OAc tBuOMe 	OAc 
rac-63 (S)-64 
90-95% e.e. 
Thioesters have also proved fruitful substrates in dynamic resolution processes. 81 It 
has been shown that the a-protons of thioesters can be removed under basic 
conditions that do not deprotonate the corresponding oxoesters. Most of the 
resolutions were carried out in aqueous media, however, in the case of the thioesters 
of 2,4-dichlorophenoxypropionate 65, it was discovered that non-enzymatic 
hydrolysis occurred, resulting in low e.e.'s. 82 To overcome unwanted hydrolysis the 
transesterification was performed in toluene with lipase PS-30. The n-butyl ester 66 
was obtained in 75% e.e. at 98% conversion. 
CI 	0 
X5I° S 	CF3 CI 
lipase PS-30 
Et3N, toluene 
98% conversion CI 
rac-65 
	
(R)-66 (75% e.e.) 
Scheme 29 Dynamic resolution of2,4-dichlorophenoxypropionate trfluoroethyl thioester 
Another example of base catalysed substrate racemisation was demonstrated by 
Ogasawara and co-workers 83 ' 84 in the dynamic kinetic resolution of tricyclic acyloins 
67. In the presence of triethylamine, the racemic acyloins 67 formed the meso- 1,2- 
22 
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enediol intermediate 68. On exposure to Lipase PS, the (-)-endo-acyloin acetates 70 
were obtained in yields of 75 and 67% and e.e.'s of 97 and 99% when n= 1 and 2 
respectively. 
(CH2) 	 (CH2) 
£JtO 	[itoH] 
HO H 	 OH 
1, 2 
(+)-67 	 meso-68 
Scheme 30 
	
(CH2)n 	 (CH2) lipase PS 
OH THF, Et3N 






5(4H)-Oxazolones 71 have also been used as substrates for dynamic kinetic 






1.2.6. Dynamic kinetic resolution with transition metals 
An interesting area that has emerged over the last few years is the use of transition 
metals as racemisation agents, coupled with an enzymatic resolution. For this 
approach to be effective, the enzyme and the product must be unreactive to the 
transition metal used. Williams et al.85 used a ruthenium catalyst and enzyme 
combination in the resolution of phenyl ethyl alcohol 72 as illustrated in Scheme 31. 
The role of the transition metal is to facilitate a temporary oxidation of the alcohol to 
the corresponding ketone, which in turn is reduced by hydrogen transfer catalysis. 
Coupling the racemisation reaction with an enzymatic acylation using Pseudomonas 
fluorescens lipase resulted in good to excellent e.e.'s for the product acetate 73 as 
shown in Table 5. 
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Pseudomonas sp. lipase 
OH 	o-phenanthroline (6 mcI %) 	QAC 
PhCH3OAc PhCOMe (1 equiv.) Ph
' 
. 
 ~_ CF13 
catalyst, KOH 
	
rac-72 	 (S)-73 
Scheme 31 
Entry 	Catalyst 	 Solvent 	Temp.! C 	Cony.! % 	e.e.! % 
1 	3 mol %, [Rh2(cod)Cl] 2 	cyclohexane 	50 	 76 	 80 
2 a 	2 mol % Rh2(OAc)4 	CH2C12 	20 	60 	 98 
a) no KOH 
Table 5 
Bäckva1186'87 used ruthenium catalyst 76 in the synthesis of a number of optically 
pure acetates of secondary alcohols in the presence of the Novozyme®  as illustrated 
in Scheme 32 and Table 6. The choice of acyl donor proved crucial for reaction 
success. When normal enol esters were employed, the resulting aldehydes or ketones 
were reduced to alcohols under the reaction conditions. These alcohols then 
participated in the acylation process reducing the yield of the desired product. The 
use of p-chlorophenyl acetate prevented this from occurring as the p-chlorophenol 
released does not contain an cc-proton; therefore cannot interfere with the transition 
metal catalyst. 
OH 	 2mol%76 	 OAc 
R1R2 	
Novozyme®, p-Cl-PhOAc 
toluene, 70 °C, Argon 











































The use of enzymatic, transition metal assisted, dynamic kinetic resolution has 
also been extended to the production of chiral amides by Reetz et al.88 Palladium on 
carbon racemised phenyl ethylamine 77 via transient oxidation to the corresponding 
imine. Using Novozyme® in triethylamine, amide 78 was isolated in 64% yield and 
99% e.e. (Scheme 33). 
	
NH2 	 10% Pd/C, Et3N 	 NHAc 
Novozyme, EtOAc, 50 °C 
Ph ' CH3 	 PhCH3 




1.3.0. The use of lipases in combinatorial chemistry 
Over the past decade combinatorial chemistry has become extremely popular for 
generating molecular diversity to aid drug discovery. One method of generating 
diversity relies on elaborating a core substrate unit containing a number of functional 
groups with a selection of partners. However, until very recently, the derivatisation 
of polyfunctionalised core units without protection/deprotection protocols was 
problematic due to a lack of sufficiently selective chemical procedures. The inherent 
regioselectivity offered by enzymes proved attractive and was employed by 
Adamczyk and co-workers 89 in the lipase catalysed solution phase synthesis of a 
library of 26 compounds as shown in Scheme 34. When 1 ,2-phenylenedioxydiacetate 
79 was simultaneously exposed to five mono Boc protected amines in the presence 
of lipase from Pseudomonas cepacia species, followed by deprotection of the 
resulting Boc-amides, a yield of 93% based on the average weight of the bis-amide 
TFA salt product was obtained. ESMS analysis identified twenty-six different 
products including all fifteen desired bis-amides 80, five mono-amide mono-esters 
81, and five mono-amide mono-acid 82 products from their corresponding MH peak 
(the hydrolysis products attributed to the presence of water in the hygroscopic 
monoprotected amine substrates). 
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Khmelnitsky et al.90 synthesised a 167 member library of regioselectively acylated 
derivatives of the polyhydroxylated flavanoid, bergenin 84 (Scheme 35). 
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A mixture of four lipases (Chirazymes L-2 and L-9, and lipases PS30 and FAP-15) 
was identified as the best catalyst for the initial regioselective acylation at position-
11. Subtilisin was utilised in the second regioselective acylation step at position-4, 
followed by selective hydrolysis at position- 11, again mediated by the lipase 
mixture. In all, twelve acyl donors were employed, resulting in a library of N 2+2N 
compound. All but one of the expected products was identified by HPLC/MS. The 
unaccounted product, a diacylation product from two bulky aromatic acyl donors, 
was discounted due to unfavourable steric interactions in the second acylation step. 
1.4.0. Closing remarks 
The utility of enzymes, and their diversity of applications is increasing in the field 
of chemistry. Aswell as the areas covered in this article, the rapidly growing area of 
directed evolution has the potential to provide enzymes designed for specific 
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substrates or reactions. 9 ' Industrially enzymes offer a clean, reusable, and with the 
advances in cloning and purification technologies, a cheap alternative to 
conventional approaches. Biocatalysis in non-aqueous media has grown into an 
independent discipline and due to the increased understanding of enzyme properties 
provides an invaluable tool to the synthetic chemist. 
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2.0.0. Results and Discussion I 






The formation of 5(4H)-oxazolones 71, also known as oxazolin-5(4H)-ones or 
azlactones, in peptide synthesis has been documented as the main cause of 
racemisation. 92 '93 Racemisation occurs as a result of the decrease in the pKa of the C-
4 proton upon cyclisation from the activated a-amino acid residue. de Jersey et al.94 
showed that the pKa of the C-4 proton was 8.9-9.5 depending on the R' and R 2 
substituents. Deprotonation at C-4 results in the formation of the stable 
pseudoaromatic anion intermediate as depicted in Scheme 36. Reprotonation of the 
pseudoaromatic intermediate can occur from either face to produce either oxazolone 
enantiomer. 
In enzyme catalysed reactions involving serine proteases, the oxazolone can act as an 
acyl donor. One enantiomer, e.g. (S) preferentially acylates the enzyme to give an 
acyl-enzyme intermediate which is further attacked by a nucleophile (Nu), i.e. 
alcohol, amine, water etc. to produce the chiral a-amino acid derivative. The 
remaining enantiomer (R) is racemised (due to the pI( of the C-4 proton) and the 
enzyme again preferentially reacts with the (5) enantiomer, thus dynamic resolution 
occurs. For the dynamic resolution process to be effective however, the rate of 
racemisation (k), must be greater than the rate of enzymatic catalysis (kJ, which 
in turn must be much greater than the rate of chemical reaction (k chem). Furthermore, 
for the enzymatic catalysis to be enantioselective, the rates of enzymatic catalysis for 
each enantiomer must differ significantly, i.e. L > (keS) > kenv(R)) >> Lem95 
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Scheme 36 Racemisation of5(4H)-oxazolones 
Bevinakatti et al.96 described 5(411)-oxazolones as cyclic aza enol esters (Scheme 
37) and hypothesised that in organic solvents they would react in a similar manner to 
the enol esters in lipase catalysed transesterification studies. When a nucleophile 
attacks the activated carbonyl of an enol ester, the enol released tautomerises to the 
corresponding aldehyde or ketone, thus preventing reversible transesterification 
which can cause problems when normal alkyl esters are used as acyl donors. 
RJJ 	 < R 	 < 
Nu 	 Nu 	 Nu 
Alkyl ester 	Enol ester 	 Aza enol ester 
Scheme 37 Comparison of ester reactivity 
2.1.2. Biocatalytic ring opening of 5(41f)-oxazolones 
Bevinakatti 96 was the first to demonstrate the lipase catalysed ring opening of 
oxazolones in organic solvent to yield optically active a-amino acid derivatives, 
albeit with moderate enantioselectivity as illustrated in Scheme 38. 
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HNCO2 B 
Ph 
(S)-88 34% e.e. 
Scheme 38 Reagents and conditions: i. DIPE, BuOH, Lipozyme ® 
Sih et al. 95 expanded on the work of Bevinakatti and screened a number of lipases 
for the corresponding hydrolysis of phenylalanine derived oxazolone 89a using 
phosphate buffer at pH 7.6 as the solvent and the source of the nucleophile. Of the 
ten lipases tested, two were found to give opposite enantiomers in optically pure 
form. Porcine pancreatic lipase (PL Fermlipase) catalysed the formation of (S)-90a 
while Aspergillus niger lipase (AN) yielded (R)-90a as shown in Scheme 39. 
Ph 	 Ph 	 Ph 
PL (Fermilpase) N"7° 
	
AN 
HN 	 HN'CQ2H CO2H 99 % e.e. 	 99 % e.e. 
)— 0 




Scheme 39 Enantioselective hydrolysis of2-phenyl-4-benzyl-5(4H)-oxazolone 89a95 
Sih et al. also tested a selection of 2-phenyl-4-substituted-5(411)-oxazolones using 
these two lipases (Scheme 40).95  Moderate to good enantioselectivities, (Table 7) 
were observed but as with the work of Bevinakatti no yields were reported. 
R 
N'<'° 	I. 	HNCQ2H 
\\ 	I 
Ph 	 Ph'0 
0 
Scheme 40 Reagents and conditions: i. Lipase, phosphate buffer, pH 7.6 
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Entry R Lipase time/ h e.e.! % Conf. 
1 CH2CH2SCH 3 AP 5 83 R 
PL 16 80 S 
2 p-HOC6H4CH2 AP 20 37 R 
PL 20 19 S 
CH2 
AP 100 77(34)' R 
PL 100 99(55)fl S 
N 
H 
4 CH2CH(CH 3)2 AP 18 6 R 
PL 18 87 S 
5 Ph AP 20 80 R 
PL 20 76 S 
a) results in parenthesis were obtained with new enzyme 
Table 7 Results obtained for hydrolysis of5(4H)-oxazolones 95 
Bevinakatti 97 also studied the effect of solvent in the reaction with Lipozyme ® and n-
butanol as the nucleophile (Table 8). It was shown that by careful screening of 
solvents the e.e. of the product could be dramatically increased. For example, when 
the reaction was carried out in DIPE an e.e. of 33% was obtained, whereas the same 
reaction in dichloromethane produced an e.e. of 69%. As a footnote a purified 
general yield of >90% was quoted. 
R 	 R 
'H 
N' ° 	 HNCO2B 
Ph' 	 Ph0 
rac-a-d 	 (S)-a-d 
Reagents and conditions: i. Solvent Lipozyme®, BuOH 
Solvent e.e.! % 
a b c d 
DIPE 33 34 39 26 
n-BuOH 59 42 66 39 
DCM 69 47 61 43 
R= (a) CH2Ph, (b) CH31  (c) CH2CH(CH3)21  (d) CH2CH2CH3 
Table 8 Results obtained for alcoholyses of 5(4H)-oxazolones in various solvents 97 
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A far more comprehensive study documenting the methanolysis of a number of 2-
phenyl-5(411)-oxazolone derivatives with Pseudomonas cepacia lipase (P-30) in tert-
butyl methyl ether was conducted by Sih et al.98 (Table 9). The lipase catalysed 
alcoholyses were carried out in the presence and absence of five equivalents of 
water. In both cases the formation of the preferred (5) enantiomer was observed. The 
rate of the reaction in the presence of water did increase but the yields of the 
products were generally lower due to the competing hydrolysis reaction. The e.e. of 
the product appeared to increase as the C-4 substituent increased in size, but also 
slightly decreased when the reactions were carried out in the presence of water. 
R 	 R 
'H 
N'<° 	i. 	 HNCO2CH3 
'\ 	I 
)— 0 
Ph/ 	 Ph0 
Reagents and conditions: i. Lipase P-30, tBuOMe, CH30H (5 equiv.), (H20 (5 equiv.)), 50 °C 
Entry R H20 Time! h Yield! % e.e./ % 
1 CH(CH 3)2 yes 130 47 77 
2 CH2CH(CH3)2 yes 72 85 90 
no 72 82 78 
3 CH2CH2 SCH 3 yes 48 31 82 
no 114 56 71 
4 c.CH2 yes 91 83 49 
no 86 90 75 
5 CH2C6H4(pCH3) yes 84 78 63 
no 156 8 66 
6 Ph yes 84 46 75 
7 CH2Ph yes 35 80 78 
no 22 93 69 
8 CH2CH2Ph yes 42 61 93 
9 CH2CH2CH2Ph yes 72 76 95 
no 72 91 84 
Table 9 Results obtained for the methanolysis of5(4H)-oxazolones 98 
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Turner et al.99 applied the oxazolone methodology in the lipase catalysed 
synthesis of the non-proteinogenic a-amino acid L-(S)-tert-leucine 92g as shown in 
Scheme 41. 
f H 	I. 	
HCQ2Bu 	
ii-iv 
N 	94 , 




rac-89g 	 (S)-91 	 (S)-92g 
Scheme 41 Reagents and conditions: i. Toluene, Lipozyme ®, Bu0H, Et3N (0.25 equiv.), 37 °C, ii. 
Alcalase®, iii. 6 N HC1, iv. Amberlite IRA-67. 
2-Phenyl-4-tert-butyl-5(411)-oxazolone 89g was dissolved in toluene and 
Lipozyme®,  n-butanol and a catalytic amount of triethylamine were added. The 
optically pure product was isolated by chromatography in 94% yield. Alcalase ® 
mediated deprotection of the ester followed by acid hydrolysis to remove the N-
benzoyl protecting group and finally ion exchange chromatography furnished the 
optically pure L-(5)-tert-leucine 92g. 
In 1998, Fu et al.'°° published a chemical dynamic kinetic resolution of 2-phenyl-
4-substituted-5(411)-oxazolone derivatives utilising a planar chiral DMAP based 
catalyst 93. 
Me2N 
R Fe R 
R R 
(-)-93 R= CH 3 
Toluene was identified as the best solvent and the reaction proceeded with excellent 
yields and moderate e.e.'s, as illustrated in Table 10. It was also discovered that the 
reaction rate and e.e. of the product were both increased if 10% benzoic acid was 
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added to the reaction mixture. The e.e. of the product in entry 1 dropped to <2% in 
the absence of benzoic acid. No explanation for this effect was given. 
R 	 R 
'H 
N"'° 	i. 	 HNCO2CH3 
'\ 	/ )— 0 
Ph7 	 Ph0 
Reagents and conditions: i. Toluene, 5% (-)-93, 10% PhCO 2H,, MeOH, room temp. 
Entry 	 R 	 Yield! % 	 e.e./ % 
1 CH3 98 54 
2 CH2=CHCH2 94 61 
3 CH2CH(CH 3) 2 95 55 
4 CH2CH2SCH3 94 50 
5 CH(C6C II ) 93 54 
Table 10 Results obtained for the chemical dynamic kinetic resolution of 5(4H)-oxazolones'°° 
2.2.0. Aim of project 
As discussed above, Turner et al. 99 published a stereospecific high yielding route 
to L-(S)-tert-leucine 92g. However, when the optimised conditions were applied to 
less sterically demanding substrates such as 2-phenyl-4-isopropyl-5(411)-oxazolone, 
there was a dramatic drop in the observed e.e. of the product from 99% for the tert-
leucine derivative to 0% for the valine derivative. Substituting a methyl group for a 
proton resulted in a complete loss of selectivity. 10 ' 
The aim of the project was to expand this 5(4H)-oxazolone methodology to gain a 
more general route to optically active a-amino acid derivatives and later apply this to 
the synthesis of pertinent biologically active compounds. The target chosen was the 
matrix metalloproteinase inhibitors (MMPI's) of structure 94. These will be 
discussed in detail in Chapter 3. 
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94 R= alkyl, aryl 
2.3.0. Preliminary studies 
2.3.1. Synthesis of substrates 
2-Phenyl-4-benzyl-5(411)-oxazolone 89a was chosen as the substrate for the 
initial studies into the lipase catalyse dynamic kinetic resolution process. Oxazolone 
89a was synthesised in two steps from the DL-phenylalanine 92a. N-Benzoylation 
under Schotten-Baumann conditions, followed by acetic anhydride mediated 
cyclodehydration proceeded in high yield to furnish the desired oxazolone as a 
colourless solid. Oxazolone 89a decomposed readily at room temperature over a 
period of a few days. The oxazolone, and all other oxazolones subsequently prepared 















Scheme 42 Reagents and conditions: i. 2M NaOH, PhCOC1, 0 °C, ii. 1 ,4-dioxane:acetic anhydride 
(1:1), 40°C 
2.3.2. Screening of lipases 
As a starting point the Fluka Lipase Basic Kit' 02 was tested, as illustrated in 
Scheme 43, with the results shown in Table 11. Small scale reactions (0.04 mmol 
substrate and 1 mL solvent) were incubated at 37 °C with methanol as the 
nucleophile, and the progress of the reactions monitored by chiral HPLC. A sample 
of the racemic methyl ester 96a, (and all subsequent racemic derivatives), was 
prepared by acid catalysed alcoholysis of the corresponding oxazolone. The 
experimental details are given in Chapter 4. 
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Scheme 43 Reagents and conditions: i. Toluene, lipase (see Table 11), Et 3N(O.25 mmol), CH30H (2 
equiv.), 37°C 
Entry 	 Lipase 	 Conversion 	 e.e./ % 
1 Aspergillius niger + 25 
2 Candida antarctica + 3 
3 Candida cylindracea ++ 3 
4 Rhizomucor miehei + 28 
5 Pseudomonas cepacia + 43 
6 Pseudomonasfluorescens +++ 64 
7 Rhizopus arrhizus + 5a 
8 Rhizopus niveus ++ 3a 
9 Hog pancreas ++ 42 
a) Opposite enantiomer 
Table 11 Results obtained for screening of Fluka Lipase Basic Kit 
Employing the optimised conditions found for the Lipozyme ®/tert-leucine system, 
the immobilised lipases Lipozyme® (Rhizomucor miehei lipase immobilised on an 
anionic exchange resin) and Novozyme®  (Candida antarctica lipase B immobilised 
on acrylic resin) were tested, and the results are shown in Table 12. The natural (5) 
stereochemistry of the product, and subsequent biotransformation products, was 
assigned by comparison with previous results obtained using Lipozyme®  and optical 
rotation values in the literature. ' 0 ' 
The results obtained with the Fluka Lipase Basic Kit (Table 11) were disappointing 
with only poor to moderate e.e. and conversions obtained. In contrast, the 
immobilised lipases produced interesting results. The Lipozyme®  experiments, 
(entries 1 and 2, Table 12) were a repeat of previous experiments' 0 ' for reference and 
showed again the enhancement of e.e. with the addition of external triethylamine. 
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Reagents and conditions: i. Toluene, (Et3N (0.25 equiv.)), lipase, CH 30H (2.0 equiv.), 37 °C 
Entry 	 Lipase Et3N Yield/ % e.e./ % 
1 	 Lipozyme ® no 59 55 
2 	 Lipozyme ® yes 74 69 
3 	 Novozyme® no 40 64 
4 	 Novozyme® yes 53 95 
5 	 Novozyme® yes 81 95 
Table 12 Results obtained for screening Lipozymeand Novozyme 
The Novozyme®  results also exhibit a dependence on triethylamine addition to 
increase the e.e. of the product (entries 3 and 4). Although the Novozyme ® mediated 
biotransformation resulted in an excellent e.e. of 95%, (entry 4), only a moderate 
yield of 51% pure product was obtained. On closer examination of the 'H nnir (200 
MHz, CDC1 3) spectrum of the crude biotransformation product it could be seen that a 
1:1 ratio of desired product to hydrolysis product, i.e. N-benzoyl phenylalanine was 
obtained. The ratio was calculated from the integrals corresponding to the a-CU of 
each amino acid derivative, 6 5.06 and 4.94 for the ester and acid respectively. To 
minimise the formation of the undesired hydrolysis product Novozyme®  was crushed 
in a mortar and pestle and dried to constant weight. It was hoped that the use of 
phosphorus pentoxide as desiccant would remove any excess water trapped in the 
solid support, or associated with the surface of the lipase, but would not be powerful 
enough to remove the water held at the catalytic triad of the lipase that is essential 
for catalytic activity. Indeed the resulting powder, when subjected to the 
biotransformation, produced an identical e.e. of 95% while the yield increased to 
81% (entry 5). 
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2.3.3. Effect of alkyl chain length of nucleophile 
As an effective, and reproducible set of biotransformation conditions had been 
established, it seemed logical to probe the parameters of the reaction to achieve a 
greater understanding of the role of each component. The first variable to be 
investigated was the effect of the alcohol chain length and the results are shown in 
Table 13, with the previous results obtained for Lipozyme®  also shown.9910 ' 
	
Ph 	 Ph 
 
f, 
COR' N 	- 	 HN
'\ / )— 0 
Ph/ 	 Ph 
89a 	 96a-100a 
Reagents and conditions: i. Toluene, (Et3N (0.25 equiv.)), lipase, R'OH (2.0 equiv.), 37 °C 
Compound R Novozyme® 
Yield! % 	e.e./ % 
Lipozyme® 
Yield! % 	e.e./ % 
96a CH3 79 	94 55 	40 
98a CH3CH2 82 	97 53 	83 
99a CH3CH2CH2 83 	97 - 	 - 
97a CH3CH2CH2CH2 81 	95 69 	73 
lOOa CH3CH2CH2CH2CH2 32 	88 - 	 - 
Table 13 Effect of alkyl chain length of alcohol nucleophile for the alcoholysis of5(4H)-oxazolone 
89a 
The results show that there is very little effect on the resulting e.e. of the Novozyme ® 
mediated biotransformation product when the length of the alkyl chain of the 
primary alcohol nucleophile is varied. This is in direct contrast to the erratic results 
obtained in the Lipozyme ® mediated alcoholysis. 
2.3.4. Secondary alcohols 
The use of secondary alcohols as nucleophiles was also investigated. When iso-
propanol was used as the nucleophile, (Scheme 44), the biotransformation proceeded 
at a very slow rate with a reaction time of 26 days required for 100% conversion. 
The isolated product yield of only 18% with an e.e. of 29% indicates that secondary 
alcohols are poor nucleophiles under the conditions studied. An explanation for this 
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result could be that in processes where Novozyme®  has been used successfully with 
secondary alcohol nucleophiles, it has been to resolve the alcohol using achiral acyl 
donors. In the above reaction, the oxazolone is a relatively bulky chiral acyl donor. 
The resulting acyl enzyme intermediate formed will have considerable steric 
constraints in comparison to simple acyl enzyme intermediates, thus the secondary 











Scheme 44 Reagents and conditions: i. Toluene, Novozyme®,  Et3N, 'PrOH, 37°C 
2.4.0. Expansion of substrate range 
2.4.1. Synthesis of substrates 
The next and most obvious variable to probe was the C-4 substituent (R) to 
examine the scope of the substrate range tolerated by Novozyme®.  The substrates 
were all prepared in two steps as described in Section (2.3.1.) and illustrated in 
Scheme 45. They all proceeded smoothly in good to excellent yield with the results 
shown in Table 14. It was decided to carry out the biotransformations with methanol 
and n-propanol as the nucleophiles so that the two sets of results could be compared 
(see Section (2.4.2.)). 
R H 
	
L 	 0 R II 









Scheme 45 Reagents and conditions: i. 2M NaOH, PhCOCI, 0 °C, ii. 1,4-dioxane:acetic anhydride 
(1:1), 40 °C 
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Compound 	 R 	 95 Yield! % 	 89 Yield! % 
b CH2CH(CH3)2 78 81 
c CH(CHI)2 83 95 
d CH2CH2SCH 3 75 56 
CH2-1------( 
e 76 36 
H 
f CH3 70 99 
g C(CH3)3 81 82 
Table 14 Synthesis of2-phenyl-4-substituted-5(4H)-oxazolones 89b-g 
2.4.2. Testing of substrates 
Using the optimised reaction conditions each substrate was tested, Scheme 46, 
and the results are shown in Table 15. 
R 	 R 
I. 
N v 	 HN CO2R'  
'\ 	I 
)— 0 
Ph7 	 Ph 
89b-g 	 R'= Me 96b-g 
R'= Et 98f 
R'= nPr 99b-g 
Scheme 46 Reagents and conditions: i. Toluene, Et3N (0.25 equiv.), lipase, R'OH (2.0 equiv.), 37 °C 
The results in Table 15 again indicate that there is only a small change in the e.e. 
of the product when the nucleophile is changed from methanol to n-propanol. They 
also indicate that Novozyme ® prefers flexible alkyl side chains with the iso-propyl 
and iso-butyl side chains giving the highest e.e.'s. The small methyl side chain gave 
poor chiral induction, presumably due to lack of steric interactions with the lipase 
The bulky tert-butyl group gave only poor to moderate yields (after the recovery of 
starting oxazolone) and poor e.e.'s, perhaps due to excessive steric interactions with 
the lipase. As the flexibility of the C-4 side chain was increased, as in the case of the 
methyl thioethyl group, the e.e. began to fall to -80%. The aromatic indolemethylene 
side chain also gave good e.e.'s of 80 and 90%. Although the indolemethylene group 
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is relatively bulky, the methylene spacer (as in the case of the benzyl side chain) 
allowed the substrate the flexibility to fit into the active site of the lipase. 
Compound 	 R 	 R' 	 Yield! % 	e.e./ % 
96b 	CH2CH(CH3)2 	 CH3 	 96 	 97 
99b 	 CH2CH2CH3 	 89 	 98 
96c 	 CH(CH3)2 	 CH3 	 82 	 95 
99c 	 CH2CH2CH3 	 70 	 93 
96d 	CH2CH2 SCH3 	 CH3 	 69 	 80 
99d 	 CH2CH2CH3 	 64 	 83 
CH2-1----( 
96e 	 CH3 	 90 	 90 
99e 	 H 	 CH2CH2CH3 	 48 	 80 
961 	 CR3 	 CR3 	 - 	 - 
981 	 CH2CH3 	 60 	 14 
991 	 CH2CH2CH3 	 72 	 14 
96g 	 C(CH3)3 	 CR3 	 40 35 
99g 	 CH2CH2CH3 	 isa 	 19b 
a) Yield based on recovered starting material, b) not baseline separation 
Table 15 Results obtained for Novozyme ® mediated alcoholysis of 2-phenyl-4-substituted 5(4H)-
oxazolones 89b-g 
2.4.3. Studies on the effect of solvent 
To gain a further understanding of the reaction parameters the solvent was varied. 
The methanolysis of 89a was performed in the presence and absence of a catalytic 
amount of triethylamine to also examine the role of the base in the reaction. A 
number of conclusions can be drawn from the results shown in Table 16. Firstly, if 
we examine the results obtained when triethylamine was present, we can see that 
chlorinated solvents, (entries 1 and 2) gave poorer yields and e.e.'s. while ethers, 
(entries 3-5) gave excellent yields and e.e.'s comparable to the results obtained in 
toluene. The polar solvents of tetrahydrofuran and acetonitrile both produced 
products with excellent e.e.'s but with only moderate yields. Lower e.e.'s were 
observed when the same series of reactions were carried out in the absence of 
triethylamine. The effect was most prominent in the ether series (entries 3-5), where 
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the e.e. dropped from 96% to 33% in the case of DIPE. Examining the relative rates 
of reaction, it is evident that in the presence of triethylamine the reactions are much 
faster. The ethers gave relatively fast reactions both in the presence and absence of 
triethylamine and in all cases were complete after being left overnight. Chlorinated 
solvents resulted in the largest decrease in rate. 
The results obtained in tetrahydrofuran and acetonitrile in the absence of 
triethylamine are the most interesting. In the absence of triethylamine the e.e. 















Reagents and conditions: i. Solvent, (Et3N (0.25 equiv.)), Novozyme®, R'OH (2.0 equiv.), 37 °C 
Entry Solvent Time! h Et3N Present 
Yield! % 	e.e.! % 
Time! h Et3N Absent 
Yield! % 	e.e./ % 
1 DCM 41 78 	89 124 65 	75 
2 CHC13 39 66 	75 124 63 	83 
3 THF 48 64 	95 123 71 	97 
4 Et20 17 87 	97 18 90 	58 
5 tBuOMe 15 90 	96 18 91 	34 
6 DIPE 15 86 	96 18 90 	33 
7 toluene 26 82 	94 58 82 	71 
8 acetonitrile 22 44 	97 51 88 	98 
Table 16 Solvents studies for the methanolysis of 2-phenyl-4-benzyl-5(4H)-oxazolone 89a with 
Novozyme ® 
2.4.4. Acetonitrile as solvent 
To explore if the acetonitrile solvent effect discovered above was specific to 
Novozyme®,  or was a more general phenomenon, the reaction was repeated with 
Lipozyme® as illustrated in Scheme 47. 
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Scheme 47 Reagents and conditions: i. Solvent, (Et3N, 0.25 equiv.)), Lipozyme®, CH3OH, 37 °C 
Entry 	Solvent 	 Et3N 	Time! h 	Yield! % 	e.e./ % 
1 toluene No - 	 48 19 101 
2 toluene Yes - 	 55 40101 
3 acetonitrile No 23 	 94 73 
4 acetonitrile Yes 23 	 61 73 
Table 17 Acetonitrile studies for the tnethanolysis of2-phenyl-4-benzyl-5(4H)-oxazolone 89a with 
Lipozyme ® 
The results in Table 17 show that using acetonitrile as the solvent with Lipozyme ® 
produced the same effect as observed with Novozyme ®. Not only did the yield 
increase from 55% to 94% but the e.e. almost doubled from 40% to 73%. 
2.4.5. Testing of substrates with acetonitrile as solvent 
To expand on the results found with acetonitrile as solvent, the 2-phenyl-5(4H)-
oxazolones tested in Section (2.4.2.) were also subjected to the acetonitrile 
conditions with both lipases, (Table 18). 
R 	 R 
N ° 	 HNCCH3 
Ph 	 Ph 
89b-g 	 96b-g 
Reagents and conditions: i. Acetonitrile, lipase, CH30H, 37 °C 
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Yield! % e.e./ % 
Lipozyme® 
Yield! % 	e.e./ % 
a CH2Ph 88 98 94 73 
b CH2CH(CH3)2 96 97 89 	62 




0 - 98 	46 
e CH2CH2SCH3 79 73 83 	59 
I CH3 94 10 79 39 
g C(CH3)3 0 0 0 	 0 
Table 18 Acetonitrile studies for the methanolysis of2-phenyl-4-substituted-5(4H)-oxazolones 89a-g 
with Novozyme®  and  Lipozyme ® 
Examining the Novozyme ® data first, and comparing it with the results in Section 
(2.4.2.), Table 15, it can be clearly seen that for the C-4 alkyl side chains the results 
are almost identical in yield and e.e. In the case of the tert-butyl side chain the 
enzyme activity was entirely depressed and no desired product was isolated after 
several weeks. An identical result was obtained with the indolemethylene side chain 
(compared to a yield and e.e. of 90% when the reaction was carried out in toluene 
with triethylamine). An explanation for the above results could be that the use of 
acetonitrile as the solvent causes a conformational change in the lipase, resulting in a 
decrease in the accessibility of the active site of the lipase. The corresponding 
Lipozyme® reactions were generally high yielding, with only modest enhancement of 
the e.e. of the product when compared with the results obtained in 
toluene/triethylamine. The e.e. for the iso-propyl side chain increased from 0 to 19%. 
The tert-butyl side chain also gave a dramatic change in reactivity. Under the 
previous conditions a 47% yield and 80% e.e. was obtained. With acetonitrile as the 
solvent the activity was again entirely depressed. It appears that the best substrates 
for Novozyme® are flexible side chains i.e. iso-propyl or iso-butyl. It is also implied 
that the presence of a methylene spacer, as in the benzyl and methylsulfanyl-ethyl 
side chains can be advantageous as higher e.e. were observed with these substrates. 
Lipozyme® on the other hand appears to have a wider cavity at the active site and 
therefore is most stereoselective for sterically demanding side chains such as tert-
butyl. In the absence of any steric bulk, only poor enantioselectivity was achieved. In 
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addition, once the lipase has been selected for the biotransformation the choice of 
solvent between toluene and acetonitrile can dramatically effect the 
enantioselectivity. 
2.5.0. The role of the base 
The intended role of the addition of triethylamine to the reaction system was to 
increase the rate of racemisation of the oxazolone substrates. However, during the 
course of our studies it was realised that the actual role of the triethylamine was 
more complex. To gain a greater understanding of the role of the base an in depth 
kinetic study was undertaken in our laboratory by Dr. M.-C. Parker. 103 
The most reliable predictor of enzyme catalytic activity in low water organic media 
is thermodynamic water activity (a). The hydration level was controlled by 
equilibrating the enzyme and solvent (over a period of 48-72 h) with the appropriate 
saturated salt solution of known a. For example, a low a system was one where the 
solvent was poorly hydrated, therefore the enzyme was similarly poorly hydrated. At 
high a.N  the solvent was near water saturation and the enzyme was fully hydrated as 
in an aqueous system. The reaction depicted in Scheme 48 was performed in solvents 









Scheme 48 Reagents and conditions: i. Solvent, (Et3N (0.25 equiv.)), Novozyme®, BuOH (2.0 
equiv.), 37 °C 
The effect of the level of hydration on the initial catalytic rate and enantioselectivity 
found in three different solvents in the presence and absence of triethylamine is 
shown in Table 19. In the absence of triethylamine, even low levels of hydration 
present in non-polar solvents such as hexane and toluene were detrimental to the rate 
and e.e. When the reactions were carried out in the presence of triethylamine, the rate 
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did drop, but to a lesser degree, while the e.e. remained high. The conditions which 
resulted in the optimum rate and e.e. were when the lipase, solvent and triethylamine 
were rigorously dried. 
Solvent Water activity a. 
No Et3N 
initial rate 	e.e./ % 
Et3N 
initial rate e.e./ % 
n-hexane -.0 (anhydrous) 26 (±1.5) 85 (± 3) 30 (± 1.5) 90 (± 3) 
n-hexane 0.69 4 (±0.5) 55 (±2) 20 (±1) 87 (±3) 
n-hexane 0.97 1.5 (±0.15) 30 (± 5) 18 (± 0.9) 80 (± 5) 
toluene -0 15 ((± 0.8) 85 ((± 4) 27 (±1.5) 93 (± 3) 
toluene 0.22 3 61 (± 6) 17 (±1) 95 ((± 2) 
acetonitrile -0 15 >99 10 97 ((± 2) 
acetonitrile 0.1(0.5% v/v H20) no reaction - 5 (± 0.3) 90 (±4) 
acetonitrile 0.4 (2% v/v H20) no reaction - no reaction - 
Table 19 Effect of water activity on initial catalytic rate and enantioselectivity as a function of 
hydration, in the presence and absence of triethylamine 
The effect of triethylamine addition to a reaction already proceeding with poor 
enantioselectivity was also examined. Triethylamine was added to the reaction in 
hexane (a = 0.69) after 140 mm, resulting in an instantaneous increase in rate and 
e.e. as illustrated in Figure 7 
80 











10 	 Et3Nadded(B),t=140 
0 	 I 	I 	II 	I 	I 
0 50 100 150 	200 250 	300 	350 
time (mm) 
Figure 7 Effect of triethylamine on e.e. Reactions A and B were carried out under identical 
conditions (a- 0.69). At t= 140 mm, 14 mol % triethylamine was added to reaction B (arrow) 
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The addition of organic bases to increase the enantioselectivity of enzyme catalysed 
reactions carried out in organic solvents has been documented in the literature. 104-106  
One hypothesis is that the addition of external base results in the formation of an ion-
pair with any acid by-product formed during the reaction. As mentioned earlier in 
Section (2.3.2.), the formation of N-benzoyl amino acids such as 95a has been 
observed by 'H nmr in the resolution of oxazolone 89a. We have also found that 
addition of acid 95a to an already hydrated system results in loss of activity. On 
subsequent addition of triethylamine the activity was regained, presumably via ion-
pair formation. Ion-pair formation was observed in both low and high, non-hydrogen 
bonding dielectric solvents such as hexane and acetonitrile. The acid 95a was found 
to be more soluble in acetonitrile than hexane. In the absence of triethylamine, the 
dissolved acid remains bound to the surface of the lipase through electrostatic 
interactions, thus altering the protonation state, and leading to protein deactivation. 
In polar solvents such as acetonitrile, the acid by-product is more soluble and 
therefore is not bound to the surface of the enzyme and no reduction in the e.e. is 
observed. However, for reactions carried out with rigorously dried reagents and low 
a (< 0.7) there was no evidence of hydrolysis over the initial rate measurements, yet 
the addition of triethylamine did enhance the enantioselectivity of the reaction. A 
role of the triethylamine in the reaction has been identified but does not give the 
complete answer. Investigations to further understand the activation process are 
currently under way. 
2.6.0. Nitrogen nucleophiles 
2.6.1. Amines 
As well as testing alcohol nucleophiles, nitrogen based nucleophiles were 
investigated. As mentioned in Section (2.2.0.), one aim of the project was to 
synthesise a number of MMPI derivatives 94, all of which contain a methyl amide 
functionality in the position resulting from nucleophilic attack of the corresponding 
oxazolone. In control reactions 2-phenyl-4-benzyl-5(4H)-oxazolone 89a was 
subjected to the amine nucleophiles benzylamine and allylamine in the absence of 
any lipase (Scheme 49). Unfortunately in both cases the amide product 102 was 
isolated in high yield indicating that amines are too nucleophilic and would by-pass 
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the lipase and produce only racemic amide products. Shriner et al. 107  observed amide 
formation in their studies involving the reactions of 2-phenyl-4-benzyl-5(411)-
oxazolone 89a and secondary amines such as piperidine, morpholine, 
dimethylamine, diethylamine, methylaniline and ethylaniline. 
Ph 	 Ph 
	
N< O 	 HN)<CONHR 
'\ 0 / 
)— 
Ph' 	 Ph0 
89 102a-b 
Scheme 49 Reagents and conditions: i. (a) Toluene, PhCH2NH2, 77%, (b) THF, H2NCH2CH=CH2 , 
90% 
The use of a-amino acid derivatives as nucleophiles was also investigated as an 
extension of the work carried out by Sihl 08,109 . Sih subjected 2-phenyl-4-benzyl-
5(4H)-oxazolone 89a to nucleophilic attack by various a-amino acid derivatives in 
the presence of a-chymotrypsin or the cysteine protease papain. Either 
acetonitrile:phosphate buffer (1:1, pH 8) or DMF:phosphate buffer (1:1, pH 8.5) 
were used as solvent respectively, Scheme 50. 
Ph Ph 
R 	 I. 	 (HH 
NJ(O + 	V HN)(N.YCONH2 
'\ 0 / 	H2NCONH2 )— 




Scheme 50 Reagents and conditions: i. (a) a-chymotrypsin, acetonitrile:phosphate buffer (1:1, pH 8), 
(b) papain, DMF:phosphate buffer (1:1, pH 8.5) 
The experimental results obtained by Sih are shown in Table 20. They indicate that 
when optically pure oxazolone 89a was used as the acyl donor only one 
diastereomeric dipeptide (L,L) was isolated, indicating that under the reaction 
conditions the L-oxazolone did not racemise. When racemic oxazolone was used, a 
mixture of (L,L) and (D,L) diastereomers of varying ratios were produced. These 
results suggest that the enzymes show a degree of enantioselectivity. 
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Conditions Time! min Yield! % 
104 
1 L Phe-NH, a 30 64 
2 L Arg-NH2 a 30 85 
3 DL Phe-NH, a 30 59 (L,L) 
13 (D,L) 
4 DL Arg-NH2 a 5 70 (L,L) 
17 (D,L) 
5 L Ala-NH2 b 30 62 
6 L Glu-NE, b 30 80 
7 DL Ala-NH2 b 30 40(L,L) 
19 (D,L) 
8 DL Glu-NH2 b 30 62 (L,L) 
18 (D,L) 
Table 20 Results obtained by Sihfor the aminolysis of2-phenyl-4-benzyl-5(4H)-oxazolone 89a with 
a-chymotrypsin and papain'°8"°9 
It is also clear that during the course of the reaction, the oxazolone partially re-
racemised because the yield of the (L,L,) diastereomer is greater than 50%. However, 
no control experiment where the reagents were reacted in the absence of the enzyme 
is documented, therefore the optically pure diastereomers obtained in entries 1, 2, 5 
and 6 could have been formed by direct reaction of the amino acid amide with the 
oxazolone. The diastereomeric ratios of the products in entries 3, 4, 7 and 8 could 
also have been a result of chemical diastereoselectivity because a chiral nucleophile 
was used. The yields in excess of 50% could result from racemisation of the 
relatively less reactive D-oxazolone (for steric reasons). A closer examination of the 
rate of reaction could shed light on this. 
To provide more information on the mechanism of the above reaction we carried 
out the following control experiment. 2-Phenyl-4-benzyl-5(411)-oxazolone 89a was 
dissolved in toluene and freshly prepared glycine methyl ester added as shown in 
Scheme 51. The dipeptide product 105 precipitated almost instantly as a colourless 
solid, and was isolated in a yield of 80%. This is conclusive proof that these a-amino 
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Scheme 51 Reagents and conditions: i. Et20, NH3(,),  0°C, H. Toluene, room temp. 
2.6.2. Amides 
In an attempt to lower the nucleophilicity of the nitrogen nucleophiles the use of 
amides was investigated. Unfortunately, the two attempts shown in Scheme 52 
failed. It is hypothesised that in the case of phenylacetamide, (R= Ph), the amide was 
too weak a nucleophile due to the relatively poor electron withdrawing nature of the 
aromatic ring. Trifluoroacetamide, (R= CF 3) was tested in the hope that the greater 
electron withdrawing affect of the trifluoromethyl group would activate the amide 
sufficiently. Unfortunately no reaction was observed. 
Ph 	 Ph 
___ (H 
' HNy. 
Ph 	 Ph o 
89a 	 106a-b 
Scheme 52 Reagents and conditions: i. THF, Novozyme®, Et3N, a) R= Ph, phenylacetamide, 0%, b) 
R= CF3 , trifluoroacetamide, 0% 
2.6.3. Kinetic resolution with amines 
Another route for preparing amides was tested. A double resolution process was 
envisaged as illustrated in Scheme 53. Ideally, both reactions would be carried out in 
the same reaction vessel. The initial dynamic kinetic resolution, upon completion, 
would be followed by amine addition to facilitate the enzymatic kinetic aminolysis 
utilising the first product as the new substrate. Not only would this provide the 
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Scheme 53 Reagents and conditions: i. Solvent, Novozyme®, (Et3N), R'OH, 37 °C, ii. solvent, 
Novozyme®,  H2NR" 
Conde et al.33 (see Chapter 1, Section (1.2.2.)) have shown that when both 
enantiomers of diethyl Cbz-glutamate are separately exposed to Novozyme®  in the 
presence of a variety of amines, aminolysis occurs predominantly at the ct-position 
for the L-enantiomer, and predominantly at the y-position for the D-enantiomer. 
To test the utility of the aminolysis methodology, racemic N-benzoyl phenylalanine 
(R= benzyl) and N-benzoyl valine methyl esters (R= iso-propyl) were subjected to 
methyl and benzyl amine in various solvents as shown in Scheme 54 and Table 21. 
Unfortunately, no reaction was observed. 
R 
H 	
R 	 R 
I V 
	
HNSCQ2CH3 	I. 	HNCQNHR' + HNCQ2CH3 
Ph0 	 Ph0 	 Ph0 
Scheme 54 Reagents and conditions: i. Solvent, Novozyme®,  H2NR' 
Entry 	 Solvent 	Temp/ °C 	 R 	 R' 
1 toluene + Et3N 37 CH2Ph CH3 
(0.25 equiv.) 
2 1,4-Dioxane 37 CH2Ph CH2Ph 
3 DIPE 37 CH2Ph CH2Ph 
4 DIPE 60 CH2Ph CH2Ph 
5 DIPE 37 CH(CH3)2 CH2Ph 
6 DIPE 60 CH(CH3)2 CH2Ph 
Table 21 Attempted aminolysis of a-amino acid esters in the presence of Novozyme 
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In a subsequent report, Conde"° demonstrated that acyl protected amines react 
slower than their carbamate counterparts. It was hypothesised that the alkyl-oxygen 
atom of the carbamates interacted with the hydrogen bond network of the polar 
residues of the active site of the lipase. As a result, the energy required to bind the 
substrate to the active site will be significantly smaller than that for amines. Due to 
the unsuccessful results obtained in attempting to introduce nitrogen nucleophiles 
into the biotransformations, no further research on nitrogen nucleophiles was carried 
out. 
2.7.0. Conclusions 
To conclude, a reliable and reproducible assay has been developed utilising 2-
phenyl-4-substituted-5(4H)-oxazolones 89a-g as substrates in a lipase mediated 
dynamic kinetic resolution process in the synthesis of optically active L-a-amino acid 
derivatives. High enantioselectivities were achieved by the correct selection of lipase 
and solvent. It was found that Novozyme ® preferred relatively flexible C-4 
substituents, with the incorporation of a methylene spacer at C-4 proving 
advantageous for achieving a high degree of enantioselectivity. Lip ozyme® on the 
other hand required sterically demanding C-4 substituents for high 
enentioselectivities to be achieved. The addition of triethylamine to the reaction 
proved crucial in obtaining high enantioselectivities, with the base acting as a 
counter ion to any hydrolysis product formed, thus removing any inhibitory effects. 
Acetonitrile was the solvent of choice for flexible C-4 side chains, whereas toluene 
and a catalytic volume of triethylamine were preferred for bulky C-4 side chains. 
2.8.0. Future work 
As there are already viable, economical routes to the proteinogenic a-amino acids, 
the utility of this methodology lies in the synthesis of unnatural a-amino acid 
derivatives. The oxazolone skeleton can provide a template for Knoevenagel 
condensation with various imines. Subsequent reduction or alkylation yields novel 
saturated 5(411)-oxazolones 111 which can be utilised as the substrates in the 
biotransformation process as illustrated in Scheme 55. 
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Results and Discussion II 
3.0.0. Results and Discussion II 
3.1.0. Application of developed methodology: The synthesis of 
potential matrix metalloproteinase inhibitors 
3.1.1. Matrix metalloproteinases and their inhibitors 
Matrix metalloproteinases (MMPs) are a family of closely related zinc containing 
endopeptidases. Their role in the body is to cleave large biomolecules such as 
collagens, proteoglycans, and gelatins. They have also been implicated in the 
remodelling of the extracellular matrix." To date there are 14 known MMPs, and a 
high degree of sequence homology has been identified. All the MMPs have been 
found to contain a zinc (II) metal-ion at the active site and are inhibited by metal ion 
chelating agents.' 2 
The role of MMPs in nature is to cleave molecules such as collagens, (the most 
abundant protein in the body and the major structural component of many organs and 
tissues). Their activity in the body must be precisely regulated. Expression of MMPs 
is tightly controlled by pro- and anti-inflammatory cytokines and growth factors. On 
production, the MMPs are generally secreted as inactive zymogens, or pro-
enzymes." 3 To activate these zymogens the N-terminal must be modified or cleaved, 
which results in the freeing of the zinc (II) containing active site. This is achieved by 
cleaving the bond between the Cys73 residue and the Zn (II) as illustrated in Figure 
8. In the inactive form, the pro-domain is folded over, allowing the Cys73 residue to 
interact with the Zn (II), thereby preventing access to the active site by the water 
molecules that are required for the cleavage mechanism."" 4 The active forms of the 
MMPs are also regulated by natural inhibitors in the body, the tissue inhibitors of 
metalloproteinases, or TIMPs, and general plasma proteinase inhibitors such as a2- 
macroglobulin. 3 
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Figure 8 Activation of matrix metalloproteinases" 
3.1.2. Matrix metalloproteinases and disease 
In a number of pathological conditions such as cancers and arthritis, there is an 
imbalance between the levels of the active M.MPs and the native inhibitors. The 
increased levels of MMPs result in increased degradation of the extracellular matrix, 
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which in turn, cause irreversible damage to the body. For example, in various (but 
not all) cancers, abnormally high levels of MMPs cause the breakdown of the 
extracellular matrix of the cancer tumour, allowing proliferation and local invasion 
of the primary tumour. As the tumour cells travel through the blood vessels, they 
adhere to the blood vessel wall. Again MMP activity causes a breakdown of the cell 
wall allowing tumour cells to cross the vascular basement membrane, culminating in 
secondary tumour growth. In addition, there is evidence that MMP activity 
contributes to the invasive growth of new blood cells, (angiogenesis) which allows 
the tumour to grow. 112,115  This process is illustrated in Figure 9. 
re)i.tF 
4 
(I) Local invasion and spread 
Into the blood stream 
(Ii) Adhesion to blood 	(ill) Migration through 
vessel wall 	 vessel wall 
(lv) Growth of secondary 
tumour 
Figure 9 Potential sites of action of matrix metalloproteinases in tumour growth 115 
3.1.3. Synthetic matrix metalloproteinase inhibitors 
A number of pharmaceutical companies currently have active research projects 
directed towards finding an orally active matrix metalloproteinase inhibitor 
(MMPI)." 4 The strategy of treatment is the continuous administration of low toxicity 
therapeutics that will stabilise malignant disease and prevent further growth. To this 
end, the MMPI '5 do not constitute a magic bullet or a preventative treatment, but are 
better regarded as a quality of life enhancing tool for patients. Two approaches in 
MMPI development have been followed, namely the screening of natural compounds 
and the substrate-based design of pseudo-peptide derivatives. The second approach 
has been by far the most successful. The starting point for structure based design lay 
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with the sequence around the glycine-isoleucine and glycine-leucine cleavage sites 
of collagen, which frees the zinc (II) containing active site as indicated in Figure 10. 
Of the three resulting substructures, it has been MMPI's based on the right hand side 
(RHS) of the sequence that have proved the most potent. 
Collagenase Cleavage Site 
Collagen Fibril 
I Pro -Gin - Gly : lie -Ala -Gly 1 Humana 1(1) Sequence around the cleavage site 	Pro - Gin - Gly : lie -Ala - Gly 	Humana 1 (I) 
Pro - Gin - Gly Leu - Leu - Ala ) Humana 2(l) 
Enzyme subsites 	S3 S2 S1 Zn2 Si ' S2' S3' 
Natural substrate 
0 	P3. 
51 	 Combined inhibitor 
P3 	0 	P, 
LHS inhibitor 
ZBG 	 RHS inhibitor 
Figure 10 Design of matrix metalloproteinase inhibitors on the basis of the cleavage site of 
collagen 113 
A summary of the structure activity relationship (SAR) found for MMPI's is given in 
Figure 11. The incorporation of a zinc (II) binding group, (ZBG) to chelate to the 
active site of the MMPs proved essential for potent inhibitory levels. Of the zinc 
binding groups (ZBG's) tested, including carboxylate, aminocarboxylate, sulfhydryl, 
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derivatives of phosphorus acids and hydroxamic acids, it has been the hydroxamic 
acids that have been incorporated most frequently. From an X-ray crystal structure of 
a hydroxamate substrate binding to matrilysin (MMP7) it is evident that the 
hydroxamate acts as a bidentate ligand, with each oxygen at an optimum distance 
(1.9-2.3 A) from the active Zn(II) ion. The P 1 ' group fits into the S 1 ' pocket of the 
enzyme and offers the greatest opportunity for selective inhibitor design. A large 
number of the developed inhibitors have incorporated an iso-butyl group which 
results in non-selective inhibition. The P 2 ' and P3 ' groups can tolerate a variety of a-
amino acid residues which shows that the P 2' side chain does not play a major role in 
enzyme binding. Bulky R3 groups such as tert-butyl, as in the Roche compound Ro 
31-9790, and an indolemethylene as in Glycomed's Galardin, have shown enhanced 
inhibition in comparison with other P 2' alkyl groups. The use of bulky R 3 groups also 
prevents amide hydrolysis in vivo. It has also been discovered that the P,'-P2 ' and the 
P2'-P3 ' C=O and N-H are all involved in hydrogen bonding interactions with the 
enzyme. 113 
R2(P1' substituent) 	 Amide backbone 
Major determinant of activity and selectivity 	 N-Methylation reduces activity 
Small alkyl groups (particularly isobutyl) prefered for HFC activity 	Reverse amides reduce activity 
Charged and polar groups not well tQ!Q 	





R (P3 substituent) 
Hydroxamic acid prefered 
// Wide range of substituents tolerated 
Ho)(LJj,)L R4 	
Bulky/aromatic groups improve 
stromelysin activity 
H 
R 1 	o 	R3 	H 	Charged/polar groups may effect biliary 
R1 (a substituent) 	
______.v' excretion 
Increases activity against collagenase and 	 R3 (P2 substituent) 
stromelysin 1 	 Wide range of substituents tolerated 
Certain substituents allow truncation at p 27p3 	Aromatic substituents preferred for in vitro activity 
without loss of activity 	 Cyclisation to R 4 can give increased activity 
Can be modified to provide oral bioavailability 	Steric bulk close to amide is benificial for oral bloavailability 
Figure 11 Summary of the SAR for RI-IS matrix metalloproteinase inhibitors. HFC- human fibroplast 
collagenase"3 
3.2.0. Retrosynthetic analysis 
Through retrosynthetic analysis, (Scheme 56), it can clearly be illustrated how the 
oxazolone methodology developed in the previous chapter can be utilised in the 
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synthesis of the MMPI's such as Galardin (R= indolemethylene) and Ro 31 9790 
(R= tert-butyl). Through a number of simple functional group interconversions, the 
diester 112 is obtained, which can be considered as the dynamic kinetic resolution 
product from the corresponding oxazolone 113. Synthesis of oxazolone 113 from 
racemic a-amino acid methyl esters and the substituted succinate monoester 114 was 
envisaged. The first goal was therefore the synthesis of the substituted succinate 
monoester 114. 
HO N J )L N 
94 
R  




_) t 	 H BuQC  NCO2R 
0 FR 
112 









Scheme 56 Retrosynthetic analysis of matrix metalloproteinase inhibitors 
Succinate 114 can be considered as the downstream product from the alkylation 
of a unsymmetrical malonate 118 with the acceptor molecule 117 (Scheme 57). The 
acceptor molecule 117, where X = I, Br or TfO, TsO, could be synthesised from 
either enantiomer of leucine. 
tBuQC 	
> tBuOC 	 + tBuOCCOR 









Scheme 57 Retrosynthetic analysis of succinate 114 
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3.3.0. Synthesis of substituted succinate mono ester 114 
Starting from D-leucine, as illustrated in Scheme 58, the amine group was 
converted to a hydroxyl group via diazotisation to form (R)-leucic acid 119 
according to the procedure detailed by Mori."" 6 The literature yield was moderate for 
this reaction and could not be improved on. Acid catalysed benzylation furnished the 
a-hydroxy ester 120 in excellent yield after column chromatography; which was 
used to form the triflate 121 as described by Degerbeck. 1 17 Evidence for the 
formation of the triflate was obtained from the 'H and ' 3C nmr spectra. In the 'H nmr 
the a-proton was shifted downfield from 6 4.24 for the hydroxy ester 120 to 6 5.19 
due to the electron withdrawing effect of the trifluoromethyl group. In the ' 3C nmr 
spectrum of 121, a quartet at 6 118.29 with a coupling constant of 319 Hz was 
observed which is characteristic for the trifluoromethyl group of a triflate. The 
triflate was stable to chromatography but readily decomposed on standing and was 
therefore used immediately in the next stage of the synthesis. All the above reactions 
were carried out on at least a 70 mmol scale providing multigram quantities (-24 g) 
of pure triflate 121. 
51% 	 95% 	 98% 
	
H2N CO2H 	HO"CO2H 	HOCO2Bn 	TfcYCO2Bn 
D-Leucine 	 119 	 120 	 121 
Scheme 58 Reagents and conditions: i. 1M H2SO4, NaNO2, 0'C, ii. toluene, BnOH (2.0 equiv.),p-
toluenesulfonic acid (5 mol %), iii. DCM, 2,6-lutidine, (CF3 SO)20, -78 °C 
The optically purity of a-hydroxy ester 120 was also determined by HPLC 
analysis of the acetate 122 and found to be 97% e.e. (Scheme 59). This was in 
agreement with the optical purity of the D-leucine (97% e.e. commercially available) 




120 	 (R)-122 97% e.e. 
Scheme 59 Reagents and conditions: i. Pyridine, acetic anhydride, room temp. 
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The unsymmetrical malonate 125 was synthesised in high yield from the 
commercially available tert-butyl ethyl malonate 123 as illustrated in Scheme 60. 
Base hydrolysis of 123 proceeded quantitatively yielding mono tert-butyl malonate 
124. Next, the potassium salt was formed and dried overnight under vacuum before 
being used in the alkylation reaction with benzyl bromide in DMF, to furnish tert-
butyl benzyl malonate 125 in 75% yield on an 80 mmol scale. 
tBuQC'CQEt 	I. 
C CO2H tB 0 100% 	
U 2 	 tBuOCCQBfl 
123 	 124 	 125 
Scheme 60 Reagents and conditions: i. THF:H20 (1:1), LiOH, room temp., ii. THF:H20 (1:1), 
KOH, iii. DMF, BnBr 
With the two fragments in hand, the carbon-carbon bond forming reaction was 
attempted. The SN2 displacement of the triflate group with the enolate derived from 
malonate 125 proceeded in an excellent yield of 91% on a 60 mmol scale (Scheme 
61). The triester product 126 was isolated as a 1:1 mixture of diastereomers, as 
calculated from the integrals from the 'H nmr of the OCCUCH proton. Deprotection 
of the benzyl esters to furnish diacid 116 proceeded quantitatively using 10% Pd/C 
and hydrogen at atmospheric pressure. Diacid 116 was not purified but used directly 
in the subsequent decarboxylation step. 
ii. 
+ tBuQ2CCBn_ 	tBuOC 
	
tBuQC_T CO2Bn 	 002H 
Tf00O2Bn 	
CO2Bn 	 CO2H 
121 	 125 	 126 	 116 
Scheme 61 Reagents and conditions: i. THF, NaH, -10 °C, ii. THF, 10% Pd/C, H2, room temp. 
A number of conditions were screened for the decarboxylation step outlined in 
Scheme 62 in order to obtain the optimum yield. Due to the tert-butyl ester 
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functionality, acid catalysed decarboxylation was avoided. The results are 






116 	 114 
Scheme 62 Reagents and conditions. i. See Table 22 






1 toluene reflux, 20 h 60 desired product 
2 THF, reflux - - recovered starting material 
3 THF Cu20, 65 °C 
4 THF, Et3N, room temp. - - recovered starting material 
5 THF, Et3N, reflux 5 h 98 - 1:4 
6 CH3CN, Cu20, 70 °C 0 0 recovered starting material 
7 CH3CN, reflux 20 h - - 1:1 
8 CH3CN, Cu20, reflux, 1.5 h 78 - 2:7 
9 CH3CN Cu20, reflux, 5 h 92 67 desired product 
10 CH3CN, Cu20, reflux, 24 h 51 - desired product 
11 CH3CN, Et3N, reflux, 5 h 90 - 1:2 
12 CH3CN, Et3N, reflux, 19 h - 85 desired product 
Table 22 Decarboxylation studies for diacid 116 
Petit " 8 utilised catalytic (0.1 equiv.) copper (I) oxide in the decarboxylation of chiral 
diacids similar to 116 in an extension of the procedure developed by Maumy. 119 . 120  
Maumy proposed that the reaction proceeded by an ionic mechanism involving 
copper (I) carboxylates as shown in Scheme 63. Brunner et al. 121 carried out a 
number of experiments to disprove the participation of the proposed copper (I) 
carboxylates and discovered that the monoanionic malonate derivatives were the 
reactive species undergoing decarboxylation. The effect of copper (I) was attributed 
to basicity influence, therefore any compound that increases the concentration of the 
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monoanionic species will also increase the rate of decarboxylation. Brunner applied 
these experimental findings and used chiral amine alkaloids such as cinchonine, and 
cinchonidine in catalytic quantities as base to furnish chiral ethyl 2-phenyl 
propionate from mono ethyl methyiphenylmalonate in excellent yields, albeit with 
only moderate enantioselectivity (11-34% e.e.). 









R 1 \ 1CO2H 
C 
R2 "CO2Cu(I) 
R1 1CO2 H 
	 Co2 
R21Cu w 
Scheme 63 Proposed catalytic cycle for Cu(I) catalysed decarboxylation of malonic acidsl 19 
The results in Table 22 for the decarboxylation of diacid 116 show that thermal 
decarboxylation required high temperatures and proceeded with moderate yields of 
60% in toluene, entry 1. The conditions described by Petit and Maumy were also 
screened. When tetrahydrofuran was employed as the solvent, only starting material 
was recovered, entry 3. With acetonitrile and Cu (I), 5 h under reflux was required 
for complete decarboxylation, with the desired product isolated in a 67% yield, entry 
9. The use of catalytic triethylamine as base resulted in complete decarboxylation 
after 19 h, and furnished the desired succinate 114 in 85% (-40 g) yield from triester 
126, entry 11. 
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3.4.0. Synthesis of novel 5(4H)-oxazolones for lipase catalysed 
dynamic kinetic resolution 
To produce the required 4-substituted-5(4H)-oxazolones, the succinate 114 was 
coupled to racemic a-amino acids to produce a 1:1 mixture of diastereomeric amides 
127 using either of two sets of peptide coupling conditions illustrated in Scheme 64. 
The second set of conditions, (ii.), were required because uneven ratios of the 
resulting diastereomers were obtained when the reaction conditions (i.) were 
employed with leucine, tryptophan and tert-leucine methyl esters. The results in 
Table 23 indicate the good to excellent yields of amides (2R,2'RS)-127a-e obtained. 
R 
)< H 	 I. 0. 	
H 








Scheme 64 Reagents and conditions: i. (i.) DCM, HOBt, EDCI, Et3N, room temp., or (ii.) DMF, 
HOBt, TBTU, DIPEA, room temp. 
Compound 	 R 	 Method 	 Yield! % 
(2R,2RS)-127 
a 	 CH2Ph 	 i. 80 
b CH(CH3)2 	 i. 77 





e 	 C(CH3)3 	 ii. 62 
Table 23 Synthesis of]:] mixture of diastereomeric amides (2R,2'RS)-127a-e 
Succinate 114 was also coupled to L-phenylalanine methyl ester as shown in Scheme 
65. The product was isolated in 95% d.e. as calculated from the 600 MHz 'H nmr 
spectrum by comparison of the signals corresponding to the methyl ester protons, 6 
3.69 and 3.67 for the minor and major diastereomers respectively. The crystal 
structure of the amide 127a was also obtained, (see Appendix I for details), and is 
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represented in Figure 12. The structure clearly indicates that C-5 (as numbered in 
Figure 12) has an (R) configuration since the C-8 configuration was fixed as (5) due 
to the use of L-phenylalanine methyl ester. This result confirms that the synthesis of 
succinate 114 proceeded with the desired stereochemical integrity, and that the 
carbon-carbon bond forming reaction involving malonate 125 and trifiate 121 did 
proceed via an SN2 inversion mechanism. As the e.e. of cs-hydroxy ester 120 was 
determined to be 97% (Scheme 59), and amide 127a was obtained with 95% d.e. 
when reacted with optically pure L-phenylalanine, it can be concluded that (R)-
succinate 114 was obtained in 97% e.e. It should be noted that samples of the C-5-
(R)-C-8-(5)-pseudodipeptides for all five C-8 substituents were prepared in high yield 
and d.e. from coupling of succinate 114 and the corresponding L-a-amino acid ester 








(R)-114 	 (S)-115a 	 (2R,2'S)-127a 




Figure 12 X-ray crystal structure obtainedfor (2R,2'S)-127a synthesised chemically 
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As illustrated in Scheme 66, base catalysed hydrolysis of the diastereomeric 
amides (2R,2'RS)-127a-e proceeded in quantitative yield; subsequent cyclisation 
using EDCI in acetonitrile furnished the desired oxazolone substrates 129a-e in good 
to excellent yield (Table 24). The characteristic carbonyl stretch at -4818 cm' was 
observed in the infrared spectra of all oxazolone products. In the 'H nmr spectra, 
oxazolone formation was accompanied by the loss of the N-fl  signal. These 
oxazolones were considered to be relatively unstable and were used immediately, or 
stored in the freezer at -26 °C. The low yield obtained for the cyclisation of the tert-
leucine derived acid 128e appeared to be due to cleavage of the tert-butyl ester as a 
results of prolonged reaction conditions (see experimental). From the 'H and 13C nmr 
of the crude hydrolysis product 128e, it was evident that a mixture of four 
compounds (two sets of diastereomers) was obtained in an almost equal ratio. A pure 
sample of acid 128e was obtained by repeated trituration of the undesired diacid. 
Cyclisation of crude hydrolysis product 128e, followed by purification by column 





N..CO2CH3 	 NCOH 







Scheme 66 Reagents and conditions: ii. THF:H20 (1:1), LiOH (2.0 equiv.), room temp., iii. CH 3CN, 
EDCI, room temp. 
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Compound 	 R 	 128 Yield/ % 	 129 Yield! % 
a 	 CH2Ph 100 86 
b 	 CH(CH3)2 100 81 





e 	 C(CH3)3 iooa 52 
a) Product was a mixture of desired product and tert-butyl ester cleavage product (1:1) 
Table 24 Synthesis of2-alkyl-5(4H)-oxazolone substrates 129a-e 
3.5.0. Dynamic kinetic resolution of novel 5(411)-oxazolones 
3.5.1. Initial studies 
The first substrate tested was the phenylalanine derived oxazolone 129a (Scheme 
67). The compound was subjected to both sets of optimised conditions developed in 
Chapter 2, and to both the lipases Novozyme ® and Lipozyme®. The results in Table 
25. can be directly compared with those obtained in Chapter 2, where the C-2 
substituent was a phenyl group. 
Ph 









Scheme 67 Reagents and conditions: i. Solvent, (Et3N, (0.25 equiv.)), lipase, CH30H (2.0 equiv.), 37 
The use of acetonitrile as solvent was detrimental to the rate of reaction. In the case 
of Novozyme®, entry 2, a good yield of 88% was obtained but this figure is based on 
the recovery of 25% starting oxazolone 129a. Under identical reaction conditions, 
but using Lipozyme®, entry 5, only a 47% yield was obtained with 24% recovery of 
starting material after a period of 48 days These results reinforce the hypothesis from 
Chapter 2 that the use of acetonitrile as solvent causes a conformational change in 
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the lipase that results in a decrease in the size of the active site of the lipases. The 
introduction of a more complex C-2 substituent, which also contains an additional 
chiral centre, imposes greater restrictions on the fit of the substrate into the active site 
of the enzyme. 
Entry Solvent Et 3N Lipase Time! days Yield! % d.e.! % 
toluene yes Novozyme 4 85 81 
2 acetonitrile no Novozyme® 10 888 78 
3 tBuOMe yes Novozyme® 2 90 79 
4 toluene yes Lipozyme® 1 73 58 
5 acetonitrile no Lipozyme® 48 478 55 
a) Yield based on recovered starting material 
Table 25 Results obtained for the meihanolysis of5('4H)-oxazolone 129a with Novozvme® and 
Lipozvme ® 
The d.c. for the Novozyme®  and  Lipozyme®  reactions were consistent under the 
conditions studied, within the error of analysis (±5% by nmr); with Novozyme ® 
producing the higher d.e. of 80% compared to 55% for Lipozyme®. The use of tert-
butyl methyl ester as solvent with Novozyme ® did enhance the rate, as predicted from 
the results in Chapter 2, but had no positive effect on the d.e. of the product. By 
comparison of the 'H nmr of the methyl esters obtained in Table 25 with the 'H nmr 
of (2R.2'S)-127a synthesised chemically. (Scheme 65), it was ascertained that the 
products had the (S) conformation at C-8. This was proved conclusively by obtaining 
a X-ray crystal structure (See Appendix II for data) of the Novozyme ® mediated 
methanolysis product shown in Figure 13. 
(2R.,2'S)-127a 
Figure 13 X-ray crystal structure obtained for enzymatic methanolysis product (2R,2S)-1 27a 
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3.5.2. The effect of alkyl chain length of the nucleophile 
In a similar process as described in Chapter 2, the alcohol nucleophile chain 
length was varied in the biotransformation as illustrated in Scheme 68. All the 
reactions were carried out with N ovozyme® and the results reported in Table 26. 
Again, as discovered in Chapter 2, the d.e. of the product varied very little in going 
from a methyl to n-butyl alkyl chain. A range of ± 4% was observed which is within 
the accuracy of the 'H nrnr measurements (± 5%). The rate and high yield for each 











Scheme 68 Reagents and conditions: i. Toluene, Et3N, (0.25 equiv.), Novozyme®, ROH (2.0 equiv.), 
37°C 
Compound R Time! days Yield! % d.c.! % 
(2R,2'S)-127a CH3 4 85 81 
130 CH3CH2 3 76 84 
131 CH3CH2CH2 3.5 84 84 
132c CH3CH2CH2CH2 3.5 85 80 
Table 26 Effect of alkyl chain length of the nucleophile on d.e. of the product 
3.5.3. Testing of remaining substrates 
The remaining 5(411)-oxazolone substrates 129b-e were tested with both 
Lipozyme® and Novozyme® (Scheme 69) and the results, collected in Table 27. The 
results indicate the following trends. From analysis of the results obtained for the 
simple C-4 alkyl substituents, where R= iso-propyl and iso-butyl, entries 1-4, it can 
be seen that the Novozyme®  mediated reactions proceeded at a faster rate than the 
corresponding Lipozyme®  reactions. The choice of enzyme had little effect on the 
yield. In all four reactions, excellent yields of 87-96% were obtained. 
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tBuOC H N CO2CH3 
OR 
129b-e 	 (2R,2'5)-127b-e 
Scheme 69 Reagents and conditions: i. Toluene, Et3N, (0.25 equiv.), lipase, CH3OH (2.0 equiv.), 37 
OC 
Compound R Lipase Time! days Yield! % d.e./ % 
(2R,2'S)-127 
b CH2CH(CH3)2 Novozyme® 2 96 86 
b CH2CH(CH3)2 Lipozyme® 12 96 54 
c CH(CH 3)2 Novozyrne® 11 93 75 
C CH(CH 3)2 Lipozyme® 29 87 27 
d TN-10 Novozyme® 	13 - 	84 	74 
H 
CH2-11---7( 
d 	 Lipozyme® 	13 	89 	7 
H 
e 	 C(CH3)3 	Lipozyme® 	28 	12(44) 	72 
e 	 C(CH3)3 	Lipozyme®b 28 	5' 	- 
a) Yields in parentheses are based on recovered 5(4R)-oxazolones, b) n-Butanol (2.0 equiv.) as nucleophile, c) 
yield based on conversion as calculated from 'H nrnr integrals. 
Table 27 Results obtained for the methanolysis of 2-alkyl-4-substituted-5(4H)-oxazolones 129b-e 
On examination of the d.e. of each product, the N ovozyme® mediated reactions again 
produced the best optical resolution product. In the case of the indolemethylene side 
chain, high yield and good d.e. was also obtained with Novozyme ®, in contrast to 
Lipozyme® which produced almost racemic material (entries 5 and 6 respectively). 
In the case of tert-butyl side chain it was decided not to attempt the Novozyme ® 
mediated reaction due to the extremely poor results obtained with the equivalent 
substrate where the C-2 substituent was a phenyl ring. Instead, the Lipozyme ® 
reaction was investigated with methanol and n-butanol as the nucleophile. A d.c. of 
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72% was obtained for the reaction with methanol, but only a 12% yield (44% based 
on recovered starting oxazolone) was achieved after 28 days (entry 7). In the case of 
the n-butanol reaction, only 5% conversion was observed by examination of the 
crude 'H nJTlr (200 MHz, CDC1 3) after 28 days, therefore the reaction was 
abandoned. If all the d.e. results obtained in Table 27 are compared with there 
counterparts in Chapter 2, it can be seen that the chiral induction obtained at C-4 in 
reduced by 10-20% with the introduction of the chiral C-2 substituent. It is 
speculated that this effect is due to an increase in the steric interactions of the C-2 
substituent with the active site of the lipase. 
3.6.0. Introduction of methyl amide functionality 
The desired MMPI targets 94 all contain a methylamide functionality adjacent to 
the stereocentre at C-S (numbered as in Figure 12). Using the biotransformation 
product (2R,2'S)-127a from Table 25, entry 1, and the previously employed 
hydrolysis and peptide coupling conditions, (method (ii.)) with methyl amine as the 
nucleophile, the methyl amide 134 was synthesised in 85% for the two steps. On 
examination of the resulting 'H nmr (600 MHz) it was discovered that the d.e. had 
fallen from 81% to 42%. It is hypothesised that the cause of epimerisation was the 
reformation of the oxazolone 129a. 
H 	
i.-ii. 
tBuQC)y  N CO2CH3 	 tBUOC2y N CONHCH3 
Ph 	 Ph 
(2R,2'5)-127a 134a 42% d.e. 
Scheme 70 Reagents and conditions: i. THF:H20 (1:1), LiOH, room temp., ii. DMF, HOBt, TBTU, 
DIPEA, CH3NH2 .HCI, room temp. 
In an attempt to prevent reformation of the oxazolone, the Weinreb' 22" 23 amide 
approach was considered. Under Weinreb conditions, the ester (2R,2'5)-127a is 
reacted with the desired amine in the presence of trimethylaluminium to furnish the 
diamide 134a as illustrated in Scheme 71. It has recently been demonstrated that 
when such conditions were employed in the synthesis of peptides where the amine is 
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an unprotected a-amino acid, there is a 10-20% racemisation of the chiral centre 
alpha to the substrate ester. The cause of racemisation is attributed to the formation 
of the corresponding oxazolone.' 24 Unfortunately, due to lack of time, no further 




H 	 + 	Al 
I 
NCO2CH3 H3C' 'NHCH3 	
tBuQC 	
H -_ yNCONHCH3 
0 R 	 0 R 
(2R,2'S)-127a-e 	 134a-e 
Scheme 71 Reagents and conditions: Benzene, reflux 
3.7.0. Conclusions 
A high yielding synthesis of novel, chiral C-2-substituted-4-substituted-5(4H)-
oxazolones 129a-e was achieved, and their application in a dynamic kinetic 
resolution process under lipase mediated conditions in organic solvent proved 
successfuL Excellent yields as high as 96%, and high diastereomeric excesses up to 
86% were achieved for a range of C-4 substituents with the use of Novozyme®.  The 
best results were obtained when the C-2 substituent was either benzyl or iso-butyl, 
again demonstrating the apparent advantage of the incorporation of a methylene 
spacer into the C-4 side chain to be resolved by the lipase. The choice of solvent also 
proved important. The use of acetonitrile resulted in a large decrease in the rate of 
reaction compared to the corresponding reaction in toluene with triethylamine. It is 
speculated that the decreased reaction rate in acetonitrile is a result of a 
conformational change in the lipase, tightening the active site channel, thus limiting 
access to the substrate. 
3.8.0. Future work 
Obviously future work would involve the completion of the synthesis of the 
MMPI's. The introduction of the methyl amide bond could be realised utilising an 
enzyme such as papain or Subtilisin. Instead of using the methyl ester as the 
substrate more success may be obtained utilising the corresponding acid as depicted 
in Scheme 72. 
73 
Results and Discussion II 
	
tBuOC CQH 	 t 	
H Qc  
----- rNCONHCH3 
0 R 	 0 
Scheme 72 Reagents and conditions: i. Solvent, enzyme, CH 3NH2 
The synthesis of the MMPI's could then be completed using published procedures 
for the introduction of the hydroxamic acid moiety as illustrated in Scheme 73.125 
tBuOC 	 C0NHCH 	 H02C 	 C0NHCH 
0 R 	 0 R 
134 135 
ii. 
H0 	 C0NHCH 
H' 0 R 
94 
Scheme 73 reagents and conditions: i. TFA, room temp., ii. DMF, TBTU, HOBt, hydroxylamine, 
NMM or (a) BOP, Et3N, benzyl hydroxylamine, CH 2C12, 0-22 °C, (b) H 2 , 5% Pd on BaSO4, CH30H, 
room temp. 
On a broader level, the novel 2-substituted-5(4H)-oxazolone 136 could be utilised in 
alkylationlreduction reactions to generate oxazolones 137 with increased diversity at 
the C-4 position as discussed in Chapter 2. Subsequent dynamic kinetic resolution 
would furnish potentially new MMPI's. The approach outlined in Scheme 74 could 
also be used to generate a combinatorial library of potential MIIvIPI's on solid 
support. The tert-butyl ester functionality of oxazolone 136 could be used to tether a 
linker and resin. O-Hydroxyamines 139126  and 140 127 have recently been used as 
linkers to solid supports; cleavage resulting in the formation of the desirable 
hydroxamic acids. 
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4.1.0. General experimental 
'H and ' 3C nmr were recorded on Bruker AC 200, Varian Gemini 200, Bruker AC 
250, Bruker WH 360 or Varian UNITY INOVA 600 instruments. Chemical shifts 
OHI &) are reported in ppm and coupling constants (J) are in Hertz (Hz). Chemical 
shifts were referenced to residual undeuterated solvent present in the deuterated 
sample, i.e. CHCI3 in CDC1 3 . 
Electron Impact (El) and Chemical lonisation (CI) mass spectrometry were carried 
out on a Finnegan 4500 mass spectrometer. Fast atom bombardment (FAB) was 
performed on a Kratos MS50TC. 
Infra-red spectra were recorded on a Biorad FTS-7 or a Perkin Elmer Paragon 1000 
FT-JR spectrophotometer with the frequencies (v) measured in wavenumbers (cm'). 
Samples were measured on disposable JR Cards (Type 61 3M, polyethylene, 19 mm 
aperture), in CHCI 3 or as nujol mulls. 
Melting points were measured on a Gallenkamp melting point apparatus, and are 
quoted in °C and uncorrected. 
Chiral HPLC analysis was carried out using a Waters 486 Tunable Absorbance 
Detector and a Waters 600E Pump and Controller. Waters Millennium 
Chromatography Manager software package was used to analyse the results. A 
Chiracel OD column was used as the stationary phase eluting with hexane:iso-
propanol (9:1) with a flow rate of 0.5 mL min' unless otherwise stated. Retention 
times (R.) are quoted in minutes. 




Optical rotations were measured on an Optical Activity AA-1000 polarimeter 
(sodium 589 nm detection). Sample concentration was measured in g/100 mL and 
[a]are quoted in 10' deg cm' g'. 
Thin layer chromatography (tic) was carried out on 2.5 mm glass plates coated with 
silica gel 60 F254, with detection by UV (254 nm) fluorescence, ammonium 
molybdate, bromocresol, ninhydrin or potassium permanganate dips. 
Chromatography was carried out using silica gel 60 (Merck 9385). 
All reagents were used as supplied from commercial sources unless stated. 
Lipozyme® and  Novozyme®  were received as gifts from Novo-Nordisk and the Fluka 
Lipase Basic Kit was a gift from Fluka. Dichloromethane was distilled from calcium 
hydride while tetrahydrofuran was pre dried over sodium wire and distilled from 
sodium benzophenone ketal. Toluene was dried over sodium wire for 24 h before 
use. n-Butanol was dried, and distilled from sodium metal and stored over 4 A 
molecular sieves. Novozyme®  was crushed with a mortar and pestle and dried to 
constant weight over phosphorus pentoxide. 
4.2.0. Development of 5(4H)-oxazolone methodology 
4.2.1. General procedure for N-benzoyl DL-amino acids 95a-g 
Benzoyl chloride (1.05 equiv.) and aqueous sodium hydroxide (2M, 100 mL) 
were simultaneously added to a stirring solution of DL-amino acid (1.00 equiv.) in 
aqueous sodium hydroxide (2M, 10 mL per 1.00 g of amino acid) at 0 °C over a 
period of 10 mm. The resulting solution was stirred at room temperature for 30 mm. 
The reaction mixture was cooled to -10 °C and conc. hydrochloric acid added until 
precipitation was complete. The mixture was stirred for a further 1 h, filtered, dried, 




4.2.2. N-Benzoyl-DL-phenylalanine 95a 
o 	,Ph 
PhN CO2H 
The general procedure outlined above (4.2.1) with DL-phenylalanine (10.00 g, 
60.0 mmol) and benzoyl chloride (7.38 mL, 63.6 mmol, 1.05 equiv.) was followed 
and gave the title compound as a colourless solid (12.1 g, 74%). 
Mp 186-188 °C (EtOH:water), Lit. 128  187-189 °C; u(nujol)/cm' 3322 (NH), 2800-
2500 (acid OH), 1717 (acid C=O), 1612, 1536 (CONH); oH ((CD3)2S0; 200 MHz), 
12.76 (1 H, br s, 011), 8.73 (1 H, d, J 8.0, Nil), 7.83-7.77 (2 H, m, CL),  7.71-7.41 
(3 H, m, CHar), 7.31-7.12(5 H, m, CH,), 4.60(1 H, ddd,J 11.0, 8.0 and 5.0, NHCH), 
3.18 (1 H, dd, J 16.5, 11.0, CHAHBPh), 3.08 (1 H, dd, J 16.5, 5.0, CHAHBPh); E 
((CD3)2S0; 63 MHz) 173.3, 166.6 (O 2H, ONH), 138.9, 134.1 (ipso-Ar), 131.5, 
129.2, 128.4, 128.3, 127.5, 126.5 (cH ar), 54.4 (HNcH), 36.4 (cH 2Ph); m/z (FAB) 
270 (90%, MH), 224 (82, M-CO 2H), 105 (85, 224-NHCHCH2Ph), 77 (72, 105-CO). 
4.2.3. N-Benzoyl-DL-leucine 95b 
Ph)LN H 
The general procedure outlined above (4.2.1) with DL-leucine (10.00 g, 76 mmol) 
and benzoyl chloride (9.29 mL, 80 mmol, 1.05 equiv.) was followed and gave the 
title compound as a colourless solid (14.07 g, 78%). 
Mp 140-142 °C, (EtOH:water), Lit. 129  141-143°C; Umax(rnijol)i'cm', 3271 (NH), 2800-
2500 (acid OH), 1720 (acid C=O), 1634, 1536 (CONH); OH ((CD3)2S0; 200 MHz) 
8.59 (1 H, d, J 8.0, NH), 7.92-7.86 (2 H, m, CH), 7.58-7.42 (3 H, m CL),  4.44 (1 
H, m, NHCH), 1.85-1.55 (3 H, m, CH2CH(CH3)2 and CH2CH(CH3)2), 0.92 (3 H, d, J 
6.0, CU3ACHCH3H), 0.88 (3 H, d, J 6.0, CH3ACHCH3B); ö ((CD 3)2 S0; 63 MHz) 
174.4, 166.6 (cO 2H, cONR), 134.1 (ipso-Ar), 131.5, 128.3, 127.6 (-CH), 51.0 
(HNCH), 24.7 (cH(CH 3 )2) 23.1, 21.3 (CH(cH 3)2); m/z (FAB), 236 (94%, MH), 190 
(82, M-CO2H,), 105 (94, 190-NHCHCH 2CH(CH3 )2 ,), 77 (76, 105-CO,). 
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4.2.4. N-Benzoyl-DL-valine 95c 
Ph 	NCO2H 
The general procedure outlined above (4.2.1) with DL-valine (10.00 g, 85 mmol) 
and benzoyl chloride (10.4 mL, 87 mmol, 1.05 equiv.) was followed and gave the 
title compound as a colourless solid (15.75 g, 83%). 
Mp 127-129 °C, (EtOH:water), Lit. 130  129.5-130.5 °C; o max(nujo cm' 3330 (OH), 
2800-2475 (acid OH), 1727 (acid C=O), 1626, 1537 (CONH); oH,  ((CD3)2SO; 250 
MHz) 12.51 (1 H, br S, 011), 8.44 (1 H, d, J 8.0, NH), 7.89 (2 H, d, J 8.0, CH,), 7.57 
7.43 (3 H, m, CH,), 4.28 (1 H, dd, J 8.0, 7.0, NHCH),  2.19 (1 H, dq, J 7.0, 
Cff(CH0 2), 0.97 (3 H, d, J 7.0, CH3ACHCH30 0.95 (3 H, d, J 7.0, CH3ACHCH3B); 
((CD3)2S0; 63 MHz) 173.3, 167.1 (0 2H, cONH), 134.3 (ipso-Ar), 131.4 128.3, 
127.8 (cHar), 58.5 (HNcH), 29.6 (cH(CH3)21 19.5 18.9 (2 x çH3); mlz (FAB) 222 
(80%, MR), 176 (97, M-CO2H, 97), 105 (100, 176-NHCHCHCH3), 77 (88, 105-
CO). 




The general procedure outlined above (4.2.1) with DL-methionine (10.00 g, 67 
mmol) and benzoyl chloride (8.17 mL, 70 mmol, 1.05 equiv.) was followed and gave 
the title compound as a colourless solid (12.78 g, 75%). 
Mp 146-148 °C, (EtOH:water), Lit. 131  146-149 °C; u o (nujol)/cm' 3320 (NH), 2800-
2500 (acid OH), 1717 (acid C=O), 1626, 1537 (CONH); OH ((CD3)2 S0; 200 MHz) 
8.63 (1 H, d, J8.0, NH), 7.90-7.84(2 H, m, CH), 7.53-7.41 (3 H, m, CH), 4.51 (1 
H, ddd, J 8.0, 7.5, 7.0, NHCH),  2.59-2.47 (2 H, m partially obscured by DMSO peak, 
CH2CH2S), 2.05 (2 H, dd, J 7.5, CU2S), 2.03 (3H, s, SCH3); 8 ((CD 3)2S0; 63 MHz) 
173.6, 166.9 (c02H, cONH), 134.1 (ipso-Ar), 131.6, 128.4, 127.6 (CH), 51.8 
(HNCH), 30. 4, 30.3 (cH 2cH2S), 14.7 (CH 3); m/z (FAB) 254 (100%, MW), 206 (26, 
M-SCH3), 105 (85, 206-NHCH(CH2CH2SCH3)CO2H), 77 (50, 105-CO). 
79 
Experimental 
4.2.6. IvaBenzoy1DLtryptophan  95e 
j 
Ph N CO2H 
H 
The general procedure outlined above (4.2.1) with DL-tryptophan (7.70 g, 37.7 
mmol) and benzoyl chloride (4.60 mL, 40 mmol, 1.05 equiv.) was followed and gave 
the title compound as a colourless solid (8.85 g, 76%). 
Mp 192-194 °C, (EtOH:water), Lit) 32 192-193 °C; u(nujol)/cm' 3392 (indole 
NH), 3359 (amide NH), 2800-2500 (acid OH), 1729 (acid C=O), 1628, 1547 
(CONH); 6H ((CD3)2S0; 250 MHz); 10.85 (1 H, d, J 2.0, NlijndoIe), 8.67(1 H, d, J 8.0, 
Nifam ide), 7.86-7.80 (2 H, m, CH,), 7.62-7.59 (1 H, m, Cfl r), 7.56-7.31 (4 H, m, 
CL), 7.22(1 H, d,J2.5, CL),  7.10-6.96(2 H, m, CH,), 4.68 (1H, ddd,J 10.0, 8.0, 
5.0, NHCH), 3.31 (1 H, dd, J 14.5, 5.0, CffAHBIndole), 3.23 (1 H, dd, J 14.5, 10.0, 
CHAUBIndole); 5c ((CDSO; 63 MHz) 173.8, 166.6 (O 2H, cONH), 136.3, 134.1 
(ipso-Ar), 131.4, 128.4, 127.5 (cHar), 127.3 (ipso-Ar), 123.7, 121.1, 118.5, 118.3, 
111.6 (cHar), 110.6 (ipso-Ar), 53.9 (HNcH), 26.8 (çH 2); m/z (FAB) 331 
(100%,[M+Na]), 309 (57, MH), 263 (51, M-0O2H), 105 (62, 263-
NHCHCH2Ind01e), 77 (54, 105-CO). 
4.2.7. N-Benzoyl-DL-alanine 95f 
Ph 
A 
 N 1CO2H 
The general procedure outlined above (4.2.1) with DL-alanine (10.00 g, 112 
mmol) and benzoyl chloride (13.7 mL, 118 mmol, 1.05 equiv.) was followed and 
gave the title compound as a colourless solid (15.28 g, 70%). 
Mp 164-165 °C, (EtOH:water), 165-166 °C 133 ; o(nujol)/cm' 3367 (NH), 2800-
2500 (acid OH), 1723 (acid C=O), 1662, 1546 (CONH); 8H  ((CD3)2 S0; 200 MHz) 
8.65 (1 H, d, J 7.5, Nfl),  7.89-7.84 (2 H, m, CHar), 7.53-7.40 (3H, m, CL),  4.43 (1 
H, dq,J7.5, NHCII),  1.37(3 H, d,J7.5 CR3); 6C ((CD 3)2 S0; 63 MHz) 174.4, 166.4 
(c02H, cONH), 134.1 (ipso-Ar), 131.6, 128.4, 127.6 (cH), 48.3 (HNcH), 14.7 ( 
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H3); mlz (FAB) 194 (100%, MH), 148 (35, M-0O2H), 105 (97, 148-NHCHCH 3), 
77 (97, 105-CO). 
4.2.8. N-Benzoyl-DL-tert-leucine 95g 
Ph NCO2H 
The general procedure outlined above (4.2.1) with DL-tert-leucine (1.00 g, 7.6 
mmol) and benzoyl chloride (1.43 mL, 8.4 mmol, 1.10 equiv.) was followed with 
recrystallisation from ethanol:water (1:1) and furnished the title compound as a 
colourless solid (1.46 g, 8 1%). 
Mp 165-166 °C, (EtOH:water), Lit. 134  165-166 °C; u m (nujo1)/cm' 3362(NH), 1724 
(acid C=O), 1625, 1540 (CONH); 6H  ((CD3)2 S0; 200 MHz) 8.13 (1 H, d, J8.0, NH), 
7.86-7.81 (2 H, m, CL),  7.56-7.39 (3 H, m, CHar), 4.34 (1 H, d, J8.0, NHCH), 1.02 
(9 H, s, CU3); ö ((CD 3)2S0; 63 MHz) 172.6, 167.2 (cO 2H, ONH), 134.4 (ipso-Ar), 
131.4, 128.3, 127.8 (H), 61.1 (HNcH), 33.7 (C(CH 3)3), 27.0 (C(H3)3); mlz 
(FAB) 236 (100%, MH), 190 (64, M-CO 2H), 105 (34, 190-NHCHC(CH 3)3), 77 (11, 
105-CO). 
4.2.9. General procedure for (SR)-2-phenyl-4-substituted-5(411)-
oxazolones 89a-g 
A solution of N-benzoyl DL-amino acid in 1,4-dioxane:acetic anhydride (1:1, 10 
mL per 1.00 g of N-benzoyl amino acid) was stirred at 22-60 °C until a clear solution 
was obtained. On cooling, the solution was filtered and concentrated under reduced 
pressure. The excess acetic anhydride was co-evaporated with toluene to give the 




4.2.10. (SR)-2-Phenyl-4-benzyl-5(4H)-oxazolone 89a 
Ph 
N ° 
The general procedure outlined above (4.2.9.) with N-benzoyl-DL-phenylalanine 
(5.17 g, 19.2 mmol) was followed with recrystallisation from hexane:diethyl ether 
(1:1) to give the title compound as a colourless solid (4.30 g, 89%). 
Rf (Hexane:EtOAc, 4:1) 0.62; Mp 67-69 °C, Lit. 135 68-70 °C; um (CHCl3)/cm' 1819 
(C0), 1652 (C=N); oH  (CDC13 ; 250 MHz) 7.94 (2 H, m, CH,), 7.587.40 (3 H, m, 
CH,), 7.29-7.20 (5 H, m, CHar),  4.68 (1 H, dd, J 6.5, 5.0, CHCH2), 3.32 (1 H, dd, J 
14.0, 5. 0, CHAHBPh), 3.25 (1 H, dd, J 14.0, 6.5, CHAHBPh); 8 (CDC1 3 ; 63 MHz) 
177.3 (=O), 161.7 (=N), 135.0 (ipso-Ar), 132.7, 129.4, 128.6, 128.3, 127.8, 127.1 
(CHar), 125.5 (ipso-Ar), 66.3 (H), 37.1 (cH2Ph);  m/z (FAB) 252 (100%, MH), 224 
(49, MHtCO). 
4.2.11. (SR)-2-Phenyl-4-iso-butyl-5(411)-oxazolone 89b 
Ph ° 
The general procedure outlined above (4.2.9.) with N-benzoyl-DL-leucine (2.10 g, 
8.9 mmol) was followed with recrystallisation from hexane:diethyl ether (1:1) to 
give the title compound as a colourless solid (1.58 g, 8 1%). 
Rf (Hexane:EtOAc, 8:1) 0.66; Mp 54-55 °C, Lit. 135  54-56 °C; u(nujol)/cm' 1812 
(C=O), 1653 (C=N); OH (CDC13 ; 200 MHz) 8.02-7.97 (2 H, m, CL),  7.61-7.43 (3 H, 
m, CL),  4.41 (1 H, dd, J9.0, 5.5, NCR), 2.06(1 H, ddq, J7.0, 6.5, 6.0, Cfl(CH3)2), 
1.84 (1 H, ddd, J 13.5, 7.0, 5.5, CHCHAHB), 1.69 (1 H, ddd, J 13.5, 9.0, 6.5, 
CHCHAHB), 1.03 (3 H, d, J 6.5, CJi3ACHCH3B), 1.00 (3 H, d, J 6.5, CH3CHCU38); oc 
(CDC13 ; 63 MHz) 178.9 (c=O), 161.2 (=N), 132.5, 128.6, 127.7, (CH), 125.9 
(ipso-Ar) 63.8 (NCH), 40.7 (CHH2), 25.1 (Cff(CH 3)2), 22.6, 21.9 (2x H3); m/z 
(FAB) 218 (12%, MH). 
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The general procedure outlined above (4.2.9.) with N-benzoyl-DL-valine (2.00 g, 
9.0 mmol) was followed with recrystallisation from hexane:diethyl ether (1:1) to 
give the title compound as a colourless solid (1.74 g, 95%). 
Rf (Hexane:EtOAc, 4:1) 0.61; Mp 48-51 °C, Lit."' 48-51 °C; Umax(CH 3)/cm' 1821 
(C=O), 1652 (C=N); 6 H  (CDC13 ; 200 MHz) 8.05-7.99 (2 H, m, CL),  7.61-7.44 (3 H, 
m, CH), 4.29(1 H, d,J4.5, NCH), 2.39(1 H, dqq,J7.0, 4.5, Cfl(CH3)2), 1.15(3 H, 
d, J 7.0 CH3ACHCH3B), 1.12 (3 H, d, J 7.0 CH3ACHCU3B); E (CDC1 3 ; 63 MHz) 
177.7 (c=O), 161.5 (ç=N),  132.5, 128.6, 127.7, (CHar), 125.8 (ipso-Ar) 70.6 (NH), 
31.1 (NCHH), 18.6, 17.4 (2 x H3); m/z (FAB) 204 (74%, MH), 176 (47, MW-  
CO). 
4.2.13. (SR)-2-Phenyl-4-(2-methylsulfanyl-ethyl)-5(4H)-oxazolone 89d 
(s 
Ph' 
The general procedure outlined above (4.2.9.) with N-benzoyl-DL-methionine 
(2.50 g, 9.9 mmol) was followed and the crude product purified by column 
chromatography, eluting with hexane:diethyl ether (7:1) to give the title compound 
as a colourless oil (1.31 g, 56%). Spectroscopic data was in agreement with 
previously reported results. 136 
Rf (Hexane:EtOAc, 1:1) 0.40; u m (CHCl3)/cm' 1825 (C=O), 1653 (C=N); 8 H 
(CDC13 ; 200 MHz) 8.02-7.99 (2 H, m, CH,), 7.98-7.43 (3H, m, CH,), 4.69 (1 H, dd, 
J 7.5, 6.0, NCU),  2.74 (2 H, t, J 7.0, CH2 S), 2.29 (1 H, ddd, J 14.5, 7.0, 6.0, 
CHCHAHBCH2), 2.22 (1H, ddd,J 14.5, 7.5, 7.0, CHCHAUBCH2), 2.11 (3 H, s, Sd 3); 
c (CDCl; 63 MHz) 178.26 (=O), 161.8 (ç=N),  132.6, 128.6, 127.7, (H), 125.6 
(ipso-Ar) 63.5 (NH), 30.2, 29.9 (cH2H2S), 14.9  (çH3); m/z (FAB) 236 (42%, 
MH), 208 (32, MH-CO). 
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4.2.14. (SR)-2-Phenyl-4-(1H-indol-3-ylmethyl)-5(41f)-oxazolone 89e 
Ph" 
The general procedure outlined above (4.2.9.) with N-benzoyl-DL-tryptophan 
(2.00 g, 6.5 mmol) was followed with recrystallisation from ethyl acetate to give the 
title compound as a colourless solid (669 mg, 36%). 
Rf (Hexane:EtOAc, 1:1) 0.75; Mp139-142 °C, Lit. 137  142 °C; um (CHCl3)/cm' 3477 
(NH), 3018 (CHar), 1817 (C=O), 1651 (C=N); 6 H  (CDC13 ; 200 MHz) 8.05 (1 H, br s, 
Nijindole) 7.89 (2 H, d, J 7.0, CEPh), 7.74-7.70 (1 H, m, Cfli ndo le), 7.56-7.37 (3 H, m, 
Cffph), 7.3-7.25 (2 H, m, CHindo le), 7.18-7.08 (2 H, m, CUi ndole), 4.76 (1 H, dd, J 6.0, 
5.5, NCFL),  3.51 (1 H, dd, J 15.0, 5.5, CHCUAHB), 3.42 (1H, dd, J 15.0, 6.0, 
CHCHAHB); 6 (CDC13 ; 63 MHz) 177.9 (C=O), 161.6 (c=N), 135.7 (ipso-Ar), 132.4, 
128.5, 127.65 (CHar), 127.2, 125.6 (ipso-Ar), 123.3, 121.8, 119.3, 118.9, 110.9 
(CHar), 66.4 (NCH), 27.1 (H 2); m/z (FAB) 291 (67%, MH), 263 (33, MH-CO), 130 
(100, CH2Indole), 105 (51 (PhCO). 
4.2.15. (SR)-2-Phenyl-4-methyl-5(4H)-oxazolone 89f 
N ° 
Ph' 
The general procedure outlined above (4.2.9.) with N-benzoyl-DL-alanine (2.00 g, 
10.3 mmol) was followed and the crude product purified by column chromatography, 
eluting with hexane:ethyl acetate (4:1) to give the title compound as a colourless 
solid (1.79 g, 99%). 
Rf (Hexane:EtOAc, 4:1) 0.52; Mp 36 °C, Lit. 135 37-38 °C; u m (CHCl3)/cm' 1825 
(C=O), 1653 (C=N);6 H (CDC13 ; 200 MHz) 8.02-7.96 (2 H, m CH), 7.61-7.43 (3 H, 
m, CH), 4.44(1 H, q, J7.5, NC), 1.58 (3 H, d, J7.5, Cff3); ö (CDC1 3 ; 63 MHz) 
178.6 (CO), 161.3 (EN), 132.5, 128.5, 127.6 (CH ar), 125.4 (ipsoAr), 60.7 (CH), 
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16.6 (H3); m/z (FAB) 176 (31%, MH), 148 (11, MHtCO), 105 (100, 148-
NHCHCH3). 




The general procedure outlined above (4.2.9.) with N-benzoyl-DL-tert-leucine 
(1.25 g, 5.3 mmol) was followed and the crude product purified by column 
chromatography, eluting with hexane:diethyl ether (14:1) to give the title compound 
as a colourless solid (0.94 g, 82%). 
Rf (Hexane:EtOAc, 6:1) 0.70; Mp 72-73 °C, Lit. 134  73-74 °C; )max(CHC13)/'m' 1820 
(C=O), 1656 (C=N)6 H (CDC13 ; 200 MHz) 8.01 (2 H, d, J 7.0, CL),  7.60-7.43 (3 H, 
m, CIj r), 4.07 (1 H, s, NC), 1.13 (9 H, s, C113); & (CDC13 ; 63 MHz) 176.8 (c=O), 
161.1 (=N), 132.5, 128.6, 127.8 (CHar), 125.9 (ipso-Ar), 73.9 (NH), 35.8 
(c(CH3)3), 26.1 (C(cH 3)3); m/z (FAB) 218 (56%, MH), 190 (24, MH-CO), 105 
(100, 1 90-NHCHC(CH 3)3). 
4.2.17. General procedure for N-benzoyl-DL-amino acid esters 
To a solution of(RS)-2-phenyl-4-substituted-5(4R)-oxazolones 89a-g (100 mg) in 
alcohol (5 mL) was added a catalytic volume of conc. hydrochloric acid (30 !.LL). The 
solution was heated under reflux overnight, cooled and the solvent removed under 
reduced pressure. The crude product was purified by column chromatography as 
described, furnishing the desired ester as a colourless solid unless stated. 





The general procedure outlined above (4.2.17.) with oxazolone 89a in methanol 
was followed. Product purified by column chromatography, eluting with 
hexane:ethyl acetate (4:1), (96 mg, 85%). 
Rf (Hexane:EtOAc, 6:1) 0.12; R, 19.57 and 25.72; Mp 85-87 °C, Lit. 138 86.5-87.5 °C; 
Umax(CHCl3)/cm' 3410 (NH), 3029 (CH) 1740 ester C=O), 1644, 1526 (CONH); oH 
(CDC13 ; 250 MHz) 7.74-7.70 (2 H, m, Cflar), 7.53-7.28 (3 H, m, CL),  7.27-7.21 (3 
H, m, CHar), 7.15-7.11 (2 H, m, CHar), 6.63 (1 H, d, J7.0, NH), 5.09 (1 H, ddd, J 
7.0, 6.0, 5.5, NHCH), 3.75 (3 H, s, 0C113),  3.29 (1 H, dd, J 14.0, 6.0, CHCHACHB), 
3.23 (1 H, dd, J 14.0, 5.5, CHCHACHB); 8 (CDC1 3 ; 63 MHz) 171.9, 166.7 (0 2CH31  
ONH), 135.7 133.7 (ipso-Ar), 131.6, 129.1, 128.4, 127.0, 126.8 (H), 53.4 
(HNcH), 52.3 (0cH 3), 37.7 (HA); m/z (FAB) 284 (68%, MH), 268 (13, M-Me), 
224 (73, 268-0O2), 105 (100, 224-NHCHCH 2Ph), 77 (37, 105-CO). 
4.2.19. N-Benzoyl-DL-phenylalanine ethyl ester 98a 
o çPh 
PhN 	CO2Et 
The general procedure outlined above (4.2.17.) with oxazolone 89a in ethanol was 
followed. Product purified by column chromatography, eluting with hexane:ethyl 
acetate (4:1), (96 mg, 85%). 
R (Hexane:EtOAc, 6:1) 0.18; R, 12.13 and 16.78; Mp 90-92 °C, Lit. 139 94-95 °C; 
um (CHCl3)/Cm' 3321 (NH), 3029 (CH ar), 1740 (ester C=O), 1641, 1534 (CONH); 
8H (CDC13 ; 250 MHz) 7.75-7.70 (2 H, m, CHar), 7.537.37 (3 H, m, CL)  7.32-7.20 
(3 H, m, CL),  7.16-7.12(2 H, m, CHar), 6.65(1 H, d,J7.0, NH), 5.06(1 H, ddd,J, 
6.0, 5.5, NIHCU), 4.22 (2 H, q, J 7.5, OCfl2), 3.28 (1 H, dd, J 14.0, 6.0, CUACHBPh), 
3.24 (1 H, dd, J 14.0, 5.5, CHACUBPh); 1.28 (3 H, t, J 7.0, CH2CH3); Oc (CDC1; 63 
MHz) 171.4, 166.6 (c02CH2, CONH), 135.7 133.8 (ipso-Ar), 131.6, 129.2, 128.4, 
128.4, 127.0, 126.8 (H), 61.5 (ocH 2), 53.4 (HNH), 37.7 (cHPh), 14.0 
(CH2CH3); m/z (FAB) 298 (49%, MH), 252 (30, M-OEt), 224 (73, 252-CO), 105 
(100, 224-NHCHCH 2Ph), 77 (45, 105-CO). 
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4.2.20. N-Benzoyl-DL-phenylalanine propyl ester 99a 
o 	Ph A
PhN CO2p1 
The general procedure outlined above (4.2.17.) with oxazolone 89a in n-propanol 
was followed. Product purified by column chromatography, eluting with 
hexane: ethyl acetate (8:1), (109 mg, 88%). 
Rf (Hexane:EtOAc, 8:1) 0.18; R 11.67 and 17.47; Mp 69-69 °C; u m (CHCl3)/cm' 
3332 (NH), 3030 (CHar), 1736 (ester C=O), 1647, 1522 (CONH); 6H (CDC13 ; 200 
MHz) 7.75 (2 H, m, CH), 7.55-7.40 (3 H, m, CHar), 7.38-7.23 (3 H, m, CH), 7.21 
7.12 (2 H, m, CHar), 6.6 (1 H, d, J 7.0, NH), 5.08 (1 H, ddd, J 7.0, 6.0, 5.5, NHCH), 
4.11 (1 H, dt, J 10.5, 6.5, OCHAHBCH2), 4.10 (1 H, dt, J 10.5, 6.5, OCHAHBCH2). 
3.28 (1 H, dd, J 13.5, 6.0, CHAHBPh), 3.24 (1 H, dd, J 13.5, 5.5, CHAHBPh), 1.66 (2 
H, tq, J7.5, OCH2CH2), 0.93 (3 H, t, J7.5, CEO; E (CDC1 3 ; 63 MHz) 171.5, 166.7 
(c02CH2 1 cONH), 135.7 133.8 (ipso-Ar), 131.5, 129.2, 128.4, 126.9, 126.8 (CH), 
67.0 (OH2), 53.4 (HNH), 37.8 (cH 2Ph), 21.7 (OCH2cH2), 10.2 (CH2CH3); m/z 
(FAB) 312 (81%, MH), 252 (30, M-OPr), 224 (76, 252-CO), 105 (100, 224-
NHCHCH2Ph), 77 (46, 105-CO), Found (FAB) 312.1592, C 19H22NO3 requires 
312.1600. 
4.2.21. N-Benzoyl-DL-phenylalanine butyl ester 97a 
o 	,Ph 
Ph A  N CO2Bu 
The general procedure outlined above (4.2.17.) with oxazolone 89a in n-butanol 
was followed. Product purified by column chromatography, eluting with 
hexane:ethyl acetate (9:1), (121 mg, 93%). 
Rf (Hexane:EtOAc, 9:1) 0.29; R 13.70 and 17.12; u max(CHC13)/cm' 3325 (NH), 3030 
(CH), 1736 ester C=O), 1654, 1517 (CONH); H  (CDC13 ; 200 MHz) 7.74-7.70 (2 H, 
m, CH), 7.51-7.40 (3 H, m, CH,), 7.38-7.20 (3 H, m, CHar),  7.19- 7.11 (2 H, m, 
CL), 6.64 (1 H, d, J7.5, Nif), 5.07 (1 H, ddd, J7.5, 6.0, 5.5, NHCH),  4.14(1 H, dt, 
J 11.0, 6.5, OCHAHBCH2), 4.11 (1 H, dt, J 11.0, 6.5, OCHAUBCH2), 3.26(1 H, dd, J 
14.0, 6.0, CUAHBPh), 3.24 (1 H, dd, J 14.0, 5.5, CHAHBPh), 1.68-1.54 (2 H, m, 
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OCH2CU2), 1.34(2 H, septet, J7.5, CH2CH3), 0.92 (3 H, t, J7.5, Cff3); 8c (CDC13 ; 
63 MHz) 171.5, 166.6 (02CH21  ONH), 135.8, 133.8 (ipso-Ar), 131.5, 129.2, 
128.4, 128.4, 126.9, 126.8 (H), 65.3 (ocH 2), 53.4 (HNH), 37.8 (HA), 30.3, 
18.9 (0CH2 H2cH2), 10.2 (CH2CU3); mlz (FAB) 326 (94%, MH), 252 (25, M-
OBu), 224 (53, 252-CO), 105 (100, 224-NHCHCH2Ph), 77 (35, 105-CO), Found 
(FAB) 326.1579, C 20H24NO3 requires 326.1756. 
4.2.22. N-Benzoyl-DL-phenylalanine pentyl ester 100a 
o 	Ph A
PhN CO2Pn 
n-Pentanol (87 p.!, 0.80 mmol, 2.0 equiv.) was added to a solution of oxazolone 
89a (100 mg, 0.40 mmol) in toluene (8 mL). Conc. hydrochloric acid (30 PL) was 
added, and the solution heated under reflux for 6 h. On cooling, the solvent was 
removed under reduced pressure and the crude product purified by column 
chromatography, eluting with hexane:ethyl acetate (10:1), to furnish the desired 
product as a colourless wax (129 mg, 95%). 
Rf (Hexane:EtOAc, 8:1) 0.48; R 11.20 and 13.08; Umax(CHC1 3)km t 3432 (NH), 3030 
(CH), 1735 (ester C=O), 1658, 1515 (CONE); oH  (CDC13 ; 200 MHz) 7.77-7.70 (2 
H, in CL),  7.62-7.37 (3 H, m, CUar), 7.34-7.21 (3 H, m, CUar), 7.19-7.11 (2 H, in 
CH,), 6.62 (1 H, d, J7.5, NH), 5.08 (1 H, ddd, J7.5, 6.0, 5.5, NHCH),  4.14 (1 H, dt, 
J, 10.5, 6.5, OCFIACHBCH2), 4.12 (1 H, dt, J, 10.5, 6.5, OCHACHBCH2), 3.26 (1 H, 
dd, J 14.0, 6.0, CHAHBPh), 3.24 (1 H, dd, J, 14.0, 5.5, CHAHBPh), 1.63 (2 H, m, 
OCH2CII2), 1.32 (4 H, m, CH2(C112)2CH3), 0.90 (3 H, t, J 6.5, CU3); Oc (CDC1 3 ; 63 
MHz) 171.5, 166.6 (02CH2, ONH), 135.8, 133.8 (ipso-Ar), 131.6, 129.2, 128.4, 
128.4, 126.9, 126.8 (H), 65.6 (OH2), 53.4 (HINH), 37.8 (cH 2Ph), 28.0, 27.8, 
22.1 (OCH2 H2 H2 H2), 13.8 (CH2CH3); m/z (FAB) 340 (93%, MH), 252 (53, M-
OPen), 224 (77, 252-CO), 120 (100, 224-CHCH 2Ph), 105 (68, 120-NH), 77 (21, 105-
CO), Found (FAB) 340.1903, C 21 H26NO3 requires 340.1913. 
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4.2.23. N-Benzoyl-DL-phenylalanine iso-propyl ester 101a 
o f Ph 
PhN 	CO2'Pr 
The general procedure outlined above (4.2.17.) withoxazolone 89a in iso-
propanol was followed. Product purified by column chromatography, eluting with 
hexane:ethyl acetate (8:1), (114 mg, 92%). 
Rf (Hexane:EtOAc, 4:1) 0.50; R 1 13.00 and 17.00; Mp 97-99 °C; o m (CHCl3)/cm' 
3332 (NH), 3030 (CH), 1737 (ester C=O), 1644, 1533 (CONH); oH (CDC13 ; 200 
MHz) 7.75-7.70 (2 H, m, CL),  7.61-7.37 (3 H, m, CH,), 7.33-7.20 (3 H, m, CL), 
7.18-7.13 (2 H, m, CL),  6.62 (1 H, d, J7.5, NH),  5.11-4.95 (2 H, m, NHCU and 
Cff(CH0 2), 3.26 (1 H, dd, J 6.0, 13.5, CHAHBPh), 3.23 (1 H, dd, J 13.5, 6.5, 
CHAUBPh), 1.25 (3 H, d, J 6.5, CHCH3), 1.24 (3 H, d, J 6.5, CHCH3); O (CDCl; 63 
MHz) 171.0, 166.6 (02CH, ONH), 135.8, 133.9 (ipso-Ar), 131.5, 129.3, 128.4, 
128.4, 126.9, 126.8 (CH ar), 69.4 (OCH), 53.5 (HNCH), 37.8 (CH2Ph), 21.6, 21.5 
(CH(CH3)2); m/z (FAB) 312 (63%, MH), 252 (25, M-OP?), 224 (80, 252-CO), 120 
(88, 224-CHCH2Ph), 105 (100, 120-NH), 77 (69, 105-CO), Found (FAB) 312.1594, 
C, 9H22NO3 requires 312.1600. 
4.2.24. N-Benzoyl-DL-leucine methyl ester 96b 
PhN 	CH3 
The general procedure outlined above (4.2.17.) with oxazolone 89b in methanol 
was followed. Product purified by column chromatography, eluting with 
hexane:ethyl acetate (6:1), (92 mg, 80%). 
Rf (Hexane:EtOAc, 8:1) 0.14; R 9.63 and 13.28; Mp 94-96 °C, Lit. 138 95-96 °C; 
Umax(Card)km 3317 (NH), 3030 (CH ar), 1747 (ester C=O), 1641, 1534 (CONH); 0H 
(CDC1 3 ; 200 MHz) 7.82-7.76 (2 H, m, CL),  7.54-7.37 (3 H, m, CL), 6.59 (1 H, d, 
J 8.5, NH), 4.55 (1H, ddd, 8.5, 5.5, NHCH), 3.74 (3 H, s, OCfl3),  1.69 (3 H, m, 
CU2CH and CH2CH), 0.97 (3 H, d, J 6.5, CH3ACHCH3B), 0.96 (3 H, d, J 6.5, 
CH3ACHCH3B); Oc (CDC1 3 ; 63 MHz) 173.5, 167.0 (CO2CH31 CONH), 133.8 (ipso- 
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Ar), 131.5, 128.4 126.90 (cHar), 52.1 (OcH3), 51.0 (HNcH), 41.6 (cH 2CH), 24.8 
(cH(CH3)2), 22.6, 21.8 (CH(CH 3)2), m/z (FAB) 250(100%, MH), 234(11, M-CH 3), 
190 (67, 234-0O2), 105 (53, 190-NHCHCH 2CH(CH3)2), 77 (37,105-CO). 
4.2.25. N-Benzoyl-DL-leucine propyl ester 99b 
0 
Ph 	N 	Pr 
The general procedure outlined above (4.2.17.) with oxazolone 89b in n-propanol 
was followed. Product purified by column chromatography, eluting with 
hexane:ethyl acetate (8:1), (114 mg, 93%). 
Rf (Hexane:EtOAc, 8:1) 0.32; R 8.22 and 16.02; Mp 62-63 °C; u m (Card)/cm"; 
3329 (NH), 3029 (CH ar), 1743 ester (CO), 1642, 1535, (CONH); oH (CDC13 ; 200 
MHz) 7.82-7.76 (2 H, m, CHar), 7.54-7.37 (3 H, m, CH,), 6.58, (1 H, d, J 7.5, NE), 
4.84 (1H, ddd, 8.5, 7.5, 5.5, NHCH), 4.11 (2 H, t, J6.5 OC112), 1.79-1.59 (5 H, m, 
CHCH2CH, CHCH2CH, and CU2CH3), 0.99 (3 H, d, J 6.0, CH3ACHCH3B), 0.97 (3 H, 
d, J 6.0, CH3ACHCH3B), 0.95 (3 H, t, J 7.5, CH2CH3); E (CDC13 ; 63 MHz) 173.2, 
166.9 (CO2CH21  cONH), 133.9 (zpso-Ar), 131.5, 128.4, 126.9 (!CH), 66.8 (OcH2), 
51.1 (HNcH), 41.8 (CHcH2), 24.9 (cH(CH 3)2), 22.6, 22.0 (CH(cH3)2), 21.8 
(cH2CH3), 10.2 (CH2cH3); m/z (FAB) 278 (81%, MH), 218 (16, M-OPr), 190 (66, 
218-CO), 105 (100, 190-NHCHCH2CH(CH3)2), 77 (12, 105-CO), Found (FAB) 
278.1744, C 16H23NO3 requires 278.1756. 




The general procedure outlined above (4.2.17.) with oxazolone 89c in methanol 
was followed. Product purified by column chromatography, eluting with 
hexane:ethyl acetate (6:1), (87 mg, 75%). 
R1 (Hexane:EtOAc, 4:1) 0.23; R 9.55 and 11.38; Mp 84-86 °C, Lit. 140  86 °C; 
u,,,.,(nujo1)/cm' 3436 9NH), 3018 (CH), 1734 (ester C=O), 1663, 1517 (CONH); OH 
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(CDC13 ; 200 MHz) 7.84(2 H, m, CL),  7.55-7.39(3 H, m, CH), 6.63(1 H, d,J7.0, 
NH), 4.76 (1 H, dd, J 7.0, 8.5, NHCU),  3.76 (3 H, s, OCR3), 2.26 (1 H, dqq, J 7.0, 
8.5 CUCH3), 1.00 (3 H, d, J 7.0 CHC113), 0.98 (3 H, d, J 7.0 CHCH3); ö (CDC1; 63 
MHz) 172.5, 167.1 (CO2CH3
1 ONH), 134.0 (ipso-Ar), 131.6, 128.5, 126.9 (CHar), 
57.3, (NH-CH), 52.1 (OHO, 31.5 (H(CH3)2), 18.9, 17.8 (CH(H 3)2); m/z (FAB) 
236 (81%, MH), 204 (3, M-OMe), 176 (30, 204-CO), 105 (100, 176-
NHCHCH(CH3)2), 77 (25, 105-CO). 
4.2.27. N-Benzoyl-DL-valine propyl ester 99c 
Ph 	NCO2Pr 
The general procedure outlined above (4.2.17.) with oxazolone 89c in n-propanol 
was followed. Product purified by column chromatography, eluting with 
hexane:ethyl acetate (10:1), (105 mg, 8 1%). 
Rf (Hexane:EtOAc, 10:1) 0.18; R 6.43 and 8.35; Mp 53-54 °C; o m (nujol)/cm' 3432 
(NH), 3017 (CH), 1730 (ester C=O), 1663, 1517 (CONH); oH (CDCI3 ; 200 MHz) 
7.78 (2 H, M, CL),  7.50-7.33 (3 H, m, CH ar), 6.59 (1 H, d, J 9.0, NH),  4.72 (1 H, 
dd, J 9.0, 7.0, NHCH), 4. 10 (1 H,dt,J12.1, 6.5, OCHAHB), 4.04 (1 H, dt, J 12.1, 6.5, 
OCHAHB)2.21 (1 H, ddq, J 7.0, 6.5, Cfl(CH3)2) 1.63 (2 H, tq, J 7.0, OCH2CH2), 0.96 
(3 H, d, J 7.0, CH3ACHCH3B), 0.92 (3 H, d, J 7.0, CH3ACHCH3B), 0.90 (3 H, t, J 7.5, 
CH2CH3); Oc (CDC1; 63 MHz) 172.1, 167.1 (c0 2CH2 1 CONE!), 134.1 (ipso-Ar), 
131.6, 128.5, 126.9, (CHar), 66.9 ((0CH2), 57.2 (NHCH), 31.6 (Cfl(CH 3)2), 21.8 
(OCH2CH2), 18.9, 17.8 (CH(Cfl3)2),  10.3 (CH2CH3); m/z (FAB) 264 (71%, MH+), 
204 (39, M-OPr) 176 (78, 204-CO), 105 (100, 176-NHCHCH(CH 3)2), 77 (46, 105-
CO), Found (FAB) 264.1599, C 15H22NO3 requires 264.1600. 




The general procedure outlined above (4.2.17.) with oxazolone 89d in methanol 
was followed. Product purified by column chromatography, eluting with 
hexane:ethyl acetate (6:1), (98 mg, 83%). 
Rf (Hexane:EtOAc, 8:1) 0.10; R 15.08 and 20.70; Mp 85-87 °C, Lit. 131  87.5-88 °C; 
omax(Card)/cm' 3322 (NH), 3030 (CH ar), 1734 (ester C=O), 1642, 1534 (CONH); 6H 
(CDC1 3 ; 200 MHz) 7.84-7.77 (2 H, m, CH,), 7.55-7.38 (3 H, m, CH), 6.99 (1 H, d, 
J 6.5, NH), 4.92 (1 H, ddd, J 7.5, 7.0, 6.5, NHCH), 3.78 (3 H, s, 0C113), 2.57 (2 H, 
dd, J 8.0, 7.5, CH2S), 2.36-2.21 (2 H, m, CHAHBCH2 S and CHAHBCH2S), 2.09 (3 H, 
s, SCH3); 6 (CDCI 3 ; 63 MHz) 172.4, 166.9 (c0 2CH3 , cONH), 133.5 (ipso-Ar), 
131.6, 128.4, 126.9 (H), 52.4 (OH3), 51.9 (HNH), 31.4, 29.9 (cH 2 H2S), 15.3 
(SH3); m/z (FAB) 268 (96%, MH), 236 (19, M-OMe), 208 (51, 236-CO), 105 (83, 
208-NHCHCH2CH2SCH3), 77 (50, 1 05-CO). 
4.2.29. N-Benzoyl-DL-methionine propyl ester 99d 
o 
Ph 	N 	CO2Pr 
The general procedure outlined above (4.2.17.) with oxazolone 89d in n-propanol 
was followed. Product purified by column chromatography, eluting with 
hexane:ethyl acetate (8:1), (107 mg, 86%). 
Rf (Hexane:EtOAc, 8:1) 0.29; R 11.57 and 20.03; Mp 76-78 °C; o max(Card)/cm' 
3326 (NH), 3029 (CH), 1740 (ester C=O), 1643, 1534 (CONH); 8H (CDC13 ; 200 
MHz) 7.82-7.77 (2 H, m, CH), 7.54-7.38 (3 H, m, CHar), 6.98 (1 H, d, J 7.5, NH), 
4.91 (1 H, ddd, J 7.5, 7.0, 5.0, NHCH), 4.13 (2 H, t, J 7.0, OC112), 2.58 (2 H, m, 
CH2S), 2.34-2.04 (2 H, m, CHCEAHBCH2 and CHCHAHBCH2), 2.09 (3 H, s, Sd 3), 
1.69 (2 H, tq, J 7.0, 7.5, OCH2CH2), 0.95 (3 H, t, J 7.5, CH2CU3); & (CDCl; 63 
MHz) 172.0, 166.9 (0 2CH2 , cONH), 133.6 (ipso-Ar), 131.6, 128.4, 126.9 (CH), 
67.1 (OH2), 52.0 (HNcH), 31.6, 29.9 (cH 2CH2 S and CH2cH2 S), 21.7 (OCH2 H2), 
15.3 (SH3), 10.2 (CH2 H3); m/z (FAB) 296 (100%, MH), 280 (7, M-CH3), 248 
(63, 280-S), 236 (17, M-OPr), 208 (33, 236-CO), 105 (31, 208-




4.2.30. iYZBenzoylDLtryptophan methyl ester 96e 
c-NH 
PhN CO2CH3 
The general procedure outlined above (4.2.17.) with oxazolone 89e (60 mg, 0.21 
mmol) in methanol was followed. Product purified by column chromatography, 
eluting with hexane:ethyl acetate (2:1), (65 mg, 98%). 
Rf  (Hexane:EtOAc, 1:1) 0.46; R (Hexane:EtOH, 9:1) 5 0. 10 and 53.92 (not baseline 
separation); Mp 105-107 °C, Lit. 14 ' 109-110 °C; u max(CHC13)/cm'; 3475 (indole NH), 
3424 (amide NH), 3017 (CH), 1738 (ester C=O), 1656, 1519 (CONH); 6H (CDCI3 ; 
200 MHz) 8.27 (1 H, br 5, Nli(lndole)), 7.62-7.57 (2 H, m, CHar), 7.49-7.24 (5 H, m, 
CH), 7.17-6.95 (2 H, m, CHar), 6.90(1 H, d, J2.0, CH,), 6.64(1 H, d, J7.5, NH), 
5.07 (1 H, ddd, J 7.5, 5.5, 5.0, NHCH), 3.63 (3 H, S, 0Cff3), 3.45 (1 H, dd, J 15.0 
5.5, CHACHBInd01e) 3.43 (1 H, dd, J 15.0, 5.0 CHACHBIndole); ö (CDC1 3 ; 63 MHz) 
172.3, 167.0 (02CH3, ONH), 136.0, 133.5 (ipso-Ar), 131.6, 128.4 (CH), 127.4 
(zpso-Ar), 126.9, 122.8, 122.0, 119.4, 118.3, 111.3, (cH ar) 109.5 (ipso-Ar), 53.4 
(IiNcH), 52.3 (0cH3), 27.4 (CHcH2); m/z (FAB) 323 (28%, MH), 291 (2, M-
OMe), 263 (13, 291-CO), 130 (100, CH 2Indole), 105 (69, 263-NHCHCH 2Indo1e), 77 
(15,105-CO). 
4.2.31. VaBenzoy1DLtryptophan propyl ester 99e 
c-NH 
Ph 	N 	CO2Pr 
H 
The general procedure outlined above (4.2.17.) with oxazolone 89e (60 mg, 0.21 
mmol) in n-propanol was followed. Product purified by column chromatography, 
eluting with hexane:ethyl acetate (1:1), (65 mg, 89%). 
Rf (Hexane:Et20, 1:1) 0.16; R (Hexane:EtOH, 9:1) 38.75 and 41.73 (not baseline 
separation); Mp 104-106 °C; o m (CHCl3)/cm'; 3476 (indole NH), 3421 (amine NH), 
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3017 (CHar), 1736 (ester C0), 1656, 1519; 6H (CDC1 3 ; 200 MHz) 8.46 (1 H, br s, 
NH(J ndo le)), 7.70-7.66 (2 H, m, CHar), 7.59-7.21 (5 H, m, CH,), 7.177.03 (2 H, m, 
CL), 6.98(1 H, d, J2.0, NHCfl ar), 6.74(1 H, d, J7.5 Nfl),  5.15 (1 H, ddd, J7.5, 
5.5, NIHCH), 4.07 (1 H, dt, J 10.5, 6.5, OCIIACHBCH2), 4.04 (1 H, dt, J 10.5, 6.5, 
OCHACHBCH2), 3.45 (1 H, dd, J 15.5, 5.5, CflACHBIndole) 3.43 (1 H, dd, J 15.5, 
5.5, CHACHBInd01e); 1.63 (2 H, tq, J 7.5, 7.0, OCH2CU2), 0.89 (3 H, t, J 7.5, 
CH2CU3); 5c (CDC13 ; 63 MHz) 171.9, 166.9 (0 2CH3 , ONH), 136.0, 133.7 (ipso-
Ar), 131.5, 128.4 (H), 127.5 (ipso-Ar), 126.9, 122.7, 122.0, 119.4, 118.4, 111.2, 
(H), 109.7 (ipso-Ar), 53.4 (HNCH), 27.6, 21.7 (OCH 2CH2  and CHcH2), 10.1 
(CH2 H3); mlz (FAB) 351 (15%, MH), 291 (3, M-OPr), 263 (15, 291-CO), 130 
(100, CH2Indole), 105 (62, 263-NHCHCH 2Indo1e), 77 (13, 105-CO), Found (FAB) 
351.1705, C 21 H23N203 requires 351.1709. 
4.2.32. N-Benzoyl-DL-alanine methyl ester 96f 
Ph 	1CO2CH3 
The general procedure outlined above (4.2.17.) with oxazolone 89f in methanol 
was followed Product purified by column chromatography, eluting with hexane:ethyl 
acetate (6:1), (97 mg, 82%). 
Rf (Hexane:EtOAc, 4:1) 0.13; R 10.61 and 14.21; Mp 80-82 °C, Lit. 142 80-82 °C; 
u(nujo1)/cm' 3431 (NH), 3017 (CH), 1740 (ester C=O), 1653, 1517 (CONH); 8 H 
(CDC13 ; 200 MHz) 7.78 (2 H, m, CL),  7.52-7.37 (3 H, m, CL),  6.81 (1 H, b d, J 
5.5, Nil), 4.63 (1 H, dq, J 7.0, NHCU), 3.76 (3 H, s, OCfl3), 1.50 (3 H, d, J 7.0, 
CHCH3); 8c (CDC13 ; 63 MHz) 173.5, 160.7 (02C, ONH), 133.7 (ipso-Ar), 131.6, 
128.4, 126.9 (cH ar), 52.4 (OcH3), 48.3 (CH), 18.4 (CHcH 3); m/z (FAB) 208 (100%, 
MH), 176 (6, M-OMe), 148 (13,176-CO), 105 (55, 148-NHCHCH3). 






The general procedure outlined above (4.2.17.) with oxazolone 89f in methanol 
was followed Product purified by column chromatography, eluting with hexane:ethyl 
acetate (6:1), (107 mg, 85%). 
Rf (Hexane:EtOAc, 6:1) 0.15; R, 10.97 and 14.07; Mp 75 °C; Uma (nujol)/Cm' 3431 
(NH), 3018 (CH), 1734 (ester C=O), 1653, 1517 (CONH); oH  (CDC13 ; 200 MHz) 
7.83 (2 H, m, CH,), 7.54-7.38(3 H, m, CHar),  6.77 (1 H, d, J6.0, Nfl),4.75 (1 H, dq, 
J7.0, NIHCJj),  4.23 (2 H, q, J7.0, OCfj2),  1.51, (3 H, d, J7.0, CHCH3), 1.30, (3 H, t, 
J 7.0, CH2CH3); 8c (CDCl; 63 MHz) 173.1, 166.6 (c0 2CH2 , cONH), 133.8 (ipso-
Ar), 131.5, 128.4, 126.9 (CH), 61.5 (OcH2), 48.4 (CH), 18.6 (CHH3), 14.01 
(CH2CH3); m/z (FAB) 222 (100%, MH), 176 (92, M-OEt), 148 (99, 176-CO), 105 
(48, 148-NHCHCH 3), 77 (37, 105-CO), Found 222.1136, C 12H 16NO3 requires 
222.1130. 
4.2.34. N-Benzoyl-DL-alanine propyl ester 99f 
Ph N 1CO2Pr 
The general procedure outlined above (4.2.17.) with 89f in n-propanol was 
followed Product purified by column chromatography, eluting with hexane:ethyl 
acetate (6:1), furnished the desired product (95 mg, 7 1%). 
Rf (Hexane:EtOAc, 6:1) 0.18; R 1 10.43 and 13.90; Mp 60-61 °C; u m (nujol)/cm' 
3429 (NH), 3016 (CH), 1731 (ester C=O), 1655, 1518 (CONH); OH (CDC13 ; 200 
MHz) 7.83-7.77 (2 H, m, CH,), 7.54-7.38 (3 H, m, Cifar), 6.78 (1 H, d, J 6.0, NH), 
4.79 (1 H, dq, J 7.0, NHCII), 4.17 (1 H, dt, J 11.5, 6.5, OCUAHBCH2), 4.10 (1 H, dt, 
J 11.5, 6.5, OCHAUBCH2), 1.78-1.60 (2 H, m, OCH2CH2), 1.52 (3 H, d, J 7.0, 
CHCU3), 0.95 (3 H, t, J 7.5, CH2CH3); O (CDC13 ; 63 MHz) 173.2, 166.7 (c02CH2 , 
cONH), 133.8 (ipso-Ar), 131.5, 128.4, 126.9 (CHar), 67.0 (OCH2), 48.4 (NH-CH), 
21.8 (OCH2CH2), 18.6 (CHCH3), 10.2 (CH2CU3); m/z (FAB) 236 (100%, MH) 176 
(78, M-OEt), 148 (81, 176-CO), 105 (39, 148-NHCHCH 3), 77 (29, 105-CO), Found 
236.1290, C 12H 18NO3 requires 236.1286. 
Experimental 
4.2.35. N-Benzoyl-DL-tert-leucine methyl ester 96g 
Ph 	NCO2CH3 
The general procedure outlined above (4.2.17.) with oxazolone 89g in methanol 
was followed Product purified by column chromatography, eluting with hexane:ethyl 
acetate (6:1), (96 mg, 84%). 
Rf (Hexane:EtOAc, 4:1) 0.28; R (Heptane:IPA, 98:2, not baseline separation) 48.13 
and 51.50; Mp 65-66 °C, Lit. 143  66 °C; umax(CHC13)/cm'; 3437 (NH), 3018 (CH), 
1736 (ester C=O),1664, 1518 (CONH); 6 H  (CDC13 ; 200 MHz) 7.80-7.76 (2 H, m, 
CHar), 7.50-7.37(3 H, m, CHar), 6.67 (1 H, d, J9.0 NH), 4.76 (1 H, d, J9.0, NHCII), 
3.73 (3 H, s, 0C113), 1.04 (9 H, s, C(C113)3); ö (CDCl; 63 MHz) 172.0, 166.9 
(02CH3 , cONIH), 134.0 (ipso-Ar), 131.5, 128.4, 126.8 (cH ar), 60.0 (NHcH), 51.7 
(OcH3), 34.9 (c(CH3)3), 26.4 (C(cH3)3); m/z (FAB) 250 (100%, MH), 105 (36, M-
NHCH(C(CH3)3)CO2CH3), 77 (5,105-CO). 
4.2.36. N-Benzoyl-DL-tert-leucine propyl ester 99g 
PhNtCO2nPr  
The general procedure outlined above (4.2.17.) with 89g in n-propanol was 
followed Product purified by column chromatography, eluting with hexane:ethyl 
acetate (8:1), (95 mg, 74%). 
R1 (Hexane:EtOAc, 6:1) 0.41; R (Heptane:IPA, 98:2) 40.35 and 43.52; Mp 60-62 °C; 
um (CHCl3)/m' 3435 (NH), 3018 (CH ar), 1725 (ester C=O), 1663, 1517 (CONH); 
6,., (CDC13 ; 200 MHz) 7.81-7.77 (2 H, m, cH ar), 7.54-7.39 (3 H, m, CH), 6.69 (1 H, 
d,J9.0, NH), 4.69(1 H, d,J9.0, NHCU),  4.10(2 H, t,J7.0, 0C112),  1.69(2 H, tq,J 
7.5, 7.0, OCH2CII2),  1.04 (9 H, s, C(cH 3)3), 0.95 (3 H, t, J 7.5, CH2CH3); 6c (CDC13 ; 
63 MHz) 171.7, 166.9 (c0 2cH2, cONH), 134.1 (ipso-Ar), 131.5, 128.4, 126.8 
(!CH.), 66.6 (OcH 2), 60.1 (NIIcH), 35.1 (c(CH 3)3), 26.5 (C(cH3)3), 21.7 (cH2CH3), 
10.3 (CH2cH3); m/z (FAB) 278 (100%, MH), 105 (67, M-NHCH(C(CH 3)3)CO2Pr), 
Found (FAB) 278.1764, C, 6H24NO3 requires 278.1756. 
96 
Experimental 
4.2.37. General procedure for the lipase catalysed ring opening of 
(RS-2-phenyl-4-substituted-5(4H)-oxazo1ones 89a-g 
L In the presence of triethylamine 
Catalytic triethylamine (0.25 equiv.), lipase (crushed and dried Novozyme, 100 
mg pre-dried weight, or Lipozyme®, 100 mg) and alcohol (2.0 equiv.) were added to 
a solution of (RS)-2-phenyl-DL-4-substituted-5(4H)-oxazolone 89a-g (100 mg) in 
solvent (8 mL). The flask was stoppered and placed in an orbital incubator at 37 °C 
and 200 rpm. The reactions were monitored by tic and on complete consumption of 
the starting 5(4H)-oxazolone the lipase was filtered, washed with solvent (2x 10 mL) 
and the combined organic fractions concentrated under reduced pressure. 
Purification by column chromatography, as described for the corresponding 
racemate, furnished the desired product as a colourless solid unless otherwise stated. 
Spectroscopic data for all purified products were in agreement with the 
corresponding racemic sample. 
ii. In the absence of triethylamine 
As above with the elimination of triethylamine. 
4.2.38. N-Benzoyl-L-phenylalanine methyl ester 96a 
The general procedure outlined above (4.2.37.i.) was followed using oxazolone 
89a, toluene, methanol, triethylamine, and Novozyme ®. Reaction time 26 h, (93 mg, 
82%). 
R 25.72, e.e. 94%; [a]+96.4 (c 1.00, CHC1 3); Mp 86-88 °C. 
4.2.39. N-Benzoyl-L-phenylalanine ethyl ester 98a 
The general procedure outlined above (4.2.37.i.) was followed using oxazolone 
89a, toluene, ethanol, triethylamine and Novozyme ®. Reaction time 26 h, (94 mg, 
79%). 
R 16.78, e.e. 97%; [a] 20  +92.0 (c 1.00, CHC13); Mp 95-97 °C. 
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4.2.40. N-Benzoyl-L-phenylalanine propyl ester 99a 
The general procedure outlined above (4.2.37.i.) was followed using oxazolone 
89a, toluene, with n-propanol, triethylamine and N ovozyme® .  Reaction time 26 h, 
(103 mg, 83%). 
R 17.47, e.e. 97%; [a] 21  +85.8 (c 1.00, CHC13); Mp 78-79 °C. 
4.2.41. N-Benzoyl-L-phenylalanine butyl ester 97a 
The general procedure outlined above (4.2.37.1.) was followed using oxazolone 
89a, toluene, n-butanol, triethylamine and Novozyme ® (100 mg as supplied). 
Reaction time 2 days, (69 mg, 53%). 
R 17.12, e.e. 95%; [a]°+78.6  (c 1.00, CHC1 3). 
4.2.42. N-Benzoyl-L-phenylalanine butyl ester 97a 
The general procedure outlined above (4.2.37.11.) was followed using oxazolone 
89a, toluene, n-butanol, and Novozyme®  (100 mg as supplied). Reaction time 6 days, 
(51 mg, 40%). 
R1 17.12, e.e. 64%; [a] 20  +54.0 (c 1.00, CHC13). 
4.2.43. N-Benzoyl-L-phenylalanine butyl ester 97a 
The general procedure outlined above (4.2.37.i.) was followed using oxazolone 
89a, toluene, with n-butanol, triethylamine, and Novozyme®.  Reaction time 2 days, 
(104 mg, 81%). 
R 17.12, e.e. 95%; [a]°+78.6  (c 1.00, CHC13); Mp 68-70 °C. 
4.2.44. N-Benzoyl-L-phenylalanine butyl ester 97a 
The general procedure outlined above (4.2.37.1.) was followed using oxazolone 
89a, toluene, n-butanol, triethylamine, and Lipozyme ®. Reaction time 2 days, (96 
mg, 74%). 
R 17.12, e.e. 69%; [a]+52.7  (c 1.00, CHC1 3). 
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4.2.45. N-Benzoyl-L-phenylalanine butyl ester 97a 
The general procedure outlined above (4.2.37.ii.) was followed using oxazolone 
89a, toluene, n-butanol, and Lipozyme ®. Reaction time 3 days, (76 mg, 59%). 
R1 17.12, e.e. 55%. 
4.2.46. N-Benzoyl-L-phenylalanine pentyl ester lOOa 
The general procedure outlined above (4.2.37.i.) was followed using oxazolone 
89a, toluene, n-pentanol, tnethylamine, and Novozyme®.  Reaction time 26 h, (43 
mg, 32%). 
R 13.08, e.e. 88%; [a] 20  +75.4 (c 1.00, CHC1 3); Mp 55-58 °C. 
4.2.47. N-Benzoyl-L-phenylalanine iso-propyl ester 101a 
The general procedure outlined above (4.2.37.i.) was followed using oxazolone 
toluene, iso-propanol, triethylamine, and Novozyme®.  Reaction time 26 days, 
(22 mg, 18%). 
R 17.00, e.e. 29%; Mp 95-97 °C. 
4.2.48. N-Benzoyl-L-leucine methyl ester 96b 
The general procedure outlined above (4.2.37.i.) was followed using oxazolone 
toluene, methanol, triethylamine, and Novozyme ®. Reaction time 2 days, (110 
mg, 96%). 
R 13.28, e.e. 97%; [a] ° -22.1 (c 0.98, CH 3OH), Lit)44 [a] 21 	(c 0.80, CH30H); 
Mp 101-103 °C. 
4.2.49. N-Benzoyl-L-leucine propyl ester 99b 
The general procedure outlined above (4.2.37.1.) was followed using oxazolone 
89b, toluene, methanol, triethylamine, and Novozyme®.  Reaction time 2 days. 
Product obtained as a colourless oil (114 mg, 89%). 
R 16.02, e.e. 98%; [a]-21.4  (c 1.20, CH 3011). 
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4.2.50. N-Benzoyl-L-valine methyl ester 96c 
The general procedure outlined above (4.2.37.1.) was followed using oxazolone 
89c, toluene, methanol, triethylamine, and Novozyme ®. Reaction time 6 days, (95 
mg, 82%). 
R 11.38, e.e. 95%; [a]+40.2  (c 1.02, CHC1 3), Lit. [a]+35  (c 0.4, CHC1 3); MP 
109-110°C. 
4.2.51. N-Benzoyl-L-valine propyl ester 99c 
The general procedure outlined above (4.2.37.i.) was followed using oxazolone 
toluene, n-propanol, triethylamine, and Novozyme®.  Reaction time 6 days, (91 
mg, 70%). 
R, 8.35, e.e. 93%; [a]+36.4 (c 0.52, CHC13); Mp 59-60 °C. 
4.2.52. N-Benzoyl-L-methionine methyl ester 96d 
The general procedure outlined above (4.2.37.1.) was followed using oxazolone 
toluene, methanol, triethylamine, Novozyme ®. Reaction time 26 h, (79 mg, 
69%). 
R, 20.70, e.e. 80%; [a] 20  +27.9 (c 1. 12, CHC1 3); Mp 79-81 °C. 
4.2.53. N-Benzoyl-L-methionine propyl ester 99d 
The general procedure outlined above (4.2.37.1.) was followed using oxazolone 
89d, toluene, n-propanol, triethylamine, and Novozyme ®. Reaction time 26 h, (80 
mg, 64%). 
R 20.03, e.e. 83%; [a] " +27.0 (c 1. 18, CHC1 3); Mp 51-53 °C. 
4.2.54. ]V-Benzoyl-L-tryptophan methyl ester 96e 
The general procedure outlined above (4.2.37.1.) was followed using oxazolone 




R1 50.10, 90%; [a] -39.7 (c 0.70, CH3OH), Lit. 146 [a] -  45 (c 0.175, CH30H); Mp 
102-104 °C. 
4.2.55. 1V1-Benzoyl-L-tryptophan propyl ester 99e 
The general procedure outlined above (4.2.37.i.) was followed using oxazolone 
toluene, n-propanol, triethylamine, and Novozyme® .  Reaction time 7 days, (58 
mg, 48%). 
R 38.73, e.e. 80%; [a] 20  -30.9 (c 0.80, CH 30H); Mp 107-109 °C. 
4.2.56. N-Benzoyl-L-alanine ethyl ester 98f 
The general procedure outlined above (4.2.37.i.) was followed using oxazolone 
toluene, ethanol, triethylamine, and Novozyme®.  Reaction time 6 days, (76 mg, 
60%). 
R 14.07, e.e. 14%; [a]-1.7 (c 0.24, CHC1 3); Mp 74-76 °C. 
4.2.57. N-Benzoyl-L-alanine propyl ester 99f 
The general procedure outlined above (4.2.38.i) was followed using oxazolone 
89f, toluene, n-propanol, triethylamine, and Novozyme®.  Reaction time 6 days, (97 
mg, 72%). 
R 13.90, e.e. 14%; [a] 20  +0.4 (c 0.54, CHC13); Mp 45-46 °C. 
4.2.58. N-Benzoyl-L-tert-leucine methyl ester 96g 
The general procedure outlined above (4.2.37.1.) was followed using oxazolone 
toluene, methanol, triethylamine, and N ovozyme® .  After 21 days, the 
incomplete reaction was worked up. Purification by column chromatography, eluting 
with hexane:ethyl acetate (6:1) furnished recovered starting oxazolone, (22 mg, 
22%) and desired product, (36 mg, 31%, or 40% based on recovered oxazolone. 
R (Heptane:IPA 98:2, not baseline separation) 51.50, e.e. 35%. 
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4.2.59. N-Benzoyl-L-tert-leucine propyl ester 99g 
The general procedure outlined above (4.2.37.i.) was followed using oxazolone 
89g, toluene, n-propanol, triethylamine, and Novozyme ®. After 21 days, the 
incomplete reaction was worked up. Purification by column chromatography, eluting 
with hexane:ethyl acetate (8:1) furnished recovered starting oxazolone (42 mg, 42%, 
and desired product, (11 mg, 11%, or 15% based on recovered oxazolone). 
R (Heptane:IPA, 98:2), 43.52, e.e. 19%; Mp 57-58 °C. 
4.2.60. Solvent studies: N-benzoyl-L-phenylalanine methyl ester 96a 
in the presence of triethylamine 
The general procedure outlined above (4.2.37.1.) was followed using oxazolone 
89a in (a) dichloromethane, (b) chloroform, (c) tetrahydrofuran, (d) diethyl ether, (e) 
tert-butyl methyl ether (f), diisopropylether, and (g) acetonitrile, with methanol, 
triethylamine, and Novozyme®.  Reaction times are quoted after the yield. Products 
were purified by column chromatography, eluting with hexane: ethyl acetate (8:1). R 1 
25.72; (a) (88 mg, 78%, e.e. 89%), 41 h, (b) (74 mg, 66%, e.e. 75%), 39 h, (c) (72 
mg, 64%, e.e. 95%), 48 h, (d) (98 mg, 87%, e.e. 97%), 17 h (e) (102 mg, 90%, e.e. 
96%) 15 h, (f) (97 mg, 86%, e.e. 96%), 15 h, (g) (49 mg, 44%, e.e. 97%), 22 h. 
4.2.61. Solvent studies: N-benzoyl-L-phenylalanine methyl ester 96a 
in the absence of triethylamine 
The general procedure outlined above (4.2.37.ii.) was followed using oxazolone 
89a in (a) dichloromethane, (b) chloroform, (c) tetrahydrofuran, (d) diethyl ether, (e) 
tert-butyl methyl ether (f), diisopropylether, and (g) acetonitrile, with methanol and 
Novozyme® .  Reaction times are quoted after the yield. Products were purified by 
column chromatography, eluting with hexane:ethyl acetate (8:1). R 25.72; (a) (73 
mg, 65%, e.e. 75%), 124 h, (b) (71 mg, 63%, e.e. 83%),124 h, (c) (80 mg, 71%, e.e. 
97%) 123 h, (d) (102 mg, 90%, e.e. 58%), 18 h, (e) (103 mg 91%, e.e. 34%), 18 h, 
(f) (102 mg, 90%, e.e. 33%), 18 h, (g) (99 mg, 88%, e.e. 98%), 51 h. 
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4.2.62. N-Benzoyl-L-phenylalanine methyl ester 96a 
The general procedure outlined above (4.2.37.i.) was followed using oxazolone 
89a, acetonitrile, triethylamine, methanol, and Lipozyme ®. Reaction time 23 h, (69 
mg, 61%). 
R 25.72, e.e. 73% 
4.2.63. N-Benzoyl-L-phenylalanine methyl ester 96a 
The general procedure outlined above (4.2.37.ii.) was followed using oxazolone 
acetonitrile, methanol, and Lipozyme ®. Reaction time 23 h, (106 mg, 94%). 
R 25.72, e.e. 73% 
4.2.64. N-Benzoyl-L-leucine methyl ester 96b 
The general procedure outlined above (4.2.37.ii.) was followed using oxazolone 
acetonitrile, methanol, and Novozyme ®. Reaction time 19 h, (110 mg, 96%). 
R1 13.28, e.e. 97% 
4.2.65. N-Benzoyl-L-leucine methyl ester 96b 
The general procedure outlined above (4.2.37.ii.) was followed using oxazolone 
89b, acetonitrile, methanol, and Lipozyme ®. Reaction time 4 days, (102 mg, 89%). 
R 13.28, e.e. 62% 
4.2.66. N-Benzoyl-L-valine methyl ester 96c 
The general procedure outlined above (4.2.37.ii.) was followed using oxazolone 
89c, acetonitrile, methanol, Novozyme ®. Reaction time 4 days, (96 mg, 83%). 
R 11.38, e.e. 97%; [a]+  1.63 (c 1.66, CHC1 3). 
4.2.67. N-Benzoyl-L-valine methyl ester 96c 
The general procedure outlined above (4.2.37.ii.) was followed using oxazolone 
89c, acetonitrile, methanol, and Lipozyme®.  After 21 days, the incomplete reaction 
was worked up. Purification by column chromatography, eluting with hexane:ethyl 
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acetate (4:1), afforded starting oxazolone, (34 mg, 34%) and desired product (52 mg, 
45%, or 68%, yield based on recovered starting oxazolone). 
R 11.38, e.e. 19% 
4.2.68. N-Benzoyl-L-methionine methyl ester 96d 
The general procedure outlined above (4.2.37.11.) was followed using oxazolone 
89d, acetonitrile, with methanol, and Novozyme ®. Reaction time 16 h, (90 mg, 79%). 
R 20.70, e.e. 73% 
4.2.69. N-Benzoyl-L-methionine methyl ester 96d 
The general procedure outlined above (4.2.37.11.) was followed using oxazolone 
acetonitrile, methanol, and Lipozyme ®. Reaction time 2 days, (94 mg, 83%). 
R1 20.70, e.e. 59% 
4.2.70. N-Benzoyl-L-tryptophan methyl ester 96e 
The general procedure outlined above (4.2.37.ii.) was followed using oxazolone 
acetonitrile, methanol, and Novozyme®.  Reaction time 16 days. Column 
chromatography, eluting with hexane:ethyl acetate (2:1), (0 mg, 0%). 
4.2.71. N-Benzoyl-L-tryptophan methyl ester 96e 
The general procedure outlined above (4.2.37.11.) was followed using oxazolone 
89e, acetonitrile, methanol, and Lipozyme ®. Reaction time 4 days, (109 mg, 98%). 
R, 50. 10, e.e. 46% 
4.2.72. N-Benzoyl-L-alanine methyl ester 96f 
The general procedure outlined above (4.2.37.ii.) was followed using oxazolone 
89f, acetonitrile, methanol, and Novozyme ®. Reaction time 19 h, (111 mg, 94%). 
R 14.2 1, e. e. 10% 
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4.2.73. N-Benzoyl-L-alanine methyl ester 96f 
The general procedure outlined above (4.2.37.ii.) was followed using oxazolone 
acetonitrile, methanol, and Lipozyme ®. Reaction time 4 days, (94 mg, 79%). 
R 14.21, e.e. 39%; Mp 79-81 °C. 
4.2.74. N-Benzoyl-L-tert-leucine methyl ester 96g 
The general procedure outlined above (4.2.37.ii.) was followed using oxazolone 
acetonitrile, methanol, and Novozyme®.  Reaction time 22 days. No product 
formation was observed by tic, hexane:ethyl acetate (6:1), or 'H nmr (200 MHz, 
CDC13). (0 mg, 0%). 
4.2.75. N-Benzoyl-L-tert-leucine methyl ester 96g 
The general procedure outlined above (4.2.37.ii.) was followed using oxazolone 
89g, acetonitrile, methanol, and Lipozyme ® . Reaction time 22 days. No product 
formation was observed by tic, hexane:ethyl acetate (6:1), or 'H nmr (200 MHz, 
CDC13). (0 mg, 0%). 
4.2.76. Nitrogen based nucleophiles 
4.2.77. Amine nucleophiles 
4.2.78. N-Benzyl-DL-phenylalanine benzylamide 102a 
PhNN 	Ph 
To a solution of oxazolone 89a (50 mg, 0.20 mmol) in toluene (5 mL) was 
added triethylamine (8 j.tL, 0.25 equiv.) and benzylamine (44 PL, 0.4 mmol, 2.0 
equiv.). The solution was stirred at room temperature and almost instantly a white 
precipitate formed. The solid was filtered, washed with toluene (2 x 10 mL) and 
dried under vacuum overnight to give the product (55 mg, 77%). 
Rf (Hexane:EtOAc, 8:1) 0.31; Mp 210-211 °C Lit. ' 44 211-212 °C; Umax(IR Card)/cm' 
3239 (NH), 1664, 1633, 1570, 1537 (CONH); 6H  ((CD3)2S0; 200 MHz) 8.64 (1 H, d, 
J 8.0, NFJCH), 8.62 (1H, d, 5.5, NHCH2), 7.81 (2 H, m, CH),  7.72-7.16 (13 H, 
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CL), 4.75(1 H, ddd, 10.0, 8.0, 5.0, NHCH),  4.32(2 H, d,J5.5, NHCH2), 3.13(1 H, 
dd, J 13.5, 5.0, CHAHBPh), 3.03 (1 H, dd, J 13.5, 10.0, CHAHBPh); ö ((CD) 2SO; 63 
MHz) 171.51, 166.47 (ONH), 139.41, 138.51, 134.17 (ipso-Ar), 131.42, 129.31, 
128.37, 128.29, 128.23, 127.58, 127.20, 126.85, 126.39 (CHar), 55.25 (NH-CH), 42.25 
(N}iH2), 37.41 (cH2Ph); m/z (FAB) 359 (75%, MH), 252 (45, M-NHBn), 224 
(100, 252-CO), 105 (224-NHCHCH2Ph). 







To a solution of oxazolone 89a (100 mg, 0.40 mmol) in tetrahydrofuran (3 mL) 
was added allylamine (30 tL, 0.4 mmol, 1.0 equiv.) and the solution stirred at room 
temperature. The solvent was evaporated under reduced pressure and the resulting 
colourless solid purified by column chromatography, eluting with hexane:ethyl 
acetate (1:1) to furnish the product (110 mg, 90%). 
R (Hexane:EtOAc, 1:1) 0.50; Mp 160-161°C, Lit. 129  164-166 °C; Umax(CHC13)/'Cm ' 
3435 (NH), 3018 (CH), 1653, 1646, 1517 (CONK); 6,., (CDC1 3 ; 200 MHz); 7.83 (2 
H, m, CL),  7.65-7.40(3 H, m, CH,), 7.397.25 (5 H, m, CH r) 5.85(1 H, ddtJ 17.0, 
10.0, 5,5, Cli=CH2), 5.19 (1 H, ddt, J 17.0, 2.0, CH=CHff fl,)), 5.14 (1 H, ddt, J 
10.0, 1.5, C=CHH(CIS)), 4.91 (1 H, dd, J, 8.5, 6.5, NHCU), 3.87 (2 H, ddd, J 5.5, 2.0, 
1.5, OCkI2CH), 3.30 (1 H, dd, J 13.5, 6.5, CUAHBPh), 3.16 (1 H, dd, J 13.5, 8.5, 
CHAkJBPh); 6 (CDC13 ; 63 MHz) 171.58, 168.17 (ONH), 136.64, 133.36 (ipso-Ar), 
133.20, 120.90, 128.46, 127.57, 126.53 (CH ar), 125.89 (HCH2), 114.37 
(CH=H2), 54.94 (N}icH), 40.80 and 37.16 (CH 2Ph and cH2CH=CH2); m/z (FAB) 
309 (55%, MH), 252 (100, M-CH2CH=CH2), 224 (48, 252-CO), 105 (87, 224-
NHCHCH2Ph), 77 (15,105-CO). 
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4.2.80. Amino acid ester nucleophiles 




Glycine methyl ester was prepared following the procedure outlined by Frankel. 147 
Glycine methyl ester hydrochloride (2.70 g, 21.5 mmol) was suspended in ether (25 
ml) and ammonia gas bubbled through the vigorously stirred mixture for a period of 
1 h. Nitrogen gas was bubbled through the resulting suspension to remove any 
excess ammonia and the precipitated ammonium chloride was filtered. The solvent 
was removed by distillation at 40 °C and the crude product was distilled, collecting 
the fraction boiling at 62 °C, 15 mm Hg to give the desired product as a colourless 
oil (0.99 g, 51%). 'H nmr (200 MHz, CDC1 3) indicated the desired product. The 
product was not characterised further but used directly in the next step of the 
synthesis. 
To a solution of oxazolone 89a (50 mg, 0.20 mmol) in toluene (3 mL) was added 
freshly prepared glycine methyl ester (20 mg, 0.22 mmol, 1.1 equiv.) and the 
solution stirred at room temperature. A colourless precipitate formed almost 
immediately which was filtered, washed with ether (2 x 5 mL) and dried under 
vacuum to give the product (54 mg, 80%). 
Rf (EtOAc:Hexane, 2:1) 0.37; Mp 155-157 °C; umax (CHC1 3)/cm' 3317 (NH), 3018 
(CH), 1750 (ester C=O), 1651, 1627, 1577, 1551 (CONH); oH (CDC1 3 ; 200 MHz) 
7.69 (2 H, in CH), 7.52-7.3 1 (3 H, m, CHar), 7.25 (5 H, s, CHar), 7.06 (1 H, d, 7.5 
NHCH), 6.88 (1 H, brt, NUCH 2), 4.98 (1 H, ddd, J 7.5, NHCH), 3.99 (1 H, dd, J 
18.5, 6.0, CHA HBPh), 3.95 (1 H, dd, J 18.5, 6.0, CHAHBPh), 3.68 (3 H, s, OCH3), 
3.19 (2 H, d, J 7.0, NHCjj2); O  (CDC1 3 ; 63 MHz) 171.26, 169.65 (ONH), 167.27 
(CO2C), 136.40, 133.53 (ipso-Ar), 131.70, 129.20, 128.51, 128.43, 126.98, 126.88 
(H), 54.49 (cHCONH), 52.19 (OcH 3), 41.09 and 38.07 (cH2CO2 and H2Ph); 
m/z (FAB) 341 (100%, MW), 252 (30, M-NHCH 2CO2CH3), 224 (32, 252-CO), 105 
(44, 252-NHCHCH 2Ph). 
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4.3.0. Application of 5(4H)-oxazolone methodology: Synthesis of 
matrix metalloproteinase inhibitors 
4.3.1. (R)-2-Hydroxy-4-methyl-hexanoic acid 119 
HO CO2 H 
The title compound was prepared by the method outlined by Mon. 116  To a 
solution of D-leucine (50.0 g, 0.38 mol) in aqueous sulfuric acid (0.5M, 250 mL) at 0 
°C was added a solution of aqueous sodium nitrite (41.98 g, 0.61 mol, 1.6 equiv.) in 
water (150 mL) over a period of 3 h. The resulting suspension was stirred at 0 °C for 
a further 2 h, and overnight at room temperature. The resulting clear aqueous 
solution was extracted with ether (3 x 200 mL), and the combined organic phase 
dried (Na2SO4), filtered and evaporated under reduced pressure to give a pale yellow 
solid. Recrystallisation three times from petroleum ether (40:60):diethyl ether (1:1) 
furnished the desired product as a colourless solid (25.70 g, 5 1%). 
20 	 20 
Mp 78-79 °C, Lit.' 6 80-81  °C; [a] +26.2 (c 1.0 in 1 N NaOH), Lit.' 6 [a] +26.5 
(c 1.52, 1 N NaOH); Omax(CHC13)km' 3420 (OH), 3200-2400 (acid OH), 1718 (acid 
C=O); 6H  (CDC13 ; 250 MHz) 6.99 (1 H, br s, 011),  4.28 (1 H, dd, J 7.5 7.0, HOCJJ), 
1.89 (1 H, ddq, J 6.5, Ci(CH02), 1.63, (1 H, ddd, J 14.0, 7.0, 6.5, CHCHAHBCH), 
1.61 (1 H, ddd, J 14.0, 7.5, 6.5, CHCHAHBCH) 0.95 (6 H, d, J 6.514.0, 7.5, 
CU3ACHCH3B and CH 3ACHCH3B); 8c (CDC1; 63 MHz) 188.2 (O 2H), 68.8 (HO-CH), 
43.0 (cH2CH), 24.3 (cH(CH 3)2), 23.1, 21.3 (CH(cH 3 )2 ; m/z (FAB) 113 (91%, MH), 
115 (42, M-OH), 87(69, 115-CO). 
4.3.2. (R)-Benzyl 2-hydroxy-4-methyl pentanoate 120 
L 
HOCO2Bn 
D-Leucic acid (10.00 g, 75.67 mmol) was suspended in toluene (100 mL). Benzyl 
alcohol (11.75 mL, 113.50 mmol) and p-toluenesulfonic acid (720 mg, 3.78 mmol, 
0.05 equiv.) were added and the mixture heated under reflux using Dean-Stark 
conditions for 2.5 h. The reaction was quenched with saturated aqueous sodium 
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hydrogen carbonate (100 mL) and the aqueous layer extracted with ethyl acetate (2 x 
70 mL). The combined organic extracts were washed with brine (2 x 50 MIL), dried 
(Na2SO4), filtered, and evaporation under reduced pressure produced a yellow oil. 
Purification by column chromatography, eluting with hexane:ethyl acetate (10:1) 
furnished the title compound as a colourless oil (16.02 g, 95%). 
Rf (Hexane:EtOAc, 4:1) 0.50; [a] 21  +16.1 (c 1.0, CHC13), Lit. [a] +14.4 (c 2.98, 
CHC13); Umax(neat)/cm' 3470 (OH), 2955 (saturated CH), 1738 (ester C=O); 8H 
(CDC1 3 ; 250 MHz) 7.36 (5 H, S, CHar), 5.20 (2 H, s, Cff2Ph), 4.24 (1 H, ddd, J 7.5, 
7.0, 6.0, HOCH), 2.79 (1 H, d, J 6.0 OH),  1.87 (1H, ddq, J 6.5, Cff(CH3)2), 1.60 (1 
H, ddd, J 14.0, 7.0, 6.5, CHCHAHBCH), 1.51 (1 H, ddd, J 14.0, 7.5, 6.5, 
CHCHAUBCH), 0.93 (3 H, d, J 6.6 CH3ACHCH3B) 0.92 (3 H, d, J 6.6 CH3ACHCU313); 
öc  (CDC13 ; 63 MHz) 175.6 (CO 2CH2), 135.1 (ipso-Ar), 128.5, 128.4, 128.2 (H), 
69.0 (HOcH), 67.1 (HA), 43.2 (CH 2CH), 24.2 (cH(CH3)2), 23.1, 21.4 
(CH(H3)2); m/z (FAB) 223 (42%, MH), 91(100, CH 2Ph), Found (FAB) MH 
233.1342, C 13H, 903 requires 233.1334. 
4.3.3. (R)-Benzyl 2-trifluoromethanesulfonyl-4-methyl pentanoate 121 
TfOCO2Bn 
The title compound was prepared according to the procedure outlined by 
Degerbeck.1 17 To a solution of a-hydroxy ester 120 (15.75 g, 70.86 mmol) in DCM 
(160 mL) and 2,6-lutidine (10.73 mL, 92.11 mmol, 1.3 equiv.) cooled to -78 °C was 
added trifluoromethanesulfonic anhydride (13.71 mL, 81.48 mmol, 1.1 equiv.) over a 
period of 30 minutes. The solution was stirred at -78 °C for a further 1 h, followed by 
warming to -10 °C over 40 minutes, and 40 minutes stirring at room temperature. 
The reaction was quenched with water (100 mL) and the aqueous layer extracted 
with DCM (2 x 100 mL). The combined organic fractions were dried (Na 2SO4), 
filtered and evaporated under reduced pressure. The crude brown product was 
filtered through a plug of silica, eluting with hexane:DCM (3:1) to furnish the title 
compound as a colourless oil (24.62 g, 98%). 
Experimental 
Rf (Hexane:DCM, 1:1) 0.76; [a] +42.8 (c 1.8, CH 2Cl2), Lit." [a]D  +43.8 (c 1.0, 
CH2C12); Dmax(neat)/cm' 2963 (CH), 1763 (ester C=O), 1419 (S0 2-O) 1  1208 (C-F), 
1043 (S=O); 6H (CDC13 ; 250 MHz) 7.37 (5 H, s, CH,), 5.25 (2 H, s, CU2Ph), 5.19 (1 
H, dd, J 9.0, 3.5, OCR),  1.94 (1 H, obscured ddq, CU(CH 3)2), 1.85-1.69 (2 H, m, 
CHCRAHBCH, and CHCHARBCH), 0.96 (3 H, d, J 6.0, CU3ACHCH3B), 0.95 (3 H, d, 
J 6.0, CH3ACHCR3B); 8c (CDC13 ; 63 MHz) 167.4 (CO 2CH2); 134.2 (ipso-Ar), 128.7, 
128.6, 128.4 (CHar); 118.3 (1 C, q, J 319, F30, 82.2 (HOcH), 68.1 (HA), 40.5 
(cH2CH), 23.9 (cH(CH 3)2), 22.7, 20.9 (CH(H 3)2). 
4.3.4. Mono tert-butyl malonate 124 
tB uQCCOH 
tert-Butyl ethyl malonate (15.10 g, 80.23 mmol) was suspended in a solution of 
THF:water (1:1, 350 mL) and lithium hydroxide monohydrate (3.70 g, 88.25 mmol, 
1.1 equiv.) added. The suspension was stirred at room temperature for 20 minutes 
until a clear solution was obtained. The solution was acidified to pH= 3 with aqueous 
citric acid (1M, 260 mL) and extracted with ethyl acetate (3 x 250 mL). The 
combined organic extracts were washed with brine (2 x 150 mL), dried (Na 2 SO4), 
filtered, and evaporation under reduced pressure gave the desired product as a 
colourless oil (12.85 g, 100%). 
Umax(neat)m' 3204-2400 (acid OH), 1734 (ester C=O and acid C=O); oH (CDC1 3 ; 
250 MHz) 10.42 (1 H, br s, OR),  3.34 (2 H, s, CR2),  1.48 (9 H, s, C(C113)3); Oc 
(CDC13 ; 63 MHz) 171.3, 166.3 (c0 2H, c02C), 82.9 (c(CFI3)3), 41.7 (H2), 27.7 
(C(cH3 )3); mlz (FAB) 161 (52%, MH), 57 (100, 'Bu), Found (FAB) 161.0815, 
C7H 1304 requires 161.08 13. 
4.3.5. tert-Butyl benzyl malonate 125 
tBuQCCOB fl 
Mono acid 124 (12.85 g, 80.23 mmol) was suspended in THF:water (1:1, 200 mL) 
and potassium hydroxide (4.95 g, 88.24 mmol, 1.1 equiv.) added. Once complete 
dissolution had occurred the solvent was removed under reduced pressure to give a 
colourless solid which was dried under vacuum overnight. The solid was suspended 
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in DMF (300 mL); benzyl bromide (10.50 mL, 88.25 mmol, 1.1 equiv.) was added 
and the suspension stirred at room temperature for 7 h. The resulting mixture was 
quenched with saturated aqueous ammonium chloride (200 mL) and the aqueous 
solution extracted with ethyl acetate (4 x 200 mL). The combined organic extracts 
were washed with saturated aqueous ammonium chloride (2 x 200 mL), brine (2 x 
150 mL), dried (Na2SO4), filtered, and evaporated under reduced pressure to give a 
yellow oil. Purification by column chromatography, eluting with hexane:diethyl 
ether (20:1) furnished the title compound as a colourless oil (15.06 g, 75%). 
Rf (Hexane:EtOAc, 4:1) 0.65; Umax(neat)/cm 1 2978 (saturated CH), 1729 (ester 
C=O); 8H  (CDCI 3 ; 250 MHz) 7.34 (5 H, s, CHar), 5.16 (2 H, s, CU2Ph), 3.32 (2 H, s, 
C112CO2), 1.42 (9 H, s, C (CU3)3); 5c (CDC13 ; 63 MHz) 166.6, 165.3 (2 x 
135.2 (ipso-Ar), 128.3, 128.2, 128.1, (CHar), 81.8 ((CH3)3), 66.8 (cH2Ph), 42.7 
(CH2C), 27.6 (C(cH 3)3); m/z (Cl) 251 (56%, MH), Found (El) 250.1202, C 14H 1804 
requires 250.1205. 






Malonate 125 was dissolved in THF (150 mL), cooled to -78 °C and added to a 
suspension of sodium hydride (1.45 g, 60.17 mmol, 1.0 equiv.) in THF (150 mL) at - 
78 °C via cannulation over 15 minutes. The suspension was stirred for 40 minutes 
and a solution of triflate 121 (22.39 g, 63.18 mmol, 1.05 equiv.) was added over a 
period of 15 minutes. The reaction mixture was stirred at -78 °C for 1 h followed by 
warming to -10 °C and stirring for a further 1 h until a clear solution was obtained. 
The solution was allowed to warm to room temperature for a further 1 h and 
quenched with saturated aqueous ammonium chloride (100 mL). The aqueous layer 
was extracted with ethyl acetate (3 x 200 mL), washed with brine (2 x 100 mL), 
water ( 2 x 100 mL), dried (Na2SO4), filtered, and evaporated to give a colourless oil. 
Purification by column chromatography, eluting with hexane:DCM (1:3) produced 
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the title product as a colourless oil. 'H nmr indicated a 1:1 mix of diastereomers 
(24.99 g, 91%). 
Rf (Hexane:EtOAc, 4:1) 0.68; [a']°  +22.8 (c 1.0, CHC13); umax(neat)/cm' 2959 
(saturated CH), 1733 (ester C=O); 6H (CDC13 ; 360 MHz) 7.34 (2.5 H, s, CHar), 733 
(5 H, S, CHar), 7.32 (2.5 H, s, CH), 5.20, 5.17, 5.15, 5.13, 5.11, 5.09, 5.05 and 4.99 
(total of 2 H, 8 x d, J 12.4, 12.2 and 12.0, 2 x CUAHBPh and CH AHBPh of each 
diastereomer), 3.69 (0.5 H, d, J 10.2, CHACHCO2) ,  3.66 (0.5 H, d, J 10.4, 
CHBCHCO2), 3.18 and 3.17 (total of! H, 2 x m, CHCHCO 2, of each diastereomer), 
1.7201.52 (total of 2 H, 2 x m, CHCH AHBCH and CHCHAHBCH of each 
diastereomer), 1.34, 1.33 (total of 9 H, 2 x s, C(CH 3 )3 of each diastereomer), 1.26, 
1.16 (total of 1 H, 2 x m, CH(CH 3)2 of each diastereomer), 0.90, 0.85, 0.83, 0.78 ( 
total of 6 H, 4 x d, J 6.4, CII 3ACHCH3B and CH3ACHCH3B of each diastereomer); 6 
(CDC13 ; 90 MHz) 173.6, 173,4, 167.9, 167.8, 167.5, 167.3, (!COP, 135.5, 135.1 
(ipso-Ar), 128.5, 128.4, 128.3, 128.2, 128.1, 128.0, 128.0 (CH ar), 82.3, 82.2, 
(c(CH3)3), 66.9, 66.4, 66.3 (cH 2Ph), 55.6, 55.4 (02CH2CO2), 42.7, (CHHCH2), 
39.3, 39.2 (H2CH(CH3)2), 27.5 (c(CH 3 )3), 25.5 (H(CH3)2), 23.4, 23.2, 21.1, 21.0 
(CH(H3)2); mlz (FAB) 455 (9%, MH), 399 (78, MHt tBu), 91(100, CH2Ph), 57 
(23, 'Bu), Found (FAB) 455.2424, C 27H3506 requires 455.2433. 
4.3.7. (2RS,3R)-4-tert-Butyl 2-carboxy-3-iso-butyl-succinic acid 116 
tBuOC 
T CO 2H 
HO2C 
10% Palladium on carbon (2.50 g, 10% w) was added to a solution of triester 126 
(24.99 g, 54.98 mmol) in THF (400 mL) and the reaction vessel placed under a 
atmosphere of hydrogen. The mixture was stirred at room temperature for 2 h until 
the required volume of hydrogen had adsorbed (-2.5 L). The catalyst was filtered 
through celite and washed with THF (2 x 100 mL). The combined organic fractions 
were evaporated under reduced pressure to give a colourless solid which was not 
further purified but carried directly to the next step. 
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4.3.8. (R)-2-iso-butyl-succinic acid 4-tert-butyl ester 114 
tB UOC 
Triethylamine (756 L, 5.43 mmol, 0.1 equiv.) was added to a suspension of crude 
diacid 116 (14.88 g, 54.25 mmol expected yield) in acetonitrile (250 mL) and the 
mixture heated under reflux for 14 h under and atmosphere of nitrogen. On cooling, 
the clear solution was filtered through a plug of silica, eluting with acetonitrile. The 
solvent was removed under reduced pressure to give the title compound as a pale 
yellow oil (10.76 g, 85% from triester 126). 
[a] 20 +14.0 (c 2.20, CHC1 3); umax(CHC13)/Cm' 3400-2500 (acid OH), 1733 (ester 
C=O), 1710 (acid C=O); 6H (CDC1 3 ; 360 MHz) 1.16 (1 H, br s, 011), 2.83 (1 H, m, 
CUCO2H), 2.56 (1 H, dd, J 16.4, 9.2, 02CCHAHBCH) 2.36 (1 H, dd, J 16.4, 6.4, 
02CCHAUBCH) 1.65-1.54(2 H, 2 x m, CHCHAHBCH and CHCHA11BCH), 1.41 (9 H, 
S, C(C113)3), 1.26 (1 H, m, CH(CH 3)2), 0.92 (3 H, d, J 6.4, CH3ACHCH3B), 0.88 (3 H, 
d, J 6.4, CH3ACHCH3B); ö (CDCl; 63 MHz) 181.7, 170.9 (O 2H, 02C), 80.8 
(c(CH3)3), 40.7 (o2CcH2), 39.5 (cHCO2H), 37.5 (CHcH2CH), 27.8 (c(cH3)3), 25.6 
(CH(CH3)2), 22.4, 22.1 (CH(H 3)2); m/z (FAB) 231 (82%, MH), 175 (100, MH-
tBu), 57 (71, Su), Found (FAB) 231.1592, C 12H2304 requires 231.1596. 
4.3.9. General procedure for the coupling of a-amino acid esters to 
(R)-2-iso-butyl-succinic acid 4-tert-butyl ester 114 
Method (i) 
EDCI (1.2 equiv.), HOBt (1.2 equiv.) and triethylamine (2.4 equiv.) were added to a 
solution of succinate 114 (1.0 equiv.) in DCM (40 mL). Once complete dissolution 
occurred a-amino acid ester hydrochloride (1.2 equiv.) was added and the solution 
stirred at room temperature for 6 h. The reaction mixture was diluted with DCM (50 
mL), washed with saturated aqueous ammonium chloride (2 x 50 mL), water (50 
mL), saturated aqueous sodium hydrogen carbonate (2 x 50 mL), water (50 mL), 
dried (Na2 SO4), filtered, and evaporated under reduced pressure to give the crude 




TBTU (1.2 equiv.), HOBt (1.2 equiv.) and DIPEA (3.0 equiv.) were added to a 
solution of succinate 114 (1.0 equiv.) in DMF (40 mL). a-Amino acid ester 
hydrochloride (1.2 equiv.) was added and the resulting solution stirred at room 
temperature under an atmosphere of nitrogen for 1.5 h. After quenching with 
saturated aqueous ammonium chloride (50 mL), the aqueous layer was extracted 
with ethyl acetate (3 x 50 mL). The combined organic extracts were washed with 
saturated aqueous ammonium chloride (50 mL), saturated aqueous sodium hydrogen 
carbonate (2 x 50 mL), brine (50 mL), dried (Na 2 SO4), filtered, and evaporated under 
reduced pressure to give the crude product. Purification by column chromatography 
furnished the desired product. 
4.3.10. (2R,2'S)-[4-(tert-butyl)-2-iso-butyl-succinylj -phenylalanine methyl ester 
127a 
tB UOC 	yNCO2CH3 
Ph 
The procedure outlined in Section (4.3.91) was followed using EDCI (68 mg, 
0.36 mmol, 1.2 equiv.), HOBt (48 mg, 0.36 mmol, 1.2 equiv.), triethylamine (99 PL, 
0.72 mmol, 2.4 equiv.), succinate 114 (70 mg, 0.30 mmol, 1.0 equiv.) and L-
phenylalanine methyl ester hydrochloride (78 mg, 0.36 mmol, 1.2 equiv.). Column 
chromatography, eluting with hexane:ethyl acetate (6:1) furnished the title 
compound as a colourless solid (98 mg, 83%). 'H nrnr indicated a d.e. of 95%. The 
spectroscopic data given is for the diastereomer whose absolute stereochemistry was 
determined from the crystal structure (see appendix 1). 
Rf (Hexane:EtOAc, 6:1) 0.27; d.e. 95%; Mp 97-99 °C; (Found: C, 67.58; H, 8.50; N, 
3.75; C22H33N05 requires C, 67.49; H, 8.49; N 3.58); [a] 
21 
 +62.3 (c 0.82, CHC13); 
0max(CH 3)/cm 3430 (amide NH), 3018 (saturated CH), 1726 (ester CO), 1673, 
1510 (CONE); 6 H  (CDC13 ; 600 MHz) 7.27 (2 H, tt, J 7.3, Cfl me)), 7.22 (1 H, if, J 
7.3, Cfl )),7.16 (2 H, dt, J7.3, Cj OhO)), 6.81 (1 H, d, J7.9 NH), 4.85 (1 H, ddd, 
J 7.9, 6.0, 5.9, NHCH), 3.67 (3 H, s, 0C11 3), 3.09 (1 H, dd, J 14.3, 5.9, CUAHBPh) 
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3.08 (1 H, dd, J 14.3, 6.0, CHAHBPh), 2.61 (1 H, m, CHCONH), 2.52 (1 H, dd, J 
16.6, 8.9, 02CCUAHBCHCO), 2.27 (1 H, dd, 16.6, 4.9 1 02CCHAHBCHCO), 1.55 (1 
H, ddd, J 13.6, 8.9, 5.9, CHCEAHBCH), 1.53 (1 H, m, CH(CH 3)2), 1.42 (9 H, s, 
C(C113)3), 1.15 (1 H, ddd, J 13.6, 7.6, 5.6, CHAHBCH(CH3)2), 0.85 (3 H, d, J 6.4, 
C113ACHCH3B), 0.84 (3 H, d, J 6.4, CH3ACHCH3B); 6 (CDC1 3 ; 63 MHz) 174.3, 
171.8, 171.5 (c0NH, 02R); 135.8, (ipso-Ar); 129.2 128.4, 126.9 (CH" '); 80 6 
(c(CH3)3); 53.0 (NHcH); 52.0 (CO2cH3); 41.2 (02CcH2); 40.7 (cHCONH); 38.0, 
37.9 (HPh and cH 2CH); 27.9 (C(cH3)3),  25.4 (cH(CH3)2); 22.8, 22.0 (CH(cH 3 )2); 
m/z (FAB) 392 (34%, MH), 91(100, CH 2Ph, 57 (35, 'Bu), Found (FAB) 392.2419, 
C22H34N05 requires 392.2437. 
4.3.11. (2R,2'S)- L4-(tert-butyl)-2-iso-butyl-succinyll -valine methyl ester 127b 
tB uQC 	 CO2CH3 
The procedure outlined in Section (4.3.9.i.) was followed using EDCI (70 mg, 
0.36 mmol, 1.2 equiv.), HOBt (49 mg, 0.36 mmol, 1.2 equiv.), triethylamine (102 
p.L, 0.73 mmol, 2.4 equiv.), succinate 114 (70 mg, 0.30 mmol, 1.0 equiv.) and L-
valine methyl ester hydrochloride (61 mg, 0.36 mmol, 1.2 equiv.). Column 
chromatography, eluting with hexane:ethyl acetate (6:1) furnished the title 
compound as a colourless solid (74 mg, 71%). 
Rf (Hexane:EtOAc, 6:1) 0.20; d.e. 86%; Mp 75-76°C; (Found: C, 63.05; H, 9.60; N, 
3.98; C 18H34N05 requires C, 62.95; H, 9.68; N 4.08); [a] +12.7 (c 1.26, CHC1 3); 
um (CHCl3)/cm' 3428 (amide NH), 3018 (saturated CH), 1734 (ester C=O), 1675, 
1512 (CONH); oH (CDC13 ; 600 MHz) 6.21 (1 H, d, J 8.9, NH), 4.53 (1 H, dd, J 8.9, 
4.9, NHCU), 2.68 (1 H, m, CUCONH), 2.58 (1 H, dd, J 17.0, 9.6, OCCIIAHBCH), 
2.29 (1 H, dd, J 17.0 4.0, OCCHAIIBCH), 2.14 (1 H, dqq, J 6.9, 4.9, CHCH(CH3)2), 
1.60 (1 H, ddd, J 14.6, 9.0, 5.6, CHCIIAHBCH), 1.55 (1 H, m, CH 2CH(CH3)3)
1 
 1.40 (9 
H, s, C(Cfl3)3),  1.15 (1 H, ddd, J 14.6, 8.0, 5.6, CHCHARBCH), 0.90 (6 H, d, J 6.8, 
CH(CH3A)CHCH3B and CH(CH3A)CHCH3B), 0.89, (3 H, d, J 6.8, 
CH2(CU3A)CHCH301  0.86 (3 H, d, J 6.8, CH2(CH3A)CHCH3B); ö (CDCl; 63 MHz) 
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174.56, 172.3, 171.7 (cONH, 02C), 80.6 (C(CH3)3), 56.7 (NHcH), 51.9 (OH3), 
41.2 (0CcH2CH), 40.7 (CHCONH), 38.3 (H 2CH(CH3 )2), 31.2 (CHH(CH3)2), 27.9 
(C(H3)3), 25.5 (CH2 H(CH3)2), 22.8, 22.0 (CH2CH(cH3)2), 18.8, 17.5 
(CHCH(cH3)2); m/z (FAB), 344 (70%, MH), 288 (100, MH2-tBu), 270 (11, 288-
H20), 132 (43), 72 (57) Found (FAB), 358.2595 C 19H36N05 requires 35 18.2594. 
4.3.12. (2R,2'S)-[4-(tert-butyl)-2-iso-butyl-succinyll -leucine methyl ester 127c 
tBuQC 	
IH 
 .- 	NCO2CH3 
The procedure outlined in Section (4.3.9.ii.) was followed using TBTU (117 mg, 
0.36 mmol, 1.2 equiv.), HOBt (49 mg, 0.36 mmol, 1.2 equiv.), 
diisopropylethylamine (159 L, 0.91 mmol, 3.0 equiv.), succinate 114 (70 mg, 0.30 
mmol, 1.0 equiv.) and L-leucine methyl ester hydrochloride (66 mg, 0.36 mmol, 1.2 
equiv.). Column chromatography, eluting with hexane:ethyl acetate (6:1) furnished 
the title compound as a colourless solid (80 mg, 74%). 
Rf (Hexane:EtOAc, 6:1) 0.55; d.c. 90%; Mp 106-108 °C; (Found: C, 63.25; H, 9.74; 
N, 3.79; C 19H34N05 requires C, 63.48; H, 9.87; N 3.94); [a] 20  +3.2 (c 1.44, CHCI 3); 
Umax(CH 3)/cm' 3431 (amide NH), 3018 (saturated CH), 1736 (ester C=O), 1673, 
1513 (CONH); 6 H  (CDC13 ; 600 MHz) 6.08 (1 H, d, J 8.3 NH),  4.9 (1 H, ddd, J 13.6, 
8.3, 5.0, NHCH), 3.69 (3 H, s, 0C113),  2.64 (1 H, m, OCCH2CH), 2.57 (1 H, dd, J 
16.9, 9.6, OCCUAHBCH), 2.28 (1 H, dd, J 16.9, 4.0, OCCHAHBCH), 1.68-1.49 (total 
of 5 H, m, CH2CHCHAHBCH, CH2CHCH2CH, NHCHCHAHBCH, NHCHCHAHBCH 
and NHCHCH2CH), 1.40 (9 H, s, C(CH3)3), 1.13 (1 H, ddd, J 13.3, 7.9, 5.6 
OCCH2CHCHAHB), 0.90 (3 H, 2 d, J 6.3, C113ACHCH3B(Ieucine)) 5  0.89 (3 H, 2 d, J 6.6, 
C113ACHCH3B(succinate) ), 0.88 (3 H, d, J 6.3, CH3ACHCH3B(Ieucine)), 0.86 (3 H, d, J 6.6, 
CH3ACHCII3B(succinate) ); ö (CDC1 3 ; 63 MHz) 174.6, 173.4, 171.7 (ONH, c02C), 80.6 
((CH3)3), 52.1 (OcH3), 50.4 (NH-CH), 41.6, 41.3 (OCcH 2CH and NHCHH2), 40.6 
(CHCONH), 38.3 (OCCH2CHH2), 28.0 (C(H 3)3), 25.5, 24.5 (cH(CH3)2), 23.0, 
22.8 (CH(cH3)2( SuCC i nate), 21.8, 21.7 (CH(cH 3 )2(Ieucjfle); m/z (FAB) 357 (24%, MH), 
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302 (100, MH2-'Bu), 284 (7, 302-H20), 146 (20), 86 (38), 57 (54, 'Bu), Found (FAB) 
344.2439, C 18H36N05 requires 344.2437. 
4.3.13. (2R,2'S- [4-(tert-butyl)-2-iso-butyl-succinylj -tryptophan methyl ester 
127d 
tBuOC H N..CO2CH3 
0 - /NH 
The procedure outlined in Section (4.3.9.ii.) was followed using TBTU (119 mg, 
0.37 mmol, 1.2 equiv.), HOBt (50 mg, 0.37 mmol, 1.2 equiv.), 
diisopropylethylamine (16luL, 0.92 mmol, 3.0 equiv.), succinate 114 (71 mg, 0.31 
mmol, 1.0 equiv.) and L-tryptophan methyl ester hydrochloride (94 mg, 0.37 mmol, 
1.2 equiv.). Column chromatography, eluting with hexane:diethyl ether (1:1) 
furnished the title compound as a colourless glass (109 mg, 82%). 
Rf (Hexane:Et20, 1:1) 0.20; d.e. 90%; Mp 96-97 °C; (Found: C, 66.45; H, 7.93; N, 
6.33; C24H34N205 requires C, 66.95; H, 7.96; N 6.51); [a] +64.9 (c 1.96, CHC1 3); 
umax(CHC13)/cm' 3480 (indole NH), 3428 (amide NH), 3020 (saturated CH), 1726 
(ester C=O), 1668, 1513 (CONH); 5H  (CDC1 3; 600 MHz) 8.29 (1 H, brs, 
NE(indole))7.56 (1 H, d,J7.6,Cff ar), 7.32(1 H, d,J8.0, CH,), 7.15(1 H, m, CH), 7.13 
(1 H, d, J, 2.4, CHNH(indole)), 7.09 (total of 1 H, m, CH,), 6.27 (1 H, d, J 7.8, Nil), 
4.92 (1 H, ddd, J 7.8, 5.6, 5.4, NHCH), 3.64 (3 H, s, 0Cfl3), 3.34 (1 H, dd, J 14.8, 
5.4, CHCUAHBInd01e), 3.24 (1 H, dd, J 14.8, 5.6, CHCHAUBInd01e), 2.61 (1 H, m, 
CECONH), 2.58 (1 H, dd, J 15.8, 9.0, OCCHAHBCH), 2.29 (1 H, dd, J 15.8, 4.0, 
OCCHAHBCH), 1.58-1.50 (2 H, m, CII(CH 3)2 and CH2CHCEAHBCH), 1.40 (9 H, s, 
C(C113)3), 1.17 (1 H, ddd, J 15.4, 9.8, 5.4 CH2CHCHAUBCH), 0.84 (3 H, d, J 6.4, 
CU3ACHCH30, 0.82 (3 H, d, J 6.4, CH3ACHCII3B); 6c (CDC13 ; 63 MHz) 174.4, 
172.2, 171.6 (cONIH, 0 2C), 136.0, 127.4 (ipso-Ar), 123.1, 121.9, 119.4, 118.4, 
111.1 (CHar), 109.6 (ipso-Ar), 80.5 (c(CH3)3), 52.5 (NHH), 52.1 (OcH3), 41.3 
(OCCH2CH), 40.7 (CHCONH), 37.9 (CHH 2CH), 27.9 (C(cH3)3), 27.6 
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(CH2Indole), 25.4 (CH(CH 3 )2), 22.7, 22.0 (CH(cH 3)2); m/z (FAB) 431 (1%, MH), 
375 (12, MH2ttBu), 202 (24), 130 (100, CH2Indole), 57 (41, 'Bu), Found (FAB) 
431.2550, C24H35N205 requires 431.2546. 
4.3.14. (2R,2'S)- 14-(tert-butyl)-2-iso-butyl-succinyll-tert-leucine methyl ester 
127e 
tBuQC ....- yNCO2CH3 
The procedure outlined in Section (4.3.9.ii.) was followed using TBTU (119 mg, 
0.37 mmol, 1.2 equiv.), HOBt (50 mg, 0.37 mmol, 1.2 equiv.), 
diisopropylethylamine (161 tL, 0.92 mmol, 3.0 equiv.), succinate 114 (71 mg, 0.32 
mmol, 1.0 equiv.) and L-tert-leucine methyl ester hydrochloride (67 mg, 0.37 mmol, 
1.2 equiv.). Column chromatography, eluting with hexane:ethyl acetate (6:1) 
furnished the title compound as a colourless solid (84 mg, 77%). 
Rf (Hexane:EtOAc, 6:1) 0.38; d.e. 86%; Mp 104-106 °C; (Found: C, 63.82; H, 9.67; 
N, 3.91; C 19H35N05 requires C, 63.84; H, 9.87; N 3.92); [a] 20  +5.3 (c 1.48, CHC1 3); 
Umax(CHC13)/Cm' 3433 (amide NH), 3018 (saturated CH), 1729 (ester C=O), 1675, 
1512 (CONH); 6H  (CDC13 ; 600 MHz) 6.29 (1 H, d, J9.3, NH), 4.42 (1 H, d, J9.3, 
NHCU), 3.69 (3 H, s, 0C11 3), 2.67 (1 H, m, CIICONH), 2.58 (1 H, dd, J 17.0, 9.6, 
OCCUAHBCH), 2.29 (1 H, dd, J 17.0, 4.0, OCCHAHBCH), 1.59 (1 H, ddd, J 13.6, 
8.9, 5.9, CHCHAHBCH), 1.51 (1 H, m, Cff(CH 3)2), 1.14 (1 H, ddd, J 13.6, 7.9, 5.9, 
CHCHAUBCH), 0.88 (3 H, d, J 6.6, CH3ACHCH3B), 0.84 (3 H, d, J 6.6, 
CH3ACHCII3B); ö (CDC1 3 ; 63 MHz) 174.3, 171.9, 171.7 (cONH, 0 2C), 80.6 
(Oc(CH3)3), 59.7 (NHcH), 51.6 (OH3), 41.1 (OCH2CH) 40.7 (HCONH), 38.1 
(CHH2CH), 34.7 (CH(CH3) 3), 27.9 (OC(H 3)3), 26.4 (CHC(cH 3)3), 25.5 
(H(CH3)2)
1
. 22.8, 22.1 (CH(H3)2); m/z (FAB) 358 (24%, MH), 302 (100, MH2 -




4.3.15. (2R,2'S)- t4-(tert-butyl)-2-iso-butyl-succinylj-phenylalanine methyl ester 
and (2R,2'R)-14-(tert-butyl)-2-iso-butyl-succjnylj -phenylalanine methyl ester 
127a 
tBu0c .2 NyCO2CH3 
Ph 
The procedure outlined in Section (4.3.9.i.) was followed using EDCI (1.05 g, 
5.47 mmol, 1.2 equiv.), HOBt (739 mg, 5.47 mmol, 1.2 equiv.), triethylamine (1.53 
mL, 10.94 mmol, 2.4 equiv.), succinate 114 (1.05 g, 4.56 mmol, 1.0 equiv.) and DL-
phenylalanine methyl ester hydrochloride (1.18 g, 5.47 mmol, 1.2 equiv.). Column 
chromatography, eluting with hexane:ethyl acetate (6:1) furnished the title 
compound as a colourless solid (1.42 g, 80%). 'H nmr indicated a (1:1) ratio of 
diastereomers. 
Rf (Hexane:EtOAc, 6:1) 0.27, 0.23; Mp 69-72 °C (Found: C, 67.52; H, 8.49; N, 3.49; 
C22H33N05 requires C, 67.49; H, 8.49; N 3.58); [a] 20  +7.9 (c 1.34, CHC1 3); 
Umx(CHC13)/Cm' 3429 (amide NH), 3019 (saturated CH), 1737, 1732 (ester CO), 
1668, 1510 (CONH); 5H  (CDC13 ; 600 MHz) 7.25 (1 H, tt, J7.3, Cff (me)), 7.23 (1 
H, U, J 7.3, CU B a, (meta))' 7.21-7.17 (total of 1 H, m, CU a) of each diastereomer), 
7.13 (1 H, brt, J 7.3, CH A 	 B a, (oilho))' 7.08 (1 H, brt, J 7.3, CII (oho))' 6.18 (total of 1 H, 
br d, Nfl of each diastereomer), 4.84 (total of 1 H, 2 x m, NHCU, of each 
diastereomer), 3.66 (1.5 H, s, OCfl), 3.64 (1.5 H, s, OCH), 3.11 (0.5 H, dd, J 
14.0, 5.9, CHHBPh) 3.06 (0.5 H, dd, J 14.3, 6.0, CII2HBPh)  3.05 (0.5 H, dd, J 
14.3, 5.9 CHAIIPh), 3.00 (0.5 H, dd,J 14.0, 6.9, CH AUPh), 2.57 (total of 2 H, m, 
CffCONH of each diastereomer), 2.50 (0.5 H, dd, J 16.3, 9.0, OCCUHBCH), 2.49 
(0.5 H, dd,J 16.6, 8.9, OCCII2HBCH),  2.23 (0.5 H, dd,J 16.6, 4.9, OCCH AUCH) 
2.22 (0.5 H, dd, J 16.3, 5.0, OCCHAH CH), 1.55-1.47 (total of 1.5 H, m, 
CHCU2HBCH, CHA(CH32  and CHCUHB) 1.39 (4.5 H, s, C(Cfl') 3), 1.36 (4.5 
H, s, C(CH)3),  1.32 (0.5 H, m, CHB(CH3)2),  1.13 (0.5 H, ddd, J 13.3, 7.6, 5.6, 
119 
Experimental 
CHCHAU B  CH), 1.06 (0.5 H, ddd, J 13.6, 8.6, 5.3, CHCHAffCH), 0.83 (1.5 H, d, J 
6.6, CH AA  0.81 (1.5 H, d, J 6.6, CH3CHCH B ), 0.79 (1.5 H, d J 6.6 
CH3CHCH'A ) 0.79 (1.5 H, d J 6.6 CH3CHCfl B); 6c (CDC13 ; 63 MHz) 174.3, 
174.2, 171.8, 171.5, 171.3 (cONH, 02R), 135.8 (ipso-Ar), 129.1, 129.0, 128.3, 
126.9, (CHar), 80.6, (c(CH3)3), 52.9, 52.8 (NIHcH), 52.0 (CO2cH3), 41.2, 41.0 
(02CCH2), 40.6, 40.5 (CHCONH), 38.2, 37.9, 37.8 (cH 2CH(CH3)2 and cH2Ph), 27.9, 
27.8 (C(cH 3 )3), 25.4 (cH(CH3)2), 22.9, 22.7, 22.0, 21.9 (CH(cH 3)2); m/z (FAB) 392 
(62%, MH), 336 (100, MH 2ttBu), 258 (13), 180 (52), 120 (30), 91(18, CH2Ph), 57 
(25, 'Bu), Found (FAB), 392.24 124, C 22H34N05 requires 392.2437. 
4.3.16. (2R,2'R)-[4-(tert-butyl)-2-iso-butyl-succinyl]-valine methyl ester and 
(2R,2'S)- [4-(tert-butyl)-2-iso-butyl-succinyl] -valine methyl ester 127b 
tBuOC ..- 	NCO2CH3 
0 )Q 
The procedure outlined in Section (4.3.9.i.) was followed using EDCI (1.04 g, 
5.42 mmol, 1.2 equiv.), HOBt (732 mg, 5.42 mmol, 1.2 equiv.), triethylamine (1.51 
mL, 10.84 mmol, 2.4 equiv.), succinate 114 (1.04 g, 4.52 mmol, 1.0 equiv.) and DL-
valine methyl ester hydrochloride (1.18 g, 5.47 mmol, 1.2 equiv.). Column 
chromatography, eluting with hexane:ethyl acetate (6:1) furnished the title 
compound as a colourless wax (1.20 g, 77%). 'H nmr indicated a (1:1.5) ratio of 
diastereomers. 
Rf (Hexane:EtOAc, 6:1) 0.20, 0.18;(Found: C, 62.97; H, 9.98; N, 4.01; C 18H33N05 
21 requires C, 62.95; H, 9.68; N 4.08); [a]+  4.74 (c 1. 16, CHC13); umax(CHC1 3)/cm' 
3428 (amide NH), 1734, 1730 (ester C=O), 1671, 1507 (CONH); 6H (CDC1 3 ; 600 
MHz) 6.30 (0.6 H, d, J 8.3, NUA),  6.22 (0.4 H, d, J 8.9, NHB)  4.53 (0.4 H, dd, J 8.9, 
4.9, NHCU8),  4.48 (0.6 H, dd, J 8.3, 4.9 NHCIIA),  3.70 (1.8 H, s, OCIj), 3.68 (1.2 
H, s, OCH), 2.86 (total of 1 H, m, CIICONH of each diastereomer), 2.57 (0.4 H, 
dd, J 17.0, 9.6, OCCHHBCH), 2.54 (0.6 H, dd, J 16.9, 8.6, OCCII2HBCH),  2.29 
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(0.4 H, dd, J 17.0, 4.0, OCCHAHCH), 2.2.8 (0.6 H, dd, J 16.9, 5.0, 
OCCHAU CH), 2.12 (total of 1 H, m, CHCU(CH 3)2 of each diastereomer), 1.64 (0.6 
H, ddd, J 15.0, 9.6, 5.6, CHCH2HBCH),  1.60 (0.4 H, ddd, J 14.6, 9.0, 5.6, 
CHCH Ali  CH), 1.54 (total of 1 H, m, CHCH AHBCH of each diastereomer), 1.40 
(3.6 H, s, C(CIj)3), 1.39 (2.4 H, C(CH) 3),1.14 (0.6 H, ddd, J 15.0, 8.6, 5.6 
CHCHAU CH), 1.13 (0.4 H, ddd, J 14.6, 8.0, 5.6 CHCHAH CH), 0.90 (1.8 H, d, J 
6.6, CH2(CU A )CHCH3B), 0.89 (3 H, d, J 6.9, CH(CH3A)CHCH3B of each 
diastereomer), 0.88 (3 H, d, J 6.9, CH(CU3A)CHCH3B of each diastereomer), 0.88 
(1.2 H, d, J 6.6, CH2(CH3A)CHCH B ), 0.87 (1.8 H, d, J 6.6 CH2(CH A )CHCH3B), 
0.85 (1.2 H, d,J6.6, CH 2(CH3A)CHCH B ); ö (CDC1; 63 MHz) 174.7, 174.6, 172.3, 
172.1, 171.7, 171.6 (CONH, c0 2R), 80.7, 80.6 (c(CH3 )3), 56.9, 56.7 (NHcH), 51.9 
(CO2 H3), 41.2, 41.0 (0 2CH2), 40.7, 40.6 (cHCONH), 38.4, 38.2 (CHcH 2CH), 
31.1, 30.9 (CHcH(cH3)2), 27.9 (C(H3)3), 25.6, 25.5 (CH2cH(CH3)2), 23.0, 22.8, 
22.0, 21.8 (CH2CH(CH3)2), 18.8, 18.8, 17.7, 17.5 (CHCH(cH3)2); m/z (FAB) 344 
(49%, MH), 288 (100, MH2-2Bu), 210 (17), 157 (12), 132 (59), 72 (100), 57 (55, 
'Bu), Found (FAB), 344.2432, C 18H34N05 requires 344.2437. 
4.3.17. (2R,2'R)- 14-(tert-butyl)-2-iso-butyl-succinyl] -leucine methyl ester and 
(2R,2'S)-14-(tert-butyl)_2-iso_butyl_succinyl]_leucjne methyl ester 127c 
tBuOC 	 CH3 
The procedure outlined in Section (4.3.9.ii.) was followed using TBTU (1.74 g, 
5.42 mmol, 1.2 equiv.), HOBt (732 mg, 5.42 mmol, 1.2 equiv.), 
diisopropylethylamine (2.36 mL, 13.55 mmol, 3.0 equiv.), succinate 114 (1.04 g, 
4.52 mmol, 1.0 equiv.) and DL-leucine methyl ester hydrochloride (984 mg, 5.42 
mmol, 1.2 equiv.). Column chromatography, eluting with hexane:ethyl acetate (6:1) 
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furnished the title compound as a colourless solid (1.25 g, 77%). 'H nmr indicated a 
(1:1) mixture of diastereomers. 
Rf (Hexane:EtOAc, 6:1) 0.55, 0.46; Mp 63-66 °C, (Found: C, 64.15; H, 10.02; N, 
3.68; C 19H35N05 requires C, 63.84; H, 9.87; N 3.94); [a] 20  + 6.08 (c 1.20, CHC13); 
Umax(CH 3)i'cm'; 3434 (amide NH), 1740, 1734 (ester C=O), 1675, 1672, 1517, 
1512 (CONE!); oH (CDC1 3 ; 600 MHz) 6.21 (0.5 H, d, J 8.0, NW), 6.10 (0.5 H, d, J 
8.3 Nff8),4.60 (0.5 H, ddd, J 13.6, 8.3, 5.0, NHCUB),  4.54 (0.5 H, ddd, J 13.6, 8.0, 
5.0, NHCUA),  3.69 (1.5 H, s, OCff'), 3.67 (1.5 H, s, OCH),  2.65 (total of 1 H, m, 
CUCONH of each diastereomer), 2.56 (0.5 H, dd, J 16.9, 9.6, OCCUHBCH), 2.53 
(0.5 H, dd, J 16.9, 8.6, OCCH2HBCH)  2.28 (0.5 H, dd, J 16.9, 5.3, OCCHAUCH), 
2.27 (0.5 H, dd, J 16.9, 4.0, OCCH Ali  CH), 1.66-1.48 (total of 5 H, m, 
CH2CHCUAHBCH, CH2CHCH2Cff, NHCHCHAHBCH, NHCHCHARBCH, and 
NHCHCH2Cff, of each diastereomer), 1.40 (4.5 H, s, C(CH) 3), 1.39 (4.5 H, s, 
C(CIj)3), 1.14 (0.5 H, ddd,J 13.6, 8.3, 5.6, CH2CHCHAHCH), 1.13 (0.5 H, ddd,J 
13.6, 8.3, 5.6, CH2CHCHA1iCH), 0.91 (1.5 H, d, J 6.3, CUA CHCH3S(leucine)), 0.90 
(1.5 H, d,J6.3, CH3ACHCff B(leucine)) 0.89 (1.5 H, d,J6.3, Cli A CHCH3B(!eucine)), 0.88 
(1.5 H, d, J 6.6, CH A CHCH3B(succinate) ), 0.87 (1.5 H, d, J 6.3, CH3ACHCff B( Ieuc ine)), 
0.87 (1.5 H, d, J 6.6, C11  AA CHCH3A(succinate) ), 0.86 (1.5 H, d, J 6.6, 
CH3ACHCU B(succ i nate)) 0185 (1.5 H, d, J 6.6, CH3ACHCU B(succinate)); ö (CDCl; 63 
MHz) 174.6, 174.5 (ONH), 173.3, 173.2, 171.7, 171.6 (COX, 80.7, 80.6 
((CH3)3 , 52.0 (CO2cH3), 50.6, 50.3 (NHcH), 41.5, 41.3, 41.2, 40.9, (02CH2 and 
cH2CH(CH3)2( ,eUcine)), 40.5, 40.4 (HCONH), 38.3, 38.2 (cH 2CH(CH3)2(SUCCInate) ), 27.9 
(C(H3)3), 25.6, 25.4, 24.7, 24.4 (2 x H(CH 3)2), 22.9, 22.8, 22.7, 22.6, 22.0, 21.9, 
21.7, 21.6 (2 x CH(H02); m/z (FAB) 358 (55%, MIH), 302 (100, MH2 -'Bu), 284 
(26, 284-H20), 154 (26), 146 (44), 86 (52), 57 (38, 'Bu), Found (FAB), 358.2588, 
C, 9H36N05 requires 358.2593. 
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4.3.18. (2R,2'R)- 14-(tert-butyl)-2-iso-butyl-succinyl]-tryptophan methyl ester and 
(2R,2'S)-[4-(tert-butyl)-2-iso-butyl-succinyl] -tryptophan methyl ester 127d 
tBUOC N CO2CH3 
O1 J 
The procedure outlined in Section (4.3.9.ii.) was followed using TBTU (1.82 g, 
5.68 mmol, 1.2 equiv.), HOBt (767 mg, 5.68 mmol, 1.2 equiv.), 
diisopropylethylamine (2.47 mL, 14.20 mmol, 3.0 equiv.), succinate 114 (1.09 g, 
4.73 mmol, 1.0 equiv.) and DL-tryptophan methyl ester hydrochloride (1.45 g, 5.68 
mmol, 1.2 equiv.). Column chromatography, eluting with hexane:ethyl acetate (2:1) 
furnished the title compound as a colourless solid (1.55 g, 78%). 'H nmr indicated a 
(1:1) ratio of diastereomers. 
Rf (Hexane:EtOAc, 1:1) 0.76, 0.76; Mp 51-53 °C, (Found: C, 66.93; H, 8.09; N, 
6.48; C24H34N205 requires C, 66.95; H, 7.95; N 6.51); [a]+ 21.47 (c 1.36, CHC1 3); 
Umax(CHC13)/'Cm'; 3476 (indole NH), 3433 (amide NH), 3017 (saturated CH), 1734, 
1725 (ester C=O), 1675, 1669, 1512, 1507 (CONH); oH (CDC13 ; 600 MHz) 8.29 
(total of 1 H, brs, Ni fldOIe) of each diastereomer)7.56 (total of 1 H, m, CH, of each 
diastereomer), 7.32 (total of 1 H, m, CH ar of each diastereomer), 7.15 (total of 1 H, 
m, CH of each diastereomer), 7.13 (total of 1 H, m, CUNH (indOIe) of each 
diastereomer), 7.09 (total of 1 H, m, CHar of each diastereomer), 6.27 (0.5 H, d, J 7.8, 
NW), 6.25 (0.5 H, d, .J 7.8, NW), 4.92 (0.5 H, ddd, J 7.8, 5.6, 5.4, NHCU8),  4.91 
(0.5 H, ddd, J7.8, 6.0, 5.8, NHCHA),  3.64 (1.5 H, s, OCfl),  3.61 (.5 H, s, OCff), 
3.34 (0.5 H, dd, J 14.8, 5.4, CHCflH8Indole), 3.28 (0.5 H, dd, J 5.8, 
CHCfl2H8Indole), 3.27 (0.5 H, dd, J 5.8, CHCHAflIndole), 3.24 (0.5 H, dd, J 
14.8, 5.6, CHCHAUIndole), 2.63-2.56 (1 H, m, CHCONH of each diastereomer), 
2.58 (0.5 H, dd, J 15.8, 9.0, OCCHHBCH), 2.53 (0.5 H, dd, J 16.2,5.6, 
OCCHHBCH), 2.29 (0.5 H, dd,J 15.8, 4.0, OCCHAHCH), 2.26 (0.5 H, dd, J 16.2, 
5.2, OCCHAUCH), 1.58-1.48 (total of 1.5 H, m, CUA(CH 3)2, CHB(CH3)2, 
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CH2CHCU2HBCH and CH2CHCUHBCH), 1.40 (4.5 H, s, C(Cff) 3), 1.38 (4.5 H, 
S, 
C(Cfl)3), 1.37 (0.5 H, m, obscured by 'Bu peaks, CHB(CH3)2),  1.17 (0.5 H, ddd, J 
15.4, 9.8, 5.4 CH2CHCHA1iCH), 1.11 (0.5 H, ddd, J 13.8, 8.4, 5.8 
CH2CHCH All  CH), 0.84 (1.5 H, d, J 6.4, CH A CH 3B), 0.82 (1.5 H, d, J 6.4, 
CH3ACHCU B ), 0.76 (1.5 H, d, J 6.4, CHA CH 3B), 0.75 (1.5 H, d, J 6.4, 
CH3ACHCfl B );8c (CDC1; 63 MHz) 174.5, 174.4, 172.2, 171.6, 171.4 (ONH, 
OR,  136.0, 136.0, 127.4 (ipso-Ar), 123.1, 122.7, 122.0, 121.9, 119.4, 119.3, 
118.4, 118.3, 111.1, 111.0 (CH ar), 109.8, 109.6 (ipso-Ar), 80.6, 80.6 ((CH 3)3), 52.6, 
52.5 (NHH), 52.0 (02 H3), 41.3, 40.9 (02CH2), 40.8, 40.5 (HCONH), 38.2, 
37.9, (cH2CH(CH3)2), 27.9, 27.8 (C(H 3)3), 27.6 (H2Indole), 25.4, 25.3 
(H(CH3)2), 22.7, 22.6, 22.0, 21.9 (CH(cH 3)2); m/z (FAB) 431 (50, MH), 375 (88, 
MH2 -'Bu), 201(83), 159 (42), 130 (100, CH 2Indole), 57 (58, 'Bu), Found (FAB), 
431.2533, C24H35N205 requires 431.2546. 
4.3.19. (2R,2'R)- [ 4-(tert-buty1)-2-iso-butyI-succiny1 -tert-leucine methyl ester and 
(2R,2'S)- [4-(tert-butyl)-2-iso-butyl-succinylj -tert-leucine methyl ester 127e 
tBUOC 	
IH 
, y NyCO2CH3 
The procedure outlined in Section (4.3.9.ii.) was followed using TBTU (1.52 g, 
4.73 mmol, 1.2 equiv.), HOBt (639 mg, 4.73 mmol, 1.2 equiv.), 
diisopropylethylamine (2.06 mL, 11.83 mmol, 3.0 equiv.), succinate 114 (908 mg, 
3.94 mmol, 1.0 equiv.) and DL-tert-leucine methyl ester hydrochloride (788 g, 4.34 
mmol, 1.1 equiv.). Column chromatography, eluting with hexane:ethyl acetate (6:1) 
furnished the title compound as a colourless wax (873 g, 62%). 'H nmr indicated a 
(1:1). ratio of diastereomers. 
Rf (Hexane:EtOAc, 6:1) 0.38, 0.32; [a] + 5.78 (c 1.16, CHC1 3); umax(CHC13)/cm' 
3432 (amide NH), 3010 (saturated CH), 1731 (ester C=O), 1673, 1513 (CONH); oH 
(CDC13 ; 600 MHz) 6.35 (0.5 H, d, J 9.3, NH"),  6.29 (0.5 H, d, J 9.3, NHB)  4.42 (0.5 
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H, d, J9.3, NHCUB),  4.38 (0.5 H, d, J9.3, NHCHA),  3.69 (1.5 H, s, OCll), 3.67 
(1.5 H, s, OCkI), 2.68 (total of 1 H, m, CHCONH of each diastereomer), 2.58 (0.5 
H, dd, J 17.0, 9.6, OCCUHBCH), 2.51 (0.5 H, dd, J 16.9, 9.0, OCCff 2 HBCH), 2.29 
(0.5 H, dd, J 17.0, 4.0, OCCHAU CH), 2.28 (0.5 H, dd, J 16.9, 5.0, OCCHAH CH), 
1.65 (0.5 H, ddd, J 13.6, 9.3, 5.6, CHCII2HBCH), 1.59 (0.5 H, ddd, J 13.6, 8.9, 5.9, 
CHCUHBCH), 1.58-142 (total of 1 H, m, CII(CH3)2 of each diastereomer), 1.14 
(0.5 H, ddd, J 13.6, 7.9, 5.9, CHCHAU CH), 1.13 (0.5 H, ddd, J 13.6, 8.3, 5.6, 
CHCU2HBCH), 0.90 (1.5 H, d, J 6.6, CUA CHC H3B), 0.88 (1.5 H, d, J 6.6, 
CIIA CHCH3B), 0.87 (1.5 H, d, J 6.6, CH3ACHCHB), 0..84 (1.5 H, d, J 6.6, 
CH3ACHCfl B ); 8c (CDC13 ; 63 MHz) 174.6, 174.3, 171.9, 171.7, 171.6 (cONH, 
02C), 80.7, 80.6 (Oc(CH 3)3), 60.0, 59.7 (NHH), 51.5, 51.5 (0CJ43), 41.1, 41.0 
(02CH2), 40.7 (cHCONH), 38.4, 38.2 (CHcH 2CH), 34.7, 34.3 (CH(CH3)3), 27.9, 
27.9 (OCC(cH 3 )3), 26.5, 26.4 (CHC(cH 3)3), 25.7, 25.5 (CH(CH3)2), 23.0, 22.8, 22.1, 
21.8 (CH(H3)2); mlz (FAB), 358 (24%, MH), 302 (100, MH2t'Bu), 284 (16, 302-
H20), 242 (12), 86 (30), 57 (30, 'Bu), Found (FAB) 358.2593, C 19H36N05 requires 
358.2594. 
4.3.20. General procedure for the hydrolysis of (2R,2'RS)-14-(tert-
butyl)-2-iso-butyl-succinylj -a-amino acid methyl esters 1 27a-e 
To amide 127a-e suspended in THF:water (1:1, 20 mL), was added lithium 
hydroxide monohydrate (2.0 equiv.) and the resulting suspension stirred for 30 
minutes at room temperature until a clear solution was obtained. The reaction 
mixture was acidified to pH 3 with aqueous citric acid (1M), and the aqueous layer 
extracted with ethyl acetate (2 x 50 mL). The combined organic extracts were 
washed with brine (30 mL), dried (Na 2 SO4), filtered, and evaporated under reduced 
pressure to give the desired product. 
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4.3.21. (2R,2'S)- [4-(tert-butyl)-2-iso-butyl-succinyl] -phenylalanine and (2R,2'R)-





The general procedure outlined in Section (4.3.20.) was followed with DL-
phenylalanine derived amide 127a (1.03 g, 2.63 mmol) and lithium hydroxide 
monohydrate (221 mg, 5.26 mmol, 2.0 equiv.) to furnish the title compound as a 
colourless gum (0.99 g, quantitative). 'H nmr indicated a (1:1) ratio of diastereomers. 
[a] 20+ 11.02 (c 1.18, CHC1 3); umax(CHC13)/cm'; 3425 (amide NH), 3200-2400 (acid 
OH), 3019 (saturated CH), 1723 (ester C=O, and acid C=O), 1671, 1516 (CONH); oH 
(CDC13 ; 600 MHz) 7.29-7.25 (total of 2 H, m, of each diastereomer), 7.24-7.21 
(total of 2 H, m, CH, of each diastereomer), 7.19-7.17 (total of 1 H, m, Ci, r of each 
diastereomer), 6.46 (0.5 H, d, J 7.8., NRA),  6.41 (0.5 H, d, J 7.6, NH ), 4.87 (0.5 H, 
ddd, J 7.8, 5.4, NHCIIA),  4.84 (0.5 H, ddd, J 7.6, 6.4, NHCUB),  3.24 (0.5 H, d, J 
14.2, 5.4, CR2HBPh),  3.17 (0.5 H, d,J 14.0, 5.6, CffHBPh), 3.12 (0.5 H, d,J 14.0, 
6.4, CH Ali  Ph), 3.03 (0.5 H, d, J 14.2, 8.0, CHAIIPh), 2.67-2.57 (total of 1 H, m, 
CRCONIH of each diastereomer), 2.54 and 2.50 (total of 1 H, 2 x dd, J 16.0, 9.0, and 
16.6, 8.8, OCCHAHBCH of each diastereomer), 2.29 and 2.25 (total of 1 H, 2 x dd, J 
16.6, 5.0, and 16.0, 4.2, OCCHARBCH of each diastereomer), 1.58-1.41 (total of 1.5 
H, CUAH13CH(CH3)2 of each diastereomer, and CIjA(CH3)2),  1.41 (4.5 H, s, 
C(Cfl)3), 1.38 (4.5 H, s, C(Cli)3 , 1.23 (0.5 H, m, CUB(CH3)2),  1.15 (0.5 H, ddd,J 
13.6, 8.0, 6.2, CHCHACUCH), 1.04 (0.5 H, ddd, J 13.6, 8.8, 5.4, CHCHACUCH), 
0.83, (1.5 H, d,J6.4 CH BA  0.82 (1.5 H, d,J6.4 CH3ACHCH'B), 0.76 (1.5 
H, d, J 6.4 CUCHCH3B), 0.75 (1.5 H, d, J 6.4 CH3ACHCH);  O (CDC13 ; 63 
MHz) 175.6, 175.2, 174.5, 174.3, 172.2, 171.8 (ONH, c02H, 02C), 135.9, 135.8, 
(ipso-Ar), 129.3, 129.1, 128.5, 126.97 (CH ar), 81.8, 81.0 ((CH 3)3), 53.2, 53.01 
(NHH), 41.0 (02CH2), 40.7, 40.5 (HCONH), 38.1, 38.0 (cH 2CH(CH3)2), 37.3, 
37.2 (HA), 27.9, 27.9 (c(cH3)3), 25.5, 25.4 (CH(CH3)2), 22.9, 22.7, 22.0, 21.9 
(CH(H3 )2); m/z (FAB) 378 (41%, MH), 322 (100, MH 2 -'Bu), 258 (8), 166 (38), 
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120 (67), 91(34, CH2Ph), 57 (62, tBu), Found (FAB), 378.2263, C 21 H32N05 requires 
378.2280. 
4.3.22. (2R,2'R)- [ 4-(tert-butyl)-2-iso-butyl-succinylj -valine and (2R,2'S)- [4-(tert-
butyl)-2-iso-butyl-succinyl]-valine 128b 
tB UQC - 	NCO 2 H 
O /\  
The general procedure outlined in Section (4.3.20.) was followed with DL-valine 
derived amide 127b (1.02 g, 2.97 mmol) and lithium hydroxide monohydrate (249 
mg, 5.94 mmol, 2.0 equiv.) to furnish the title compound as a colourless gum (0.98 
g, quantitative). 'H nmr indicated a (1.5:1) ratio of diastereomers. 
[a] 21 
 + 6.67 (c 1.08, CHC1 3); um (CHC13)Icm'; 3496 (amide NH), 3400-2400 (acid 
OH), 3020 (saturated CH), 1752 (ester C=O) 1718 (acid C=O), 1654, 1519 (CONH); 
6., (CDC1 3 ; 600 MHz) 9.88 (total of 1 H, br s, OH of each diastereomer), 6.62 (0.6 H, 
d, J 8.6, NUA),  6.50 (0.4 H, d, J 8.9, N}jB)  4.56 (0.4 H, dd, J 8.9, 4.6, NHCHA),  4.51 
(0.6 H, dd, J 8.6, 4.6, NHCHB),  2.73 (total of 1 H, m, CHCONH of each 
diastereomer), 2.58 (0.4 H, dd,J 17.3, 9.6, OCCUHBCH), 2.55(0.6 H, dd, 16.6, 8.6, 
OCCUHBCH), 2.31 (0.4 H, dd, J 17.3, 4.3, OCCHAH CH), 2.30 (0.6 H, dd, J 16.6, 
5.3, OCCH Ali  CH), 2.21 (total of 1 H, m, CHCH(CH 3)2 of each diastereomer), 1.64 
(0.6 H, ddd, J 13.3, 9.6, 5.3, CHCH2HBCH),  1.60 (0.4 H, ddd, J 13.3, 9.0, 5.9, 
CHCHHBCH), 1.56-1.49 (total of 1 H, 2 x m, CH2CU(CH3)2 of each diastereomer), 
1.39 (3.6 H, s, C(CU' )), 1.38 (5.4 H, s, C(CU)3),  1.1 (0.6 H, ddd, J 13.3, 8.6, 5.3, 
CHCH Ali  CH), 1.13 (0.4 H, ddd, J 13.3, 8.0, 5.9, CHCHAHCH), 0.95 and 0.92 
(total of 6 H, 2 x d, J 6.6, CH(CH3A)CHCH3B and CH(CH3A)CHCH3B of each 
diastereomer), 0.89, 0.87, 0.86, 0.83 (total of 6 H, 4 x d, J 6.6, CH2(CH3A)CHCH3B 
and CH2(CH3A)CHCH3B of each diastereomer); E, (CDC1 3 ; 63 MHz) 175.5, 175.3, 
175.2, 172.1, 171.9 (CONH, 0 2H, ç02C), 81.1, 80.9 ((CH3)3), 57.0, 56.8 
(NHcH), 41.0, 40.9 (02ccH2), 40.7, 40.6 (CHCONH), 38.3, 38.2 (H 2CH(CH3)2), 
30.9, 30.6 (cH(CH 3)2(vaIine)), 27.9, 27.8 (C(CH3)3),  25.6, 25.5 (H(CH3)2(succinate) ) 9 22.9 2 
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22.8, 22.1, 22.0, 21.8, (CH(cH3)2(succjflate) ), 18.9, 18.8, 17.5, 17.3 (CH(cH3)2(yaljfle)); m/z 
(FAB), 330 (25%, MH), 274 (100, MH2ttBu), 256 (16, 274-H20),210 (7), 157 (9), 
118 (37), 72 (46), 57 (30, 'Bu), Found (FAB), 330.2283, C 17H32N05 requires 
330.2280. 
4.3.23. (2R,2'R)- [ 4-(tert-buty1)-2-iso-buty1-succjny1 -leucine and (2R,2'S)-[4-(tert-
butyl)-2-iso-butyl-succinylJ-leucine 128c 
tB UQC 	 CO2H 
o 
The general procedure outlined in Section (4.3.20.) was followed with DL-leucine 
derived amide 127c (1.12 g, 3.13 mmol) and lithium hydroxide monohydrate (263 
mg, 6.26 mmol, 2.0 equiv.) to furnish the title compound as a colourless gum (1.08 
g, quantitative). 'H nmr indicated a (1:1) ratio of diastereomers. 
[a] 20 
8.56 (c 1.32, CHC1 3); umax(CHC13)/cm'; 3442 (amide NH), 3200-2450 (acid 
OH), 3019 (saturated CH), 1720 (ester C=O and acid C=O), 1655, 1522 (CONH); 6 H 
(CDC13 ; 600 MHz) 8.16 (total of 1 H, br s, Off of each diastereomer), 6.49 (0.5 H, d, 
J 8.0, NW), 6.35 (0.5 H, d, J 8.0, NH8), 4.58 (0.5 H, ddd, J 9.6, 8.0, 4.9, NHCII8), 
4.53 (0.5 H, ddd, J 9.3, 8.0, 4.6, NHCHA),  2.62 (total of 1 H, m, CHCONH), 2.58 
(0.5 H, dd, J 16.9 10.0, OCCUHBCH), 2.56 (0.5 H, dd, J 16.9, 9.0, OCCHHBCH) 
2.31 (0.5 H, dd, J 16.9 5. 1, OCCH All  CH), 2.30 (16.9, 4.3, OCCHAHCH), 1.71- 
1.51 (total of 5 H, m, CH2CHCH2CH, CH2CHCH2CH, NHCHCH2CH, and 
NHCHCHAHBCH, of each diastereomer), 1.40 (total of 9 H, s, C(Cff 3)3 of each 
diastereomer), 1.15 (0.5 H, ddd, J 13.6, 8.3, 5.6, CH2CHCHACHCH(CH3)2), 1.14 
(0.5 H, ddd, J 13.6, 7.9, 6.0, CH2CHCHACHCH(CH3)2 , 0.94, 0.92, 0.91, 0.90, 
0.89(2), 0.87, 0.85 (total of 12 H, 8 x d, J 6.6, CU3ACHCH3B and CH3ACHCH3B of 
each iso-butyl group of each diastereomer); & (CDC1 3 ; 63 MHz) 176.5, 176.2, 175.8, 
175.3, 172.1, 171.9 (cONH, c0 2H, 02C), 81.2, 80.9 ((CH 3)3), 50.9, 50.8 
(NHcH), 41.1 (0 2CcH2), 40.9, 40.7 (cH2CH(CH3)2(Ieucine)), 40.6, 40.5 (HCONH), 
38.3, 38.1 (H2CH(CH3)2(succinate)), 27.9 (C(H 3)3), 25.7, 25.4 (cH(CH3)2(succinate)), 24.8, 
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24.5 (cH(CH3)2(Ieucjfle)), 22.9, 22.8, 22.7, 22.6, 22.0, 21.9, 21.6 (2 x CH(H 3)2); m/z 
(FAB), 344 (23%, MH). 288 (100, MH 2ttBu), 270 (18, 288-H20), 229 (30), 157 
(17), 132 (53), 86 (81), 57 (72, tBu), Found (FAB), 344.2445, C 18H34N05 requires 
344.2437. 
4.3.24. (2R,2'R)- [4-(tert-butyl)-2-iso-butyl-succinylj -tryptophan and (2R,2'S)- 14-
(tert-butyl)-2-iso-butyl-succinyl]-tryptophan 128d 
tBuQC 	 CO2H 
NH 
0 
The general procedure outlined in Section (4.3.20.) was followed with DL-
tryptophan derived amide 127d (1.35 g, 3.14 mmol) and lithium hydroxide 
monohydrate (263 mg, 6.27 mmol, 2.0 equiv.) to furnish the title compound as a 
colourless foam (1.31 g, quantitative). 1H nmr indicated a (1:1) ratio of 
diastereomers. 
Mp 77-79°C; [a] 21  + 22.82 (c 1. 10, CHCI3); um (CHC13)/cm 1 ; 3476 (amide NH and 
indole NH), 3400-2400 (acid OH), 3019 (saturated CH), 1720 (ester C=O and acid 
C=O), 1669, 1519 (CONH); SH  (CDC13 ; 600 MHz) 8.46 (total of 1 H, ,br s, NJ(I ndO Ie) 
of each diastereomer),7.63 and 7.55 (total of 1 H, 2 X d, J 7.9, CHar of each 
diastereomer), 7.32 and 7.31 (total of 1 H, 2 x d, J 7.3, CH r  of each diastereomer), 
7.16 (total of 1 H, m, CL of each diastereomer), 7.08 (total of 1.0 H, m, CL of 
each diastereomer) 7.06 (0.5 H, d, J 2.3, CHar), 6.97 (0.5 H, d, J 2.3, CHar), 6.45 and 
6.42 (total of 1 H, 2 X d, J 7.6, NH(amide)  of each diastereomer), 4.92 and 4.90 (total of 
1 H, 2 ddd, J7.6, 5.6, and 7.6, 5.8, NHCH of each diastereomer), 3.33 (0.5 H, dd, J, 
15.0, 6.6, CHCllHBIndo1e), 3.30 (total of 1.0 H, m, CHCU2HBInd01e  and 
CHCHAHIndo1e), 3.26 (0.5 dd, J 15.0, 6.6, NHCHCHAH), 2.61 (0.5 H, m, 
CH°CONH), 2.52 (total of 1.5 H, m, CHCONH, OCCHH BCH and OCCH2HBCH), 
2.28 (0.5 H, dd, J 16.6, 5.3, OCCHAHCH) 2.24 (0.5 H, dd, J 20.2, 8.6, 
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OCCH All ), 1.49 (total of 1 H, m, CH(CH 3 )2 of each diastereomer), 1.43 (0.5 H, m, 
CHCUAHBCH), 1.39 (4.5 H, s, C(Cfl' ) 3), 	 )3) 1.35 (4.5 H, s, C(Cff, 	1 .25 (0.5 H, m, 
CHCffAHBCH), 1.14 (0.5 H, ddd,J 13.0, 9.6, 5.6, CHCHAHCH), 1.07(0.511, ddd, 
J 13.6, 8.3, 5.3, CHCHAUCH), 0.77, 0.76 and 0.70, 0.68 (total of 6 H, 4 x d, J6.3, 
CH3ACHCH3B and CH3ACHCH3B of each diastereomer); 6 (CDC1 3 ; 63 MHz) 175.7, 
175.4, 174.9, 174.7, 172.1, 171.9 (CON}{, 0 2H, c02C), 136.1, 136.0, 127.5, 127.5 
(ipso-Ar), 123.4, 123.2, 122.0, 121.9, 119.5, 119.4, 118.4, 118.3, 111.2, (CH ar), 109.4 
(ipso-Ar), 81.3, 80.9 (C(CH3)3), 53.0 (NHCH), 41.1, 40.9 (02CCH2), 40.7, 40.5 
(CHCONH), 38.1, 37.9 (CH 2CH(CH3)2), 27.9, 27.8 (C(CH3)3), 27.2, 26.9 
(CH2Indole), 25.4 (CH(CH3)2), 22.6, 22.0, 21.9 (CH(CH 3)2); m/z (FAB), 417 (3%, 
MH), 361 (21, MH2 -'Bu), 288 (10), 229 (23), 188 (19), 130 (30 , CH 21ndole), 88 
(19), 57 (100, 'Bu), Found (FAB), 417.2372, C 23H33N205 requires 417.2389. 
4.3.25. (2R,2'R)- 14-(tert-butyl)-2-iso-butyl-succinylJ-tert-leucine and (2R,2'S)-14-
(tert-butyl)-2-iso-butyl-succinyll_tert_leucine 128e 




The general procedure outlined in Section (4.3.20.) was followed with DL-tert-
leucine derived amide 127e (843 mg, 3.36 mmol) and lithium hydroxide 
monohydrate (396 mg, 9.43 mmol, 4.0 equiv.). The reaction mixture was stirred for 2 
days. The product was obtained as a colourless gum (810 mg, 100%). 'H nmr (200 
MHz) indicated a mixture of two products, the desired acid and the corresponding 
diacid amide resulting from concomitant cleavage of the tert-butyl ester in an almost 
1:1 ratio. The bulk crude product was not further purified but was used immediately 
in the next step (see Section (4.3.28.)). A portion of the crude product was purified 
by repeated trituration, (Et 20:hexane) to remove the diacid amide. The mother liquor 
was evaporated under reduced pressure to furnish a pure sample of the desired 
product. 'H nmr indicated a (1:1) ratio of diastereomers. 
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[a] +6.04 (c 1.44, CHC13); umax(CHC1 3)/cm'; 3428 (amide NH), 3200-2400 (acid 
OH), 3020 (saturated CH), 1719 (ester C=O and acid C=O), 1676, 1515 (CONH); 8 1j 
 
(CDC13 ; 600 MHz) 10.19 (total of 1 H, br s, OH), 6.69 (0.5 H, d, J9.0, NH A)  6.57 
(0.5 H, d, J 9.3, NEB  ), 4.44 (0.5 H, d, J 9.3, NHCUB),  4.39 (0.5 H, d, J 9.0, NHCUA), 
2.75 (total of 1 H, m, CHCONH of each diastereomer), 2.58 (0.5 H, dd, J 17.0, 9.6, 
CHCH 	 kI2 HBCH), 2.53 (0.5 H, dd, J 16.9, 8.6, CHCHBCH),  2.31 (0.5 H, dd, J 17.1 
4.2, CHCH Ali  CH), 2.30 (0.5 H, dd, J 16.9, 5.0, CHCHAffCH), 1.64 (0.5 H, m, 
Ckj(CH3)2 of one diastereomer), 1.61-1.49 (total of 1.5 H, m, CHCHH8CH, 
CU(CH3)2 of each diastereomer), 1.39 (OC(Cff)3),  1.38 (4.5 H, s, OC(Cff)3),  1.15 
(total of 1 H, m, CHCHAHBCH of each diastereomer), 0.99 (4.5 H, s, CHC(CH M, 
0.92 (4.5 H, s, CHC(Cfl) 3), 0.89 (1.5 H, d,J6.6, CH A CHCH3B), 0.87 (1.5 H, d,J 
6.6, Cff A CHCH3B), 0.86 (1.5 H, d, J 6.6, CH3BCHCH B ), 0.83 (1.5 H, d, J 6.6, 
CII3BCHCH 3B ); 6 (CDC13; 63 MHz) 175.3, 175.2, 175.1, 175.0, 172.1, 172.0 
(ONH, 02H, c02C), 81.2, 80.9 (O(CH3)3), 60.2, 59.9 (NHCH), 41.0, 40.8 
(02CH2), 40.6, 40.5 (CHCONH), 38.2, 38.0 (CHcH 2CH), 34.6, 34.1 (CHc(CH 3)3), 
27.9, 27.8 (OCC(cH3)3), 26.5, 26.4 (CHC(H3) 3), 25.6, 25.4 (CH(CH3)2), 22.9, 22.8, 
22.0, 21.8 (CH(cH3)2); m/z (FAB), 344 (26%, MH), 288 (100, MH 2-'Bu), 270 (39, 
288-H20), 242 (9, 270-CO), 132 (20), 86 (32), 57 (40, tBu), (FAB) 344.2436, 
C 18H34N05 requires 344.2437. 
4.3.26. General procedure for (3R,4'RS)-2'-substituted-4'-
substituted-5 ' (4'H)-oxazolones 1 29a-e 
EDCI (1.1 equiv.) was added to a solution of acid (1.0 equiv.) in acetonitrile (30 
mL) and the solution stirred at room temperature under an atmosphere of nitrogen 
for 90 minutes. The reaction was quenched with saturated aqueous ammonium 
chloride (20 mL) and the aqueous layer extracted with diethyl ether (3 x 30 mL). The 
combined organic extracts were washed with brine (2 x 20 mL), dried (Na 2SO4), 
filtered, and evaporated under reduced pressure with a water bath temperature of no 
greater than 30 °C. Purification by column chromatography yielded the desired 
product as a colourless oil. 
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4.3.27. (3R,4'RS)-5-Methyl-3-(4'-benzyl-5 '-oxo-4',5'-dihydro-oxazol-2 '-yl)-




The procedure outlined in Section (4.3.26.) was followed using DL-phenylalanine 
derived acid 128a (1.09 g, 2.89 mmol) and EDCI (1.09 g, 3.18 mmol, 1.1 equiv.). 
Column chromatography, eluting with hexane : ethyl acetate (6:1) furnished the title 
product (896 mg, 86%). 'H nmr indicated a (1:1) ratio of diastereomers. 
Rf (Hexane:EtOAc, 6:1) 0.27; {a}-1.03 (c 2.34, CHC1 3); omax(CH 3)Icm' 3019 
(saturated CH), 1817 (oxazolone C=O), 1724 (ester C=O), 1671 (C=N); 6 H  (CDC13 ; 
600 MHz) 7.26-7.18 (total of 3 H, m, Cif ar of each diastereomer), 7.17-7.15 (total of 
2 H, m, CH of each diastereomer), 4.42 (total of 1 H, m, NCH of each 
diastereomer), 3.22 (0.5 H, dd, J 13.6, 5.2, CHAHBPh of one diastereomer), 3.21 (0.5 
H, dd, J 13.6, 5.2, CHAHBPII of one diastereomer), 3.13 (0.5 H, dd, J 13.6, 5.4, 
CHAHBPh of one diastereomer), 3.11 (0.5 H, dd, J 13.6, 5.8, CHAIIBPh of one 
diastereomer), 2.93 (0.5 H, m, CHC=N of one diastereomer), 2.86 (0.5 H, m, 
CflC=N of one diastereomer), 2.45 (0.5 H, dd, J 16.0, 7.8, OCCUAHBCH of one 
diastereomer), 2.42 (0.5 H, dd, J 16.6, 8.0, OCCIIAHBCH of one diastereomer), 2.29 
(0.5 H, dd, J 16.6, 6.4, OCCHAHBCH of one diastereomer), 2.26 (0.5 H, dd, J 16.6, 
6.4, OCCHAIIBCH of one diastereomer), 1.40 (total of 9 H, s, C(C11 3)3 of each 
diastereomer), 1.37 (0.5 H, ddd, obscured by 'Butyl peak, CHCUAHBCH of one 
diastereomer), 1.30 (0.5 H, ddd, J 13.2, 8.6, 6.0, CHCHAHBCH of one 
diastereomer), 1.25 (0.5 H, m, CE(CH3)2 of one diastereomer), 1.12 (0.5 H, ddd, J 
12.8, 8.8, 5.8, CHCHAHBCH of one diastereomer), 1.10 (0.5 H, ddd, J 13.2, 8.0, 6. 0, 
CHCHAUBCH of one diastereomer), 0.93 (0.5 H, m, Cff(CH3)2 of one diastereomer), 
0.80, 0.77, 0.77, 0.74 (total of 6 H, 4 x d, J 6.6, CII3ACHCH3B and CH3ACHCH3B of 
each diastereomer); E (CDC1 3 ; 63 MHz) 177.8, 177.7 (NCH02C), 170.2, 170.1 
(02C), 167.8, 167.1 (N), 135.0, 134.7 (ipso-Ar), 129.6, 129.5, 128.3, 128.1, 
127.0 (CH ar), 80.8, 80.7 ((CH3)3), 65.5, 65.4 (NHCO), 40.5, 40.1 (0 2CcH2), 37.6, 
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37.4 (CH2CH(CH3)2), 36.6, (HA), 34.8, 34.1 (CH 2 HCN), 27.9 (C(cH 3)3), 25.2, 
25.0 (H(CH3)2), 22.7, 22.6, 21.8, 21,7 (cH(cH 3)2); m/z (FAB) 360 (69%, MH), 
304 (100, MH2 -'Bu), 286 (29, 304-H 20), 258 (96, 286-CO), 212 (10), 154 (33), 120 
(77), 91(51, CH2Ph), 57 (74, 'Bu), Found (FAB) 360. 2174, C 21 H30N04 requires 
360.2174. 
4.3.28. (3R,4'RS)-4-Methyl-2-(4'-iso-propyl-5'-oxo-4',5'-dihydro-oxazol_2 '-yl)-




The procedure outlined in Section (4.3.26.) was followed using DL-valine derived 
acid 128b (587 mg, 1.81 mmol) and EDCI (382 mg, 1.99 mmol, 1.1 equiv.). Column 
chromatography, eluting with hexane :ethyl acetate (6:1) furnished the title product 
(486 mg, 8 1%). 1 H nmr indicated a (1:1) ratio of diastereomers. 
R1 (Hexane:EtOAc, 6:1) 0.54; [a]21  -7.5 (c 1. 16, CHC13); umax(CHC13)/cm' 1819 
(oxazolone C=O), 1725 (ester C=O), 1673 (C=N); oH (CDC13 ; 600 MHz) 4.01 (0.5 H, 
d, J 5.4, NCH of one diastereomer), 4.00 (0.5 H, d, J 5.0, NCH of one diastereomer), 
3.06 (total of 1 H, m, CflC=N of each diastereomer), 2.64 (0.5 H, dd, J 16.2, 9.2, 
OCCUACHBCH of one diastereomer), 2.61 (0.5 H, dd, J 16.0, 8.2, OCCHACHBCH of 
one diastereomer), 2.44 (0.5 H, dd, J 16.0, 6.0, OCCHACHBCH of one diastereomer), 
2.42 ((0.5 H, dd, J 16.2, 5.6, OCCHACIIBCH of one diastereomer), 2.25 (0.5 H, m, 
CHCU(CH2)3 of one diastereomer), 2.24 (0.5 H, m, CHCH(CH2)3 of one 
diastereomer), 1.66- 1.58, (total of 2 H, m, CH2CH(CH3)2 and CHCIIAHBCH of each 
diastereomer), 1.42 (4.5 H, s, C(CH3)3  of one diastereomer), 1.41 (4.5 H, s, C(CH3)3 
of one diastereomer), 1.34 and 1.33 (total of 1 H, m, CHCH AHBCH of each 
diastereomer), 1.05, 1.04, 0.93(2), 0.92(2), 0.90, 0.89 (total of 12 H, 8 x d, J 6.6, 
Cff3ACHCH3B and CH 3ACHCH3B of the iso-butyl and iso-propyl groups of each 
diastereomer); O  (CDC13 ; 63 MHz) 177.9 (NCHCO 2C), 170.4, 170.2 (cO2C), 167.7, 
167,5 (c=N), 80.9, 80.8 (C(CH 3)3), 69.8, 69.7 (HcHCO), 40.6 (0 2CH2), 37.5, 37.3 
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(CHcH2CH), 34.6, 34.5 (CH2 HN), 30.6, 30.5 (CHH(CH3 )2), 27.9, 27.8 (C(CH 3)3), 
25.6, 25.5 (CH2 H(CH3)2), 22.6, 22.50, 22.1, 22.0 (CH 2CH(H3)2), 18.6, 18.5, 17.3, 
17.2 (CHCH(H3)2); m/z (FAB) 312 (49%, MH), 256 (100, MH2 -tBu), 210 (74, 
256-H20-CO), 157 (9), 111 (7), 83 (9),72 (39), 57(33, tBu), Found (FAB) 312.2171, 
C 17H22N04 requires 312.2174. 
4.3.29. (3R,4'RS)-5-Methyl-3-(4 '-iso-butyl-5'-oxo-4',5'-dihydro-oxazol-2 '-yl)-




The procedure outlined in Section (4.3.26.) was followed using DL-leucine 
derived acid 128c (753 mg, 2.19 mmol) and EDCI (462 mg, 2.41 mmol, 1.1 equiv.). 
Column chromatography, eluting with hexane : ethyl acetate (6:1) furnished the title 
product (533 mg, 75%). 'H nmr indicated a (1:1) ratio of diastereomers. 
R1 (Hexane:EtOAc, 6:1) 0.45; [a]°  -4.1 (c 1.22, CHC1 3); 1)max(CHCl3)/cm' 1822 
(oxazolone C=O), 1723 (ester C=O), 1670 (C=N); 8H  (CDC13 ; 600 MHz) 4.13 (0.5 H, 
dd, J 8.6, 5.8 HCff  of one diastereomer), 4.12 (0.5 H, dd, J 9.0, 5.8 HCII of one 
diastereomer), 3.03 (total of 1 H, m, CIIC=N of each diastereomer), 2.64 (0.5 H, dd, 
J 16.0, 9.0, CH2CHCHAHBCH of one diastereomer), 2.60 (0.5 H, dd, J 15.8, 8.4, 
CH2CHCHAHBCH of one diastereomer), 2.44 (0.5 H, dd, .1 15.8, 6.2, 
CH2CHCHAUBCH of one diastereomer), 2.42 (0.5 H, dd, J 16.0, 5.6, 
CH2CHCHAHBCH of one diastereomer), 1.96-1.90 (total of 1 H, m, 
CH2CHCH2CII(CH3)2 of each diastereomer), 1.69 (0.5 H, ddd, J 13.4, 7.4, 5.6, 
CHCHHCH of one diastereomer), 1.68 (0.5 H, ddd, J 13.4, 7.6, 5.8, CHCIIHCH of 
one diastereomer), 1.65-1.58 (total of 2 H, NCHCH 2CH(CH3)2 of one diastereomer, 
and 3 x CHCUHCH of either diastereomer), 1.52 (0.5 H, ddd, J 13.6, 8.8, 6.4, 
CHCHHCH of one diastereomer), 1.49 (0.5 H, ddd, J 13.6, 9.0, 6.4, CHCUHCH of 
one diastereomer), 1.41 (4.5 H, s, C(CH3)3 of one diastereomer), 1.40 (4.5 H, s, 
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C(CH3)3 of one diastereomer), 1.37-1.32 (total of 1 H, m, NCHCH 2CH(CH3)2 of one 
diastereomer and CHCHHCH of either diastereomer), 0.96, 0.95, 0.93, 0.92, 0.90 
0.89 (total of 12 H, 8 x d, J 6.6, CH3ACHCH3B and CH3ACHCH3B of each iso-butyl 
group of each diastereomer); & (CDC1; 63 MHz) 179.2 (NCH0 2C), 170.2, 170.0 
(02C), 167.3, 167,0 (=N), 80.8 ((CH 3)3), 63.0, 62.9 (HHCO), 40.6, 40.4 40.3, 
40.2 (02CH2 and NCHcH2), 37.5, 37.3 (02CCH2CHH2), 36.6, 34.4 (CH 2 HN), 
27.9 (C(cH3 )3), 25.6, 25.5, 24.9 (2 x cH(CH 3)2), 22.5, 22.1, 22.0, 21.9, 21.9 (2 x 
CH(H3 )2); m/z (FAB) 326 (80%, MH), 270 (86, MH2ttBu), 252 (27, 270-H20), 
224 (68, 252-CO), 182 (29), 154 (96), 136 (59), 91(23, CH2Ph), 57 (43, 'Bu), Found 
(FAB) 326.2345, C 18H32N04 requires 326.2331. 
4.3.30. (3R,4'RS)-4-Methyl-2-14 '-(1H-indol-3-ylmethyl)-5'-oxo-4',5'-dihydro-




The procedure outlined in Section (4.3.26.) was followed using DL-tryptophan 
derived acid 128d (914 mg, 2.19 mmol) and EDCI (463 mg, 2.41 mmol, 1.1 equiv.). 
Column chromatography, eluting with hexane:ethyl acetate (3:1) furnished the title 
product (900 mg, 91%). 1 H nmr indicated a (1:1) ratio of diastereomers. 
Rf (Hexane:EtOAc, 2:1) 0.60, 0.53; [a] 21  +14.9 (c 1.20, CHC13); Umax(CHC13)/Cm' 
3479 (indole NH), 1815 (oxazolone C=O), 1724 (ester CO), 1672 (C=N); 6 H 
(CDC13 ; 600 MHz)8.15 (total of 1 H, s, NH(i ndO l e) of each diastereomer), 7.64 (0.5 H, 
d, J 7.2, CL of one diastereomer), 7.63 (0.5 H, d, J 7.0, CH, of one diastereomer), 
7.29 (total of 1 H, m, CHaT  of each diastereomer), 7.15 (total of 1 H, m, CH, of each 
diastereomer), 7.10 (total of 1 H, m, CH r  of each diastereomer), 7.03 (total of 1 H, 
m, CL  of each diastereomer), 4.51 (0.5 H, dd, J 5.0 NCR on one diastereomer), 
4.49 (0.5 H, dd, J 5.0 NCR on one diastereomer), 3.45 (0.5 H dd, J 15.0, 5.0, 
135 
Experimental 
CUAHBIndole of one diastereomer), 3.44 (45 (0.5 H dd, J 15.0, 5.0, CffAHBIndole of 
one diastereomer), 3.30 (45 (0.5 H dd, J 15.0, 5.0, CHAHBInd0Ie of one 
diastereomer), 3.29 (45 (0.5 H dd, J 15.0, 5.0, CHAHBInd01e of one diastereomer), 
2.87 (0.5 H, m, CffC=N of one diastereomer), 2.79 (0.5 H, m, CHC=N of one 
diastereomer), 2.32 (0.5 H, dd J 16.0, 8.0, OCCHAHBCH of one diastereomer), 2.26 
(0.5 H, dd J 16.2, 7.8, OCCHAHBCH of one diastereomer), 2.16 (0.5 H, dd J 16.2, 
6.4, OCCHAUBCH of one diastereomer), 2.14 (0.5 H, ddJ 16.0, 6.6, OCCHAHBCH of 
one diastereomer), 1.40 (4.5 H, s, C(C113)3 of one diastereomer), 1.39 (4.5 H, s, 
C(CH3)3 of one diastereomer), 1.25 (0.5 H, ddd, J 13.6, 9.0, 5.8, CHCHAHBCH of 
one diastereomer), 1.14 (0.5 H, m, CH(CH 3)2 of one diastereomer), 1.03 (0.5 H, ddd, 
J 14.2, 8.4, 6.0, CHCHAHBCH of one diastereomer), 1.01 (0.5 H, ddd, 13.6, J 8.4, 
6.4, CHCHAHBCH of one diastereomer), 0.95 (0.5 H, m, CL(CH3)2 of one 
diastereomer), 0.82 (0.5 H, ddd, J 14.2, 8.0, 6.4, OCCHAHBCH of one diastereomer), 
0.70, 0.66, 0.64, 0.63 (total of 6 H, 4 x d, J 6.6, CIj 3ACHCH3B and CH3ACHCH3B of 
each diastereomer); ö (CDC1 3 ; 63 MHz) 178.6, 178.5 (NCH0 2C), 170.4, 170.2 
(CO2C), 167.7, 167,1 (=N), 137.7, 127.5, 127.4 (ipso-Ar), 123.2, 123.1, 122.0, 
121.9, 119.5, 119.3, 119.2, 110.9 (CHar), 109.3, 109.1 (ipso-Ar), 80.8, 80.7 
((CH3)3), 66.1, 66.0 (HHCO), 40.0, 39.9 (0 2CH2), 37.4, 37.0 (H2CH(CH3)2), 
34.6, 33.9 (CH2cHIN), 27.9, 27.8 (c(CH 3)3), 26.6, 26.5 (cH21ndole), 25.1, 24.9 
(CH2cH(CH3)2), 22.5, 22.3, 21.9, 21.5 (CH 2CH(H3) 2); m/z (FAB) 399 (36%, MH), 
361 (71), 343 (17, (MH 2 -'Bu), 297 (6, 343-H20-CO), 277 (16), 205 (12), 188 (48), 
159 (82), 130 (100, CH2Indole), 57 (36, 'Bu), Found (FAB) 399.2266, C23H31 N204 
requires 399.2283. 
4.3.31. (3R,4'RS)-4-Methyl-2-(4 '-tert-butyl-5 '-oxo-4 ',5'-dihydro-oxazol-2-yl)-





The procedure outlined in Section (4.3.26.) was followed using crude DL-tert-
leucine derived acid 128e (500 mg, 1.60 mmol) and EDCI (367 mg, 1.91 mmol, 1.2 
equiv.). Column chromatography, eluting with hexane:ethyl acetate (6:1) furnished 
the title compound as a colourless oil in a diastereomeric ratio of 2:1 as calculated 
from the integrals of the 'H ninr (244 mg, 52%). 'H nmr indicated a (1:1) ratio of 
diastereomers. 
Rf (Hexane:EtOAc, 6:1) 0.60; [a] 20  -17.3 (c 0.74, CHC1 3); Umax(CHC13)/'c;m'; 3018 
(saturated CH), 1821 (oxazolone C=O), 1729 (ester C=O), 1675 (C=N); 8H  (CDC13 ; 
600 MHz) 3.80 (0.5 H, s, NCH of one diastereomer), 3.79 (0.5 H, s, NCH of one 
diastereomer), 3.06 (total of 1 H, m, CffC=N of each diastereomer), 2.65 (0.5 H, dd, 
J 16.3 9.0, OCCUAHBCH of one diastereomer), 2.60 ( 0.5 H, dd, J 16.3 8.0, 
OCC AHBCH of one diastereomer) 2.44 (0.5 H, dd, J 16.3 6.0, OCCHAHBCH of one 
diastereomer) 2.42 (0.5 H, dd, J 16.3 5.6, OCCHALiBCH of one diastereomer), 1.66-
1.52 (total of 2 H, m, CHCHACHBCH of each diastereomer, CHCH ACHBCH of one 
diastereomer, and CH(CH 3)2 of one diastereomer), 1.42 (4.5 H, s, OC(Cff 3)3  of one 
diastereomer), 1.41 (4.5 H, s, OC(C1j3)3 of one diastereomer), 1.33 (total of 1 H, m, 
CHCHAIIBCH of one diastereomer, and CU(CH 3)2 of one diastereomer), 1.04 (4.5 H, 
s, CHC(C113)3  of one diastereomer), 1.03 (4.5 H, s, CHC(CH3)3 of one diastereomer), 
0.93, 0.92, 0.90, 0.89 (total of 6 H, 4 x d, J 6.4, CH3ACHCH3B and CH3ACHCH3B of 
each diastereomer); 6 (CDC1 3 ; 63 MHz) 177.1 (NCH0 2C), 170.4, 170.2 (cO 2C), 
167.3, 167.0 (=N), 80.8 (O(CH 3)3), 73.1 (NHCO), 40.6, 40.5 (OCcH 2), 37.5, 
37.1 (CHH2CH), 35.2 (cHC(CH 3 )3), 34.5, 34.3 (CH2 HCN), 28.0 and 27.9 
(OC(cH3)3 and CHC(H3)3), 26.0 (CHC(cH3)2),  25.6, 25.5 (cH(CH3)2) 22.5, 22.4, 
22.1, 22.0 (CH(cH3)2); m/z (FAB) 326 (100%, MH), 270 (81, MH 2 -'Bu) 252 (11, 
270-H20), 224 (30, 252-CO), 137 (10), 86 (26), 57 (50, 'Bu), Found (FAB) 
326.2328, C 38H32N04 requires 326.2331. 
4.3.32. General procedure for the lipase catalysed ring opening of 
(4RS)-2-substituted-4-substituted-5(4H)-oxazolones 1 29a-e 
L In the presence of triethylamine 
Triethylamine (0.25 equiv.), lipase (crushed dried Novozyme ®, 100 mg pre-dried 
weight, or dried Lipozyme ®, 100 mg pre-dried weight) and alcohol (2.0 equiv.) were 
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added to a solution of oxazolone 129a-e (100 mg) dissolved in solvent (8 mL). The 
flask was stoppered and placed in an orbital incubator at 37 °C at 200 rpm. The 
reactions were monitored by tic and on complete consumption of the starting 5(4H)-
oxazolone the lipase was filtered, washed with solvent (2x 10 mL), and the combined 
organic fractions concentrated under reduced pressure. Purification by column 
chromatography as described for the corresponding 1:1 mix of diastereomers 
afforded the desired product as a colourless solid. 
H. In the absence of triethylamine 
As above with the elimination of triethylamine. 
4.3.33. (2R,2'S- 14-(tert-butyl)-2-iso-butyl-succinyl] -phenylalanine methyl ester 
127a 
The procedure outlined in Section (4.3.32.1.) was followed using oxazolone 129a, 
triethylamine, Novozyme®,  methanol, and toluene. Reaction time 4 days, (93 mg, 
85%). 
Rf (Hexane:EtOAc, 6:1) 0.27; d.e. 81%; Mp 94-96 °C; [a]°  +54.7 (c 1.90, CHCI 3). 
4.3.34. (2R,2'S)- [4-(tert-butyl)-2-iso-butyl-succinyll -phenylalanine methyl ester 
127a 
The procedure outlined in Section (4.3.32.11.) was followed using oxazolone 129a, 
Novozyme®,  methanol, and acetonitrile. Reaction stopped after 10 days. Column 
chromatography, eluting with hexane:ethyl acetate (6:1) furnished starting oxazolone 
(25 mg, 25%), and the desired product as a colourless solid (72 mg, 66%, 88% based 
on recovered starting material). 
Rf (Hexane:EtOAc, 6:1) 0.27; d.e. 78%; Mp 92-95 °C; [a] 20  +60.2 (c 1.38, CHC1 3). 
4.3.35. (2R,2'S)- [4-(tert-butyl)-2-iso-butyl-succinyl] -phenylalanine methyl ester 
127a 
The procedure outlined in Section (4.3.32.i.) was followed using oxazolone 129a, 
triethylamine, Novozyme ®, methanol, and tert-butyl methyl ether. Reaction time 2 
days, (98 mg, 90%). 
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Rf (Hexane:EtOAc, 6:1) 0.27; d.e. 79%; Mp 94-96 °C; [a] 21 + 52.6 (c 1.80, CHC1 3). 
4.3.36. (2R,2'S- [4-(tert-butyl)-2-iso-butyl-succinyl] -phenylalanine methyl ester 
127a 
The procedure outlined in Section (4.3.321.) was followed using oxazolone 129a, 
triethylamine, Lipozyme ®, methanol, and toluene. Reaction time 1 day, (80 mg, 
73%). 
Rf (Hexane:EtOAc, 6:1) 0.27; d.e. 58%; Mp 89-91 °C; [a] 21  +42.6 (c 1.52, CHC13). 
4.3.37. (2R,2'S)-[4-(tert-butyl)-2-iso-butyl-succinyl] -phenylalanine methyl ester 
127a 
The procedure outlined in Section (4.3.32.11.) was followed using oxazolone 129a, 
Lipozyme® ,  methanol, and acetonitrile. Reaction stopped after 48 days. Column 
chromatography, eluting with hexane:ethyl acetate (6:1) furnished starting oxazolone 
(24 mg, 24%) and desired product, (39 mg, 36%, 47% based on recovered 
oxazolone). 
Rf (Hexane:EtOAc, 6:1) 0.27; d.c. 55%; Mp 88-90 °C; [a] +37.76 (c 0.76, CHCI 3). 




 - yNCO2Et 
Ph 
The procedure outlined in Section (4.3.32.1.) was followed using oxazol6ne 129a, 
triethylamine, Novozyrne®,  ethanol, and toluene. Reaction time 3 days. Column 
chromatography eluting, with hexane:ethyl acetate (6:1) furnished the desired 
product as a colourless solid (85 mg, 76%). Spectroscopic data given is for the major 
product diastereomer. 
Rf (Hexane:Et20, 2:1) 0.38 (major), 0.29; d.c. 84%; Mp 65-67 °C; (Found: C, 68.09; 
H, 9.00; N, 3.30; C 23H35N05 requires C, 68.12; H, 8.70; N, 3.45); [a] 21 +49.6 (c 
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1.00, CHC1); u max(CHCI3)/cm' 3435 (amide NH), 3018 (saturated CH), 1732 (ester 
C0), 1682, 1511 (CONH); 8 H (CDC13 ; 600 MHz) 7.20(2 H, d,J7.0, CHar), 7.15(1 
H, d, J 7.0, CHar), 7.11 (2 H, d, J 7.0 CHar), 6.14 (1 H, d, J 7.9, NH), 4.78 (1 H, ddd, 
J7.9, 6.0, NHCH),  4.03 (2 H, q, .17.0, OCR2),  3.04 (1 H, dd,.113.6, 5.9, CHAHBPh), 
3.01 (1 H, dd, 13.6, 6.0, CHARBPh), 2.55 (1 H, m, CHCONH), 2.47 (1 H, dd,.1 16.6, 
8.9, OCCIIAHBCH), 2.21 (1 H, dd, J 16.6, 4.9, OCCHAHBCH), 1.50 (1 H, ddd,.1 
13.6, 8.9, 5.9, CHCRAHBCH), 1.40 (1 H, m, Cff(CH 3)2), 1.36 (9 H, s, C(Cff03), 1.13 
(3 H, t, J 7.3, CH2CH3), 1.09 (1 H, ddd, obscured by CH 3 ethyl ester peak, 
Cff(CH3)2), 0.80 (3 H, d, .16.6, CkI3ACHCH3B), 0.78 (3 H, d, J 6.5, CH3ACHCH3B); ö 
(CDC1 3 ; 63 MHz) 174.2, 171.5, 171.3 (ONH, G02C), 135.9 (ipso-Ar), 129.3, 128.3, 
126.8 (cHar), 80.5 (c(CH3)3), 60.2 (OcH 2CH3), 53.0 (NHcH), 41.2  (02CcH2),  40.7 
(cHCONH), 38.0 (cH 2CH(CH3)2 and cH2Ph), 27.9 (C(çH3)3),  25.4 (cH(CH 3)2), 
22.8, 22.0 (CH(CH 3)2), 13.9 (CH2cH3); m/z (FAB) 406 (27%, MH), 378 (38, MW-
Et) 350 (74, MH2 -'Bu), 332 (15, 350-H20), 304 (12, 332-CO), 258 (25), 222 (14), 
194 (35), 157 (12), 120 (100), 91(14, CH 2Ph), 57 (30, tBu), Found (FAB), 406.2577, 
C23H36N05 requires 406.2593. 
4.3.39. (2R,2'S)- [4-(tert-butyl)-2-iso-butyl-succinyll-phenylalanine n-propyl ester 
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The procedure outlined in Section (4.3.32.1.) was followed using 129a, 
triethylamine, N ovozyme®,  n-propanol, and toluene. Reaction time 3.5 days. Column 
chromatography, eluting with hexane:ethyl acetate (6:1) furnished the desired 
product as a colourless solid (98 mg, 84%). Spectroscopic data given is for the major 
product diastereomer. 
Rf (Hexane:EtOAc, 2:1) 0.52; d.e. 84%; Mp 50-53 °C; (Found: C, 68.46; H, 9.11; N, 
20 
3.21; C24H37N05 requires C, 68.68; H, 8.89; N, 3.38); [a] +47.3 (c 1.76, CHC1 3). 
umax(CHC1 3)km' 3429 (amide NH), 3017 (saturated CH), 1728 (ester CO), 1669, 
1513 (CONH); oH (CDC1 3 ; 600 MHz) 7.21 (2 H, d, 7.0, CHar),  7.16 (1 H, d, 7.0, 
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CHar), 7.06 (2 H, d, 7.0, CH,), 6.13 (1 H, d, J 7.9, NH),  4.80 (1 H, ddd, J 7.9, 6.3, 
NHCH), 3.96 (1 H, dd, J 10.6, 6.9, OCHAHBCH2), 3.95 (1 H, dd, J 10.6, 6.6 
OCHAHBCH2), 3.04 (1 H, dd, J 13.9, 5.9, CHAHBPh), 3.01 (1 H, dd, J 13.9, 6.3, 
CHAHBPh), 2.55 (1 H, m, CHCONH), 2.47 (1 H, dd, J 16.6, 9.0, OCCHAHBCH) 2.22 
(1 H, dd, J 16.6, 4.9, OCCHAHBCH), 1.57-1.42 (total of 4 H, m, OCH 2CH2 1 
CHCHAHBCH, and Cff(CH 3 ) 2), 1.36 (9 H, 5, C(C113)3), 1.10 (1 H, ddd, J 13.6, 7.6, 
5.9, CHCHAHBCH), 0.81, (3 H, d, J 6.4, CH3ACHCH3B), 0.79 (3 H, d, J 6.4, 
CH3ACHCH3B), 0.80 (3 H, t, J 7.3, CH2CH3); 6c (CDCl; 63 MHz) 174.4, 171.7, 
171.6 (cONH, CO2C), 136.0 (ipso-Ar), 129.4, 128.5 127.0 (CH ar), 80.7 (c(CH3)3), 
66.9 (OcH2CH2), 53.1 (NHcH), 41.3 (0 2CH2), 40.8 (cHCONH), 38.2, 38.1 
(H2CH(CH3)2 and H2Ph), 28.5, (C(cH3)3), 25.5 (H(CH3 )2), 22.9 (OCH2CH2), 
22.2, 21.8 (CH(H3)2), 10.3 (CH2CH3); m/z (FAB) 420 (23%, MH), 365 (100, 
MH2t'Bu), 346 (6, 365-H20), 258 (7), 208 (20), 120 (26), 91(5, CH2Ph), 57 (9, 'Bu), 
Found (FAB), 420.2736, C 24H38N05 requires 420.2750. 
4.3.40. (2R,2'S)- 14-(tert-butyl)-2-iso-butyl-succinyl] -phenylalanine n-butyl ester 
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The procedure outlined in Section (4.3.32.i.) was followed using 129a, 
triethylamine, Novozyme®,  n-butanol, and toluene. Reaction time 3.5 days. Column 
chromatography, eluting with hexane : ethyl acetate (6:1) furnished the desired 
product as a colourless solid (103 mg, 85%). Spectroscopic data given is for the 
major product diastereomer. 
Rf (Hexane:EtOAc, 2:1) 0.55; d.e. 80%,; Mp 53-56°C; (Found: C, 68.84; H, 9.14; N, 
3.14; C26H37N05 requires C, 69.21; H, 8.99; N 3.23); [a] ° +45.2 (c 1.76, CHC1 3). 
umax(CH 3)/cm' 3427 (amide NH), 3018 (saturated CH), 1726 (ester C=O), 1675, 
1507 (CONH); ö (CDC1 3 ; 600 MHz) 7.20(2 H, d, J7.0, CHar),  7.16 (1 H, d, J7.0, 
CH), 7.11 (2 H, d, J 7.0, CH), 6.14 (1 H, d, J 7.9, NH), 4.79 (1 H, ddd, J 7.9, 6.0, 
NHCH), 4.00 (1 H, dt, J 10.6, 6.6, OCHAHBCH2), 3.99 (1 H, dt, J 10.6, 6.6, 
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OCHAHBCH2), 3.04 (1 H, dd, J 13.9, 5.6, CHAHBPh), 3.01 (1 H, dd, J 13.9, 6.3, 
CHAUBPh), 2.55 (1 H, m, CHCONH), 2.48 (1 H, dd, J 16.6, 9.0, OCCUAHBCH), 2.22 
(1 H, dd, J 16.6, 4.9, OCCHAHBCH), 1.53-1.44 (total of 4 H, m, CHCHAHBCH, 
CU(CH3 )2 , and CH2CH2CH3), 1.36 (9 H, s, C(C113 )3), 1.23 (2 H, q, J 7.3, CH2CH3), 
1.10 (1 H, ddd, J 13.6, 7.6, 5.9, CHCHAHBH), 0.83 (3 H, t, J 7.3, CH2CH3),  0.80 (3 
H, d, J 6.4, CH3ACHCH3B), 0.78 (3 H, d, J 6.4, CH3ACHCH3B); ö (CDC1; 63 MHz) 
174.3, 171.7, 171.6 (CONH, CO2C), 136.0 (ipso-Ar), 129.4, 128.4 127.0 (CH ar), 80.7 
(c(CH3)3), 65.2 (OH2CH2), 53.1 (NHH), 41.3 (0 2CCH2), 40.8 (cHCONH), 38.2, 
38.1 (H2CH(CH3)2 and cH2Ph), 30.4 (OCH2 H2), 28.1, (C(H 3 )3), 25.6 
(cH(cH3 )2), 22.9, 22.2 (CH(cH3)2),  19.0 (H2CH3), 10.3 (CH 2 H3); m/z (FAB) 434 
(32%, MH), 378 (100, MH2 -tBu), 360 (20, 378-H 20), 304 (9), 258 (17), 222 (24), 
157 (6), 120 (48), 91(5, CH2Ph), 57 (1, 'Bu), Found (FAB), 434.2896, C 25H40N05 
requires 434.2906. 
4.3.41. (2R,2'S)- [4-(tert-butyl)-2-iso-butyl-succinyl] -valine methyl ester 127b 
The procedure outlined in Section (4.3.32.i.) was followed using oxazolone 129b, 
triethylamine, Novozyme®,  methanol, and toluene. Reaction time 11 days, (103 mg, 
93%). 
Rf (Hexane:EtOAc, 6:1) 0.20; d.e. 75%; Mp 70-73 °C; [a]°  +11.36 (c 1.98, CHC1 3) 
4.3.42. (2R,2'S)- 4-(tert-butyI)-2-iso-butyl-succinylJ -valine methyl ester 127b 
The procedure outlined in Section (4.3.32.i.) was followed using oxazolone 129b, 
triethylamine, Lipozyme ®, methanol, and toluene. Reaction time 29 days, (96 mg, 
87%). 
Rf (Hexane:EtOAc, 6:1) 0.20; d.e. 27%; Mp 58-59°C; [a]+7.14 (c 1.68, CHC1 3) 
4.3.43. (2R,2'S)- 14-(tert-butyl)-2-iso-butyl-succinyl] -leucine methyl ester 127c 
The procedure outlined in Section (4.3.32.i.) was followed using oxazolone 129c, 




Rf (Hexane:EtOAc, 6:1) 0.55; d.e. 86%; Mp 102-103 °C; [a] +2.48 (c 2.06, 
CHC13) 
4.3.44. (2R,2'S)- 14-(tert-butyl)-2-iso-butyl-succinyll -leucine methyl ester 127c 
The procedure outlined in Section (4.3.32.i.) was followed using oxazolone 129c, 
triethylamine, Lipozyme®, methanol, and toluene. Reaction time 12 days, (105 mg, 
96%). 
Rf (Hexane:EtOAc, 6:1) 0.55; d.e. 54%; Mp 94-96°C; [a] 21 +1.44(c 1.88, CHC1 3) 
4.3.45. (2R,2'S)- 14-(tert-butyl)-2-iso-butyl-succinyl] -tryptophan methyl ester 
127d 
The procedure outlined in Section (4.3.32.i.) was followed using oxazolone 129d, 
triethylamine, Novozyme®,  methanol, and toluene. Reaction stopped after 13 days, 
(91 mg, 84%). 
Rf (Hexane:Et20, 1:1) 0.20; d.e. 74%; Mp 71-73 °C; [a] +60.1 (c 1.76, CHC1 3 ) 
4.3.46. (2R,2'S)- [4-(tert-butyl)-2-iso-butyl-succinyl] -tryptophan methyl ester 
127d 
The procedure outlined in Section (4.3.32.i.) was followed using oxazolone 129d, 
triethylamine, Lipozyme®,  methanol, and toluene. Reaction stopped after 13 days, 
(96 mg, 89%). 
Rf (Hexane:Et20, 1:1) 0.20; d.c. 7%; Mp 54-56°C; [a]+15.72 (c 1.80, CUd 3) 
4.3.47. (2R,2'S)- [4-(tert-butyl)-2-iso-butyl-succinyl] -tert-leucine methyl ester 
127e 
The procedure outlined in Section (4.3.32.i.) was followed using oxazolone 129e, 
triethylamine, Lipozyme®,  methanol, and toluene. Reaction time 28 days. Column 
chromatography, eluting with hexane:ethyl acetate (6:1) furnished starting oxazolone 
(73 mg, 73%) and the desired product as a colourless solid (13 mg, 12%, 44% based 
on recovered starting material). 
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Rf (Hexane:EtOAc, 6:1) 0.38; d.e. 72%; Mp 100-102 °C; [a] 21 +3.75 (c 0.24, 
CHC13) 




_) 	N ...0O2Bu 
The procedure outlined in Section (4.3.32.i.) was followed using oxazolone 129e, 
triethylamine, Lipozyme®,  n-butanol, and toluene. Reaction time 28 days. 'H nmr 
(200 MHz, CDC13) of the crude product indicated mainly starting oxazolone. The 
title compound appeared to be present in only 5% calculated by comparison of the 
integrals at 6,., 4.45 (NIiCH.) of product and 6,., 3.81 (NCH) of each diastereomer of 
starting oxazolone. Due to the low conversion no further purification was attempted. 
Rf (Hexane:EtOAc, 6:1) 0.48. 
4.3.49. (2R,2'R)- [ 4-(tert-butyl)-2-iso-butyl-succinyl] -phenylalanine-
N-methylamide and (2R,2'S)- [4-(tert-butyl)-2-iso-butyl-succinyl] - 
phenylalanine-N-methylamide 134a 
t802  ,- 	NCONHCH3 
Ph 
The general procedure outlined in Section (4.3.20.) was followed with the 
biotransformation product obtained in Section (4.3.33.) (88 mg, 0.22 mmol) and 
lithium hydroxide monohydrate (19 mg, 0.45 mmol, 2.0 equiv.) to furnish the 
hydrolysis product as a colourless gum (85 mg, quantitative). The product was not 
characterised but used directly in the next step of the synthesis. 
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The procedure outlined in Section (4.3.9.ii.) was followed using TBTU (87 mg, 0.27 
mmol, 1.2 equiv.), HOBt (37 mg, 0.27 mmol, 1.2 equiv.), diisopropylethylamine 
(118 tL, 0.67 mmol, 3.0 equiv.), the acid obtained above (85 mg, 0.22 mmol, 1.0 
equiv.) and methylamine hydrochloride (18 mg, 0.26 mmol, 1.1 equiv.). Column 
chromatography, eluting with ethyl acetate:hexane (2:1) furnished the title 
compound as a colourless solid (78 mg, 88% from starting methyl ester). 'H nmr 
indicated a (1:2.75). ratio of diastereomers. 
Rf (EtOAc, 100%) 0.50; d.e. 42%; Mp 168-171 °C; (Found: C, 67.35; H, 9.05; N, 
7.00; C22H34N204 requires C, 67.66; H, 8.78; N, 7.17); [a] 20 +46.1 (c 1.56, CHC13); 
Omax(CHCl3)/cm' 3384 (amide NH), 3019 (saturated CH), 1712 (ester C=O), 1664, 
1542 (CONH); oH  (CDC13 ; 600 MHz)7.27-7.25 (total of 2 H, m, CH, of each 
diastereomer), 7.22-7.18 (total of 3 H, m, CH,,, of each diastereomer), 6.37 (0.71 H, 
br q NIIACH3), 6.13 (0.29 H, br q, NUBCH),  5.83 (total of 1 H, d, J 8.9, NHCH of 
each diastereomer), 4.84 (0.71 H, ddd, J 8.9, 4.9, NHCHA),  4.54 (0.29 H, ddd, 
NHCHB) ,  3.30 (0. 71 H, dd, J 14.3, 5.0, CHHBPh), 3.10 (0. 29 H, dd, J 13.6, 6.6, 
CHHBPh), 3.06(0.29 H, dd,J 13.6, 7.6, CH BUPh), 3.05(0.29 H, dd,J 14.3, 8.6, 
CH BHA  Ph), 2.74 (2.13 H, d, J 4.6, NHCH), 	2.72 (0.71 H, dd, J 17.7, 11.3, 
OCH2HBCH), 2.68 (0.87 H, d, J4.9, NHCU), 	2 .57 (0.29 H, m, CH 2CHBCONH), 
2.45 (0.29 H, dd, J 16.3, 8.9, OCHHBCH), 2.34 (0.29 H, dd, J 16.3, 4.9, 
OCHI3HCH), 2.32 (0.71 H, m, CH2CHACONH),  2.18 (0.71 H, dd, J 17.6, 3.3, 
OCCH All  CH), 1.45 (0.29 H, ddd, J 14.6, 8.6, 6.0, CHCHH BCH), 1.40 (2.61 H, s, 
C(CH)3), 1.39 (0.71 H, ddd, obscured by 'Bu ester peaks, CHCH2HBCH),  1.38 
(6.39 H, s, C(CH) 3), 1.15 (0.29 H, m, Ckj °(CH3)2), 0.98 (0.71 H, m, CITIA(CH3)2), 
0.93 (0.71 H, ddd, 13.6, 9.6, 4.6, CHCH AH CH), 0.92 (0.29 H, ddd, J 14.6, 9.6, 4.9, 
CHCHAHCH), 0.84 (0.87, d, J 6.3, CH A CHCH3B), 0.80 (0.87, d, J 6.3, 
CH3ACHCU B ), 0.70 (2.13, d, J 6.3, CH A CHC 3B), 0.68 (2.13, d, J 6.3, 
CH3ACHCff B ); O (CDC1 3 ; 63 MHz) 174.8, 174.6, 173.1, 171.6, 171.3, 171.1 (0 2C 
and cONH), 136.9 (Ipso-Ar), 129.1, 129.0, 128.5, 128.4, 126.7 (cHar), 81.3, 80.9 
(c(CH3)3), 54.7, 53.6 (NHcH), 41.5, (0 2CcH2), 41.0, 40.9 (CHCONH), 38.3, 38.0, 
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37.8, 37.1 (CH2Ph and CHCH2CH), 27.9 (C(H 3) 3), 26.1, 26.0 (NHCH3),  25,5, 24.9 
(CH(CH 3)2), 23.1, 22.6, 22.2, 21.7 (CH(H 3)2); m/z (FAB) 391 (52%, MH), 335 (69, 
MH2 -'Bu), 304 (335-NH2CH3), 279 (33), 179 (27), 91(40, CH 2Ph), 57 (54, 'Bu), 
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6.0.0. Appendix I 
X-ray crystal structure for (2R,2'S) - [4-(tert-butyl)-2-iso-butyl- 
succinyI -phenylalanine methyl ester 127a synthesised chemically 
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Crystal data and structure refinement for (2R,2'S)-[4-(tert-butyl)-2-iso-butyl- 
succinyl]-phenylalanine methyl ester 127a synthesised chemically 
A. Crystal data 
Empirical formula C22H33N05 
Formula weight 391.51 
Wavelength 1.54180 A 
Temperature 150 K 
Crystal system Monoclinic 
Space group P21 
Unit cell dimensions a = 12.40 1(5) A 
b = 6.23 8(3) A 
c = 14.793(5) A 
Volume 1108.3 A3 
Number of reflections for ce1132 (20 < 0 <22°) 
a = 90° 














0.44 x 0.06 x 0.08 mm 
0 range for data collection 	0.00 to 0.00° 












C. Solution and refinement 
Solution Direct Methods (S1R92) 
Refinement type Full-matrix least-squares on F 
Program used for refinement CRYSTALS version 10 
Hydrogen atom placement Geometric 
Hydrogen atom treatment Placed geometrically after each cycle 
Data / parameters 1463/259 
Goodness-of-fit on F 2 1.1623 
R 0.0511 
R 0.0360 
Observed criterion >2. 00\s(I) 
Absolute structure parameter 0.0(1) 
Extinction coefficient 31.4(43) 
Final maximum 6/ 0.1 12713 
Weighting scheme calc 
Largest diff. peak and hole 0.31 and -0.33 e. A 3 
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Table! Atomic co-ordinates (x 10), equivalent isotropic displacement parameters 
(A2 x 103  ) and site occupancies for (2R,2'S)-[4-(tert-butyl)-2-iso-butyl-succinyl]-
phenylalanine methyl ester 127a synthesised chemically. U(eq) is defined as one 
third of the trace of the orthogonalized Uij tensor. 
Atom x y z U(eq) 0cc 
Cl 6286(4) 7985(12) 8729(4) 31 1.00 
02 5862(2) 7576(7) 7718(2) 28 1.00 
03 4059(3) 7503(8) 7758(2) 36 1.00 
C3 4768(4) 7492(11) 7332(4) 28 1.00 
C4 4534(4) 7300(10) 6283(3) 20 1.00 
C5 3407(4) 6275(9) 5873(4) 21 1.00 
C51 3185(4) 5940(10) 4807(4) 25 1.00 
C52 3280(4) 7915(1 1) 4233(3) 21 1.00 
C53 2540(5) 9747(12) 4409(4) 41 1.00 
C54 2990(5) 7339(12) 3194(4) 40 1.00 
06 4143(3) 2874(7) 6518(3) 34 1.00 
C6 3350(5) 4092(9) 6314(4) 22 1.00 
N7 2337(4) 2337(4) 6453(3) 25 1.00 
H7 1720(60) 4790(140) 6320(50) 110(30) 1.00 
C8 2176(4) 1548(1 1) 6868(4) 26 1.00 
081 254(3) 1737(7) 6008(3) 38 1.00 
C81 1010(5) 703(12) 6470(4) 26 1.00 
082 933(3) -1385(7) 6681(3) 34 1.00 
C83 -160(4) -2290(13) 6390(4) 39 1.00 
C9 2442(4) 1630(10) 7946(4) 26 1.00 
dO 1684(4) 3100(10) 8319(3) 20 1.00 
Cli 2006(5) 5140(10) 8605(4) 28 1.00 




Atom x y z U(eq) 0cc 
C13 306(5) 5786(13) 9058(4) 43 1.00 
C14 -31(5) 3729(12) 8762(4) 38 1.00 
C15 643(4) 2376(1 1) 8409(3) 29 1.00 
C16 5991(7) 6161(13) 9273(5) 65 1.00 
C17 5862(6) 10077(12) 8985(5) 53 1.00 
C18 7528(5) 8065(16) 8831(4) 62 1.00 
H41 4544 8764 6009 19 1.00 
H42 5126 6398 6122 19 1.00 
H51 2833 7277 6002 21 1.00 
H511 3733 4856 4695 25 1.00 
H512 2413 5358 4578 25 1.00 
H521 4068 8427 4430 21 1.00 
H531 2629 11009 4018 39 1.00 
H532 2763 10154 5083 39 1.00 
H533 1745 9270 4241 39 1.00 
H541 3054 8649 2820 39 1.00 
H542 3516 6218 3080 39 1.00 
H543 2211 6781 3004 39 1.00 
H81 2723 538 6705 25 1.00 
H831 -134 -3833 6576 36 1.00 
H832 -675 -1496 6695 36 1.00 
H833 -434 -2169 5697 36 1.00 
H91 3225 2146 8186 25 1.00 
H92 2370 154 8183 25 1.00 
Hill 2747 5659 8547 28 1.00 




Atom x y z U(eq) 0cc 
H131 -181 6737 9329 39 1.00 
H141 -781 3215 8804 35 1.00 
H151 393 882 8219 29 1.00 
H161 6281 6452 9956 57 1.00 
H162 6334 4814 9107 57 1.00 
H163 5164 5997 9123 57 1.00 
H171 6154 10332 9670 49 1.00 
H172 6115 11257 8629 49 1.00 
H173 5029 10047 8827 49 1.00 
H181 7918 8337 9499 49 1.00 
H182 7707 9240 8433 49 1.00 
H183 7785 6661 8630 49 1.00 
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Table 2 Bond lengths [A] for (2R,2'S)-(4-(tert-butyl)-2-iso-butyl-succinyl]-
phenylalanine methyl ester 127a synthesised chemically. 
Bond Bond Lengths (Aj Bond Bond Lengths AJ 
C1-02 1.478(6) C8-1-181 0.999(6) 
CI-C16 1.491(9) 081-C81 1.202(7) 
cl-C17 1.490(9) C81-082 1.348(8) 
cl-cl 8 1.511(7) 082-C83 1.432(6) 
02-0 1.336(5) C83-H831 1.000(8) 
03-C3 1.202(6) C83-H832 1.000(7) 
C3-C4 1.5 10(7) C83-1-1833 1.000(6) 
C4-05 1.519(7) C9-C10 1.512(7) 
C4-H41 1.001(6) C9-H91 0.999(5) 
C4-H42 1.000(5) c9-1-192 1.000(6) 
C5-051 1.546(7) clo-cll 1.364(8) 
C5-C6 1.520(7) clo-cls 1.406(7) 
C5-H51 1.000(5) Cl l-Cl2 1.381(8) 
C51-052 1.519(8) Cl 1-Hill 0.999(6) 
C51-H511 1.000(5) c12-c13 1.397(9) 
cs l-H5 12 1.000(5) c12-Hl21 1.001(7) 
C52-053 1.528(8) C13-C14 1.386(9) 
C52-054 1.531(7) ci 3-H 131 0.999(6) 
C52-1-1521 1.000(5) c 14-c 15 1.379(8) 
C53-1-1531 0.999(7) c 14-H 141 1.000(6) 
C53-H532 1.000(6) Cl 5-H 151 1.000(6) 
C53-1-1533 1.000(6) Cl 6-H 161 1.001(7) 
C54-1-1541 1.001(7) Cl 6-H 162 1.000(8) 
C54-1-1542 0.999(7) Cl 6-H 163 0.998(8) 
C54-H543 1.000(6) Cl 7-H 171 1.000(6) 
06-C6 1.219(6) C17-H172 1.000(8) 
161 
Appendices 
Table 2 cont. 
Bond Bond Lengths IA Bond Bond Lengths [Al 
C6-N7 1.365(6) C17-H173 1.001(7) 
N7-117 1.07(8) C18-H181 1.001(6) 
N7-C8 1.430(7) Cl 8-H 182 0.999(8) 




Table 3 Bond Angles (°) for (2R,2'S)-[4-(tert-butyl)-2-iso-butyl-succinyl]-




Cl 6-Cl-Cl 7 
02-Cl-C18 
C 16-Cl-Cl 8 
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Table 3 cont. 
Angle Angle Size (°) Angle Angle Size (°) 
C52-051-H512 107.8(5) C13-C12-H121 120.1(7) 
H511-051-H512 109.5(5) C12-C13-C14 118.4(6) 
C5 1-052-053 112.3(4) C12-C13-H13 1 120.8(8) 
C51-052-054 109.8(5) C14-C 1 3-H13 1 120.8(7) 
C53-052-054 110.2(4) Cl 3-C14-C1 5 121.5(6) 
C51-052-H521 107.6(5) C13-C14-H141 119.3(7) 
C53-052-H521 107.2(6) C15-C14-H141 119.2(7) 
C54-052-H521 109.6(4) CIO-Ci 5-C14 119.7(6) 
C52-053-H531 109.5(6) Ci 0-c 15-Hi 51 120.2(5) 
C52-053-H532 109.4(5) C14-C1 5-HiS 1 120.1(6) 
H531-053-H532 109.6(7) C1-C16-H161 109.4(7) 
C52-053-11533 109.4(6) ci-ci 6-Hi 62 109.4(7) 
H531-053-H533 109.5(6) H16 i-Ci6-H162 109.4(7) 
H532-c53-H533 109.5(6) C1-C16-H163 109.5(6) 
C52-054-H541 109.4(6) Hi 6i-Ci 6-Hi 63 109.6(8) 
C52-054-H542 109.5(5) Hi 62-C 16-Hi 63 109.6(7) 
H541-054-H542 109.5(5) CI-C i 7-Hi 71 109.5(6) 
C52-054-H543 109.5(5) Cl-C i 7-Hi 72 1 09.5(6) 
H541-054-H543 109.4(5) H171-C17-H172 1 09.5(7) 
H542-054-H543 109.6(7) CI-C17-H173 109.5(6) 
C5-C6-06 123.0(5) Hi 71-C i 7-H 173 109.4(7) 
C5-C6-N7 1 15.3(5) Hi 72-Cl 7-Hi 73 109.4(7) 
06-C6-N7 121 .7(5) CI-C18-H181 109.5(5) 
C6-N7-H7 116.1(43) CI-C18-H182 109.6(6) 
C6-N7-C8 120.8(5) H181-C18-H182 i 09.5(8) 
H7-N7-C8 122.6(42) CI-C18-H183 i 09.4(7) 
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Table 3 cont. 
Angle 	Angle Size (°) 	Angle 
	
Angle Size (°) 
N7-C8-C81 111.1(5) H181-C18-H183 	109.3(7) 
N7-C8-C9 113.3(5) 	Hi 82-Cl 8-Hl 83 109.5(6) 
C81-C8-C9 110.5(4) 
N7-C8-H81 105.8(5) 
Symmetry transformations used to generate equivalent atoms. 
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Table 4 Anisotropic displacement parameters (A 2 x 10') for (2R,2'S)- 14-(tert-butyl)-
2-iso-butyl-succinyl]-phenylalanine methyl ester 127a synthesised chemically. 
The anisotropic displacement factor exponent takes the form: -2 n 2 [h2 a*2  Ui 1 
2hk a*b*U12] 
Atom Ull U22 U33 U23 U13 U12 
Cl 24(3) 39(5) 26(3) -1(4) 0(2) -4(4) 
02 22(2) 39(3) 22(2) -8(2) 3(2) 4(2) 
03 23(2) 55(4) 31(2) -4(2) 10(2) -6(2) 
C3 20(3) 26(4) 36(4) 8(4) 4(3) -6(3) 
C4 24(3) 13(4) 22(3) -7(3) 3(2) -1(3) 
C5 21(3) 17(4) 26(3) 0(3) 7(2) 4(3) 
C51 20(3) 26(5) 30(3) -15(3) 7(3) -4(3) 
C52 20(3) 22(4) 22(3) 7(3) 7(2) 5(3) 
C53 41(4) 39(5) 39(4) 3(4) 0(3) -8(4) 
C54 44(4) 43(5) 31(4) 7(4) 7(3) 3(4) 
06 21(2) 28(3) 53(3) 15(3) 11(2) 5(2) 
C6 26(3) 15(4) 25(4) -1(3) 8(3) -1(3) 
N7 23(3) 29(4) 27(3) 12(3) 13(2) 6(3) 
C8 18(3) 34(5) 27(3) -5(3) 11(2) 1(3) 
081 27(2) 44(3) 39(3) 4(2) 2(2) -2(2) 
C81 25(3) 32(5) 20(3) -3(3) 3(3) -7(3) 
082 29(2) 18(3) 52(3) 12(2) 3(2) -8(2) 
C83 27(3) 36(5) 48(4) 8(4) 0(3) -15(4) 
C9 25(3) 21(4) 31(4) -1(3) 4(3) 0(3) 
CIO 28(3) 24(5) 11(3) -4(3) 7(2) 6(3) 
Cli 31(3) 27(5) 26(4) -6(3) 7(3) 5(3) 
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Table 4 cont. 
Atom U!! U22 U33 U23 U13 U12 
C12 46(4) 51(6) 20(4) -1(4) 8(3) 0(4) 
C13 39(4) 63(6) 24(4) -5(4) 6(3) 14(4) 
C14 21(3) 61(6) 33(4) 0(4) 9(3) 6(4) 
C15 33(3) 27(4) 27(3) -13(3) 6(2) -4(3) 
C16 89(6) 52(7) 41(5) 15(5) -8(4) -8(5) 
C17 65(5) 41(6) 43(5) -19(4) -8(4) 13(4) 
C18 32(3) 115(8) 32(4) -12(5) -6(3) 1(5) 
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X-ray crystal structure for (2R,2'S)- 4-(tert-butyI)-2-iso-butyI- 
succinyJ-phenyla1anine methyl ester 127a synthesised enzymatically 
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Crystal data and structure refinement for (2R,2'5)-[4-(tert-butyl)-2-iso-butyl- 
succinyl]-phenylalanine methyl ester 127a synthesised enzymatically 
A. Crystal data 
Empirical formula C22H33N05 
Formula weight 391.49 
Wavelength 1.54178 A 
Temperature 220(2) K 
Crystal system Monoclinic 
Space group P 2(1) 
Unit cell dimensions a = 12.453(3) A 
b = 6.2652(13) A 
c = 14.866(3) A 
Volume 1125.1(4) A3 
Number of reflections for ce1143 (20 < 8 <22°) 
Z 2 
Density (calculated) 1.156 Mg/m3 
Absorption coefficient 0.656 mm' 
F(000) 424 
a = 90° 
= 104.06(2) 0  
y = 90° 
B. Data collection 
Crystal description 	Colourless rod 
Crystal size 	 0.86 x 0.08 x 0.08 mm 






-13 !~h!~ 13,0:!~ k:!~ 6,0:!~ 1:!~ 16 
2216 
1813 [R(int) = 0.0521] 
Omega-theta 
Psi-scans (T in= 0.555, Tmax=0.782) 
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C. Solution and refinement 
Solution 	 Direct (SHELXS-97 (Sheidrick, 1990)) 
Refinement type 	 Full-matrix least-squares on F 2 
Program used for refinement SHELXL-97 
Hydrogen atom placement difmap and geometric 
Hydrogen atom treatment mixed 
Data/ restraints/ parameters 1813/1/368 
Goodness-of-fit on F 2 	1.014 
Conventional R [F>4c(F)] RI = 0.0433 [1393 data] 
Weighted R (F 2 and all data) wR2 = 0.1144 
Absolute structure parameter 0.2(5) 
Extinction coefficient 	0.0048(9) 
Final maximum 8/a 	0.187 
Weighting scheme 	caic 	w= 1 
where P(Fo"2"+2Fc"2'')/3 
Largest diff. peak and hole 0.155 and -0.157 e. A 3 
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Table 1 Atomic co-ordinates (x 10), equivalent isotropic displacement parameters 
(A2 x 10) and site occupancies for (2R,2'S-[4-(tert-buty1)-2-iso-butyl-succinyl]-
phenylalanine methyl ester 127a synthesised enzymatically. U(eq) is defined as 
one third of the trace of the orthogonalized Uij tensor. 
Atom x y z U(eq) 0cc 
C(l) 8708(4) 3940(10) 1281(3) 55(1) 1 
 9059(12) 2230(20) 717(8) 99(4) 0.80 
 9090(9) 6117(18) 1056(7) 71(3) 0.80 
 7470(20) 3940(40) 1183(19) 111(9) 0.80 
 8710(50) 1760(90) 840(40) 77(17) 0.20 
 9310(40) 5590(60) 830(30) 50(10) 0.20 
 7530(70) 4260(100) 1220(60) 49(13) 0.20 
0(2) 9146(2) 3593(6) 2286(2) 51(1) 1 
C(3) 10227(3) 3447(9) 2656(3) 46(1) 1 
0(3) 10937(2) 3486(8) 2234(2) 68(1) 1 
C(4) 10464(4) 3258(9) 3703(3) 44(1) 1 
C(5) 11587(3) 2221(8) 4112(3) 41(1) 1 
 11815(4) 1926(9) 5171(3) 44(1) 1 
 11739(4) 3891(9) 5745(3) 46(1) 1 
 12487(6) 5683(12) 5572(5) 68(2) 1 
 11989(6) 3330(14) 6761(4) 69(2) 1 
C(6) 11648(3) 79(8) 3676(3) 43(1) 1 
0(6) 10862(3) -1148(6) 3488(3) 63(1) 1 
N(7) 12649(4) -466(7) 3522(3) 45(1) 1 
C(8) 12808(4) -2470(9) 3114(3) 44(1) 1 
C(81) 13969(4) -3277(9) 47(1) 3532(3) 1 
0(81) 14714(3) -2226(6) 3979(2) 62(1) 1 
0(82) 14049(3) -5329(6) 3322(2) 58(1) 1 
C(83) 15138(5) -6289(14) 3619(5) 70(2) 1 
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Table 1 cont. 
Atom x y z U(eq) 0cc 
 12565(4) -2392(10) 2040(3) 48(1) 1 
 13318(4) -926(9) 1668(3) 47(1) 1 
 13012(4) 1127(10) 1398(4) 53(1) 1 
 13670(5) 2448(1 1) 1025(4) 61(2) 1 
 14705(4) 1710(12) 953(4) 63(2) 1 
 15035(4) -303(12) 1230(4) 66(2) 1 
 14350(4) -1646(10) 1581(4) 54(1) 1 
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Table 2 Bond lengths [A] for (2R,2'S)-[4-(tert-butyl)-2-iso-butyl-succinyl]-
phenylalanine methyl ester 127a synthesised enzymatically. 
Bond Bond Length [A] Bond Bond Length [A] 
C(1)-0(2) 1.477(5) C(6)-0(6) 1.223(6) 
C( 1 )-C( 16) 1.492(14) C(6)-N(7) 1.364(6) 
C(1)-C(1 8') 1.47(8) N(7)-C(8) 1.429(7) 
C(1)-C(1 8) 1.51(2) C(8)-C(8 1) 1.516(7) 
C(1)-C(1 7') 1.52(4) C(8)-C(9) 1.552(6) 
C(1)-C(17) 1.509(11) 1.552(6) 1.198(6) 
C(1)-C(1 6') 1.52(6) C(8 1)-O(82) 1.332(6) 
0(2)-C(3) 1.328(5) 0(82)-C(83) 1.451(6) 
C(3)-0(3) 1.202(5) C(9)-C( 10) 1.510(7) 
C(3)-C(4) 1.517(6) C(1 0)-C(1 1) 1.373(8) 
C(4)-C(5) 1.528(6) C( 1 0)-C( 15) 1.396(7) 
C(5)-C(6) 1.501(7) C(1 1)-C(12) 1.373(8) 
C(5)-C(5 1) 1.541(7) C(12)-C(13) 1.399(8) 
C(5 1)-C(52) 1.514(7) C(13)-C(14) 1.359(9) 




Table 3 Bond Angles[A] for (2R,2'S)-14-(tert-butyl)-2-iso-butyl-succinyl]-
phenylalanine methyl ester 127a synthesised enzymatically. 
Angle Angle Size (°) Angle Angle Size (°) 
0(2)-C( 1 )-C( 16) 112.1(6) C(6)-C(5)-C(5 1) 108.5(4) 
0(2)-C( 1 )-C( 18') 101(4) C(4)-C(5)-C(5 1) 112.4(4) 
C( 1 6)-C( 1 )-C( 18') 120(3) C(52)-C(5 1)-C(5) 117.2(4) 
0(2)-C(1)-C(1 8) 102.5(11) C(54)-C(52)-C(5 1) 110.4(5) 
C(16)-C(1)-C(1 8) 112.2(12) C(54)-C(52)-C(53) 110.8(5) 
C(1 8')-C(l)-C(l 8) 8(3) C(5 1)-C(52)-C(53) 112.4(4) 
0(2)-C( 1 )-C( 17') 116.3(17) 0(6)-C(6)-N(7) 121.2(5) 
C( 1 6)-C( 1 )-C( 17') 90.0(13) 0(6)-C(6)-C(5) 122.6(4) 
C( 1 8')-C( 1 )-C( 17') 118(3) N(7)-C(6)-C(5) 116.2(4) 
C( 1 8)-C( 1 )-C( 17') 124(2) C(6)-N(7)-C(8) 121.2(4) 
0(2)-C( 1 )-C( 17) 107.4(5) N(7)-C(8)-C(8 1) 109.6(4) 
C(16)-C(1)-C(17) 112.0(7) N(7)-C(8)-C(9) 113.4(4) 
C(1 8')-C(1)-C(17)) 103(3 C(8 1)-C(8)-C(9) 111.1(4) 
C(1 8)-C(1)-C(17) 110.3(11) 0(8 1)-C(8 1)-0(82) 124.7(5) 
C( 1 7')-C( 1 )-C(1 7) 22.1(13) 0(8 1)-C(8 I)-C(8) 125.2(5) 
0(2)-C( 1 )-C( 16') 105(2) 0(82)-C(8 I)-C(8) 110.1(4) 
C( 1 6)-C( 1 )-C( 16') 23(2) C(8 1 )-0(82)-C(83) 116.5(5) 
C( 1 8')-C( 1 )-C( 16') 102(3) C(10)-C(9)-C(8) 114.4(4) 
C(1 8)-C(1)-C(1 6') 94(2) C(1 1)-C(10)-C(1 5) 118.2(5) 
C(17')-C(1)-C(16') 112(2) C(1 1)-C(10)-C(9) 121.6(4) 
C( 1 7)-C(1)-C( 16') 133(2) C(1 5)-C( 1 0)-C(9) 120.3(5) 
C(3)-0(2)-C(1) 121.2(3) C(12)-C(1 1)-C(1 0) 122.1(5) 
0(3)-C(3)-0(2) 125.6(4) C(1 1)-C(12)-C(13) 118.9(7) 
0(3)-C(3)-C(4) 123.6(4) C(14)-C(13)-C(12) 120.0(6) 
0(2)-C(3)-C(4) 110.8(4) C(13)-C(14)-C( 15) 120.6(5) 
C(3)-C(4)-C(5) 111.9(4) C(14)-C(15)-C(10) 120.2(6) 
C(6)-C(5)-C(4) 110.2(4) 
Symmetry transformations used to generate equivalent atoms 
174 
Appendices 
Table 4 Anisotropic displacement parameters (A 2 x 10) for (2R,2'S)-[4-(tert-butyl)-
2-iso-butyl-succinyl]-phenylalanine methyl ester 127a synthesised enzymatically. 
The anisotropic displacement factor exponent takes the form: -2 it2 [ h 2 a* 2  Ui 1 + 
+2hka*b*U121 
Atom Ull U22 U33 U23 U13 U12 
C(i) 47(3) 77(4) 36(3) 0(3) 2(2) -8(3) 
C(i6) 122(11) 108(10) 55(7) -22(7) -1(7) -2(9) 
C(1 7) 78(7) 85(7) 45(6) 15(5) 10(5) -2(6) 
C(i8) 47(5) 210(20) 65(7) 33(12) -11(4) -7(10) 
0(2) 35(2) 76(2) 39(2) 9(2) 4(1) -2(2) 
 34(2) 54(3) 49(3) 5(3) 7(2) 5(2) 
0(3) 43(2) 120(4) 46(2) 13(2) 19(1) 9(2) 
 41(2) 56(3) 35(2) 6(2) 11(2) 2(2) 
C(54) 80(4) 92(5) 35(3) -13(4) 12(3) -4(4) 
C(6) 36(2) 51(3) 44(3) 4(2) 14(2) 1(2) 
0(6) 41(2) 66(2) 88(3) -16(2) 26(2) -9(2) 
N(7) 38(2) 51(3) 48(3) -6(2) 14(2) 1(2) 
 41(3) 52(3) 41(3) 1(2) 11(2) -1(2) 
C(81) 42(3) 57(3) 41(3) -2(3) 11(2) -2(2) 
0(81) 44(2) 76(3) 62(2) -13(2) 7(2) -2(2) 
0(82) 44(2) 65(3) 61(2) -8(2) 8(2) 6(2) 
C(83) 49(3) 80(5) 77(5) 1(4) 9(3) 24(3) 
 39(3) 67(4) 39(3) -1(3) 11(2) -3(2) 
 41(2) 63(4) 37(3) -5(2) 11(2) -8(2) 
 48(3) 64(4) 48(3) -6(3) 18(2) -1(3) 
 70(4) 65(4) 47(3) 0(3) 15(3) -5(3) 
 57(3) 87(5) 49(3) 3(3) 21(3) -20(3) 
 48(3) 93(5) 60(3) 2(4) 21(3) -7(3) 
 45(3) 64(4) 55(3) 5(3) 16(2) 0(3) 
175 
Appendices 
Table 5 Hydrogen co-ordinates (x 10') and isotropic displacement parameters (A 2 x 
10') for (2R,2'S)- [4-(tert-butyl)-2-iso-butyl-succinyl] -phenylalanine methyl ester 
127a synthesised enzymatically. 
Atom x y z U(eq) 
H(161) 8813 852 892 148 
H(162) 9859 2227 829 148 
H(163) 8733 2484 65 148 
H(171) 9884 6092 1120 106 
H(172) 8914 7163 1479 106 
H(173) 8719 6495 424 106 
 7277 5107 1543 167 
 7251 2598 1406 167 
 7094 4126 535 167 
H(164) 8430 1878 173 116 
H(165) 8239 794 1084 116 
H(166) 9458 1200 978 116 
H(174) 8871 5909 212 74 
H(175) 10023 5031 796 74 
H(176) 9414 6886 1201 74 
 7400 5737 1369 73 
 7295 3329 1660 73 
 7102 3940 599 73 
H(42) 9800(40) 2140(80) 3850(30) 49(13) 
H(41) 10420(30) 4900(80) 3 870(30) 30(11) 
H(5) 12150(30) 3280(70) 4000(30) 35(11) 
 11360(40) 790(80) 5260(30) 42(13) 
 12600(50) 1430(90) 5430(40) 63(16) 
H(521) 11000(30) 4230(70) 5530(30) 39(12) 
 12260(60) 6340(140) 4920(50) 110(30) 
 12500(50) 6950(1 10) 6040(40) 80(18) 
 13250(50) 5160(100) 5690(40) 75(18) 
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Table 5 cont. 
Atom x y z U(eq) 
 11550(50) 1980(120) 6880(40) 100(20) 
 12820(50) 2670(90) 6990(40) 72(17) 
 11950(40) 4370(100) 7120(40) 62(18) 
H(71) 13080(60) 260(120) 3580(50) 110(30) 
H(81) 12320(40) -3520(80) 3240(30) 48(14) 
 7840(140) -7840(140) 3320(50) 110(30) 
 15380(50) -5840(120) 4270(50) 90(20) 
 15660(50) -5550(120) 3400(50) 100(20) 
 11770(30) -1630(70) 1810(30) 30(10) 
 12580(40) -4010(90) 1780(30) 45(13) 
H(111) 12290(40) 1770(80) 1420(30) 45(13) 
H(121) 13470(40) 3720(110) 840(40) 60(18) 
H(131) 15100(40) 2880(80) 720(30) 52(14) 
H(141) 15750(40) -960(90) 1170(30) 64(15) 
H(151) 14530(30) -3010(80) 1770(30) 29(11) 
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Enhancement of Candida antarctica 11pase 13 enanfloseliectvfty and activity in 
organic solvents 
Marie-Claire Parker,*at Stuart A. Brown,b  Lindsey Robertson" and Nicholas J. Turner" 
Department of Chemistry, Joseph Black Building, University of Glasgow, Glasgow, UK G12 8QQ 
h Edinburgh Centre for Protein Technology, Department of Chemistry, University of Edinburgh, King's Buildings, West Mains 
Road, Edinburgh, UK EH9 3.1.1 
The enantioselectivity and catalytic activity of Novozym 
435® [Candida antarctica lipase B (CALB)] in organic 
solvents was found to dramatically increase upon the 
addition of a non-reactive organic base, such as Et 3N, to the 
reaction system. 
It has been shown that the unusual microenvironment of 
enzymes in organic solvents can affect a number of parameters, 
including the degree of protein hydration, 1,2  secondary struc-
ture, 3 the susceptibility of the protein to inactivation and 
variations in the ionisation state 4 of side-chain residues. 
Frequently, these differences have been shown to result in 
interesting changes in the enzymes, including reversal of 
substrate specificity and changes in stereoselectivity, although 
the underlying reasons remain poorly understood. 
It is commonly accepted that the best predictor of enzyme 
catalytic activity in low water organic media is thermodynamic 
water activity (a).11: Over the past few years although much 
has been reported on enzyme enantioselectivity in organic 
media there are as yet no predictive rules available. Crude lipase 
preparations have proved to be simple and effective biocatalysts 
for kinetic resolutions, e.g. chiral carboxylic acids and alcohols. 
However, the low purity of these preparations (presence of other 
lipases and competing hydrolases) can, in specific reactions, 
lead to low and unpredictable enantioselective behaviour. This 
effect can be compounded when using organic solvents, due to 
the effect of different solvent properties on catalytic activity. 
The starting point for the work described herein was the 
lipase (Lipozyme® Mucor miehei) catalysed dynamic resolution 
of 4-substituted oxazol-5(4H)-ones, a reaction we have pre-
viously employed for the synthesis of enantiomerically pure 
(S)-L-tert-leucine. 5 It was previously found that the modest 
enantioselectivity in toluene (ca. 68% ee) could be enhanced 
(ca. 97% ee) by the addition of a catalytic amount of Et 3N to the 
reaction; the role of Et 3N is not to facilitate racemisation of the 
substrate. 
We decided to investigate this effect in more detail by using 
a commercially available immobilised lipase,* Novozym 435 
(Candida antarctica lipase 13 6 (CALB), since a larger substrate  
range could be tested with this enzyme. The catalytic activity 
and enantioselectivity of the alcoholysis of (±)-2-phenyl-
4-benzyloxazol-5(4H)-one 1 using butan-l-ol as the nucleo-
phile (Scheme I) was monitoredli under a range of reaction 
conditions, including controlled water activity. Hydration was 
controlled by equilibratingil enzyme and solvent with the 
appropriate saturated salt solution 7 of known thermodynamic 
water activity a. Therefore a low a system will be one in 
which the solvent is poorly hydrated and the enzyme, similarly, 
has a low level of hydration, and at high a (e.g. 0.97) the 
solvent is near water saturation and the enzyme is fully hydrated 
(as would be found in an aqueous system). Table I shows the 
effect of hydration on the initial catalytic rate and enantiose-
lectivity, in three different solvents, n-hexane, toluene and 
MeCN, either with or without Et 3N.** 
It can immediately be seen that the lipase-catalysed reaction 
is very sensitive to water activity. The addition of a non-reactive 
organic base,ff Et 3N, to the reaction enhances significantly 
both the enantioselectivity and catalytic activity of the enzyme. 
Even low levels of hydration, present in the more nonpolar 
solvents such as n-hexane and toluene, are detrimental to the 
overall catalytic performance of CALB. We find that generally 
for optimum yield and enantioselectivity, both the enzyme and 
solvent should be rigorously dried prior to addition of Et 3N. We 
were interested to see if addition of Et 3N to a reaction already in 
progress and of poor enantioselectivity, could reverse this 
effect. As can be seen from Fig. 1, the addition of Et 3N after 140 
min immediately results in enhanced catalytic rate and en-
antioselectivity. 
In order to examine the generality of the effect of Et 3N we 
investigated a second reaction, namely the CALB-catalysed 
Ph, H 	Ph H 	 H Ph 	 H 
o___ 	j vase 
N "" 	N " 	 HN , CO2 Bu + HN 	CO2H 
\\ 	I \ 	/ BuOH 
Y'—O 
Ph Ph' 	 ' 	 Ph 	0 	Ph 	0 
	
(R)-1 	 (S)-1 	 (S)-2 	 3 (trace) 
Scheme 1 







Solvent' 	a.,,, 	 min' mg' 	Ee (%) 
	
mm — ' mg' 	Ee (%) 
n-hexane -o (anhydrous) 26 (± 1.5) 85 (± 3) 30 (± 1.5) 90 (± 3) 
n-hexane 0.69 4 (± 0.5) 55 (± 2) 20 (± 1) 87 (± 3) 
n-hexane 0.97 1.5 (± 0.15) 30 (± 5) 18 (± 0.9) 80 (± 5) 
toluene —0 15 (± 0.8) 85 (± 4) 27 (± 1.5) 93 (± 3) 
toluene 0.22 3 61 (± 6) 17 (± 1) 95 (± 2) 
MeCN"' —0 15 >99 10 97 (± 2) 
MeCNd 0.1 (0.5% v/v H20) NR - 5 (± 0.3) 90 (± 4) 
MeCN" 0.4 (2% v/v H20) NR - NR - 
" Initial rate for (S)-butyl ester enantiomer 2. b  Results reported are the average of three separate measurements. c Note I. d Ref. 8. No reaction. 
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Fig. 1 Effect of Et 3N on ee. Reactions A ( A ) and B (6) were carried out 
under identical conditions (a = 0.69). At t = 140 mm, 14 mol% Et3N was 
added to reaction B (arrow). 
reaction between 1 -phenylacetoxy-2-methylcyclohexene and 
butanol yielding 2-methylcyclohexanone and butyl phenyl-
acetate. 9" 5 Using n-hexane (a = 0) and MeCN (0.5% H 20, a 
= 0.1) as the solvents, we observed that the addition of Et 3N to 
the solvent resulted in a dramatic increase in the catalytic 
activity. An approximate 200-fold increase in activity was 
observed in MeCN (a = 0.1) and a 700-fold one for that in 
n-hexane (a = 0.97). The higher activity found in n-hexane is 
presumably due to a more intimate contact between the enzyme 
and Et3N in a more nonpolar environment. Similarly, the 
activation effect for (±)-2-phenyl-4-benzyloxazol-5(4H)-one 
ring-opening in MeCN is similar to that described above and is 
expected to be a result of less Et 3N adsorption to the enzyme in 
MeCN. 
The ability of organic bases to increase the enantioselectivity 
of lipase-catalysed reactions in water-saturated organic solvents 
has previously been reported. 103  In some cases' 1,12  this effect 
has been attributed to the formation of an ion-pair between the 
base and any by-product acid. Using electrospray ionisation 
mass spectrometry (ESI-MS)tl: we have detected the formation 
of carboxylic acid 3 during the course of the oxazolone reaction 
at intermediate to high water activities (e.g. a = 0.69-0.97). 
We have also found that addition of acid 3 to an already 
hydrated system results in loss of activity, which can be fully 
recovered upon addition of an organic base, presumably via 
formation of an ion pair. Ion pair formation is observed in both 
low and high dielectric non-hydrogen bonding solvents such as 
n-hexane and MeCN. In a high dielectric, non-hydrogen 
bonding solvent such as MeCN, where the acid was found to be 
more soluble, we find experimentally that dissolution of acid 3 
in n-hexane and MeCN occurs upon addition of Et 3N, thus 
removing acid from the immediate microenvironment of the 
enzyme. However, the enhancement of catalytic performance 
and enantioselectivity for rigorously dried samples, and those of 
low water activity (a s,, < 0.7) where we find no evidence for 
hydrolysis over the course of the initial rate measurement, 
cannot be explained in terms of hydrolysis products affecting 
enantioselectivity, since for an unrelated substrate, an activating 
effect on the catalytic activity has been demonstrated. 
The addition of co-solvents, such as DMF and DMSO, was 
found to solubilise the acid and thus it was anticipated that they 
would perform a similar role to Et 3N in removing any acid from 
the immediate vicinity of the enzyme. Both DMF and DMSO 
were chosen as additives to the bulk organic solvent (toluene at 
a = 0.22). Although both DMF and DMSO increased the 
enantioselectivity of the reaction to 85% ee, there was no 
significant effect on the catalytic rate as found with Et3N. Since 
the solvation of the carboxylic acid by these co-solvents occurs 
by a different mechanism to that of Et 3N, i.e. the additives are 
unable to form ion-pairs, they have limited use in reducing the 
overall effect. 
The role of Et3N therefore appears to be dual in nature, i.e. 
increasing both the enantioselectivity and catalytic activity of 
lipase-catalysed reactions. The addition of Et 3N therefore  
provides an additional strategy for improving the enantiose-
lectivity of lipase-catalysed reactions. We are currently in-
vestigating this effect with other lipolytic enzymes. 
We are grateful to Boehringer Mannheim, Germany, for the 
generous gift of lipase samples. The BBSRC is acknowledged 
for a David Phillips Fellowship (M. C. P.) and a studentship 
(S. A. B.). 
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1 The thermodynamic water activity (a,..) describes the mass action effect of 
water on hydrolytic equilibria and also describes the partitioning of various 
water phases that can compete for water binding (ref. 1). 
§ Polyacrylamide gel electrophoresis of CALB desorbed from the solid 
support exhibited a single band corresponding to the reported molecular 
weight of CALB (33 KDa) (ref. 6). 
¶ (±)-2-Phenyl-4-benzyloxazol-5(4H)-one 1 (0.16 mmol) was placed in a 4 
ml screw top vial together with the solvent, (either anhydrous or hydrated), 
butan-l-ol (0.24 mmol, 1.5 equiv.) CALB (40 mg) and Et 3N (14 mol%). 
The reaction vial was shaken at 250 rpm on a rotary shaker at 37 °C and the 
progress and ee (%) of the reaction were monitored by chiral HPLC 
(Chiralcel-OD, 250 X 4.6 mm, Mallinckrodt Baker, n-hexane—PrOH 
(90:10 v/v), UV detection I = 254 nm). 
11 Candida antarctica lipase B (CALB) was received as an immobilised 
preparation (Novozym 435, Boehringer Mannheim, Germany) and was 
dehydrated over P 205 (at room temp.) for 2-3 days. Rehydration of dried 
lipase to the desired water activity (a,,,) was carried out using saturated salt 
solutions (equilibration period 48-72 h). (±)-2-Phenyl-4-benzyloxazol-
5(4H)-one 1 was stored over P205 at 0 °C; anhydrous solvents were stored 
over freshly reactivated 3 A or 4 A molecular sieves. The water content of 
dried solvents was measured using Karl Fischer water titration (ref. 15) and 
found to be <0.001 wt%. Solvents were hydrated separately from the 
enzyme using the same water equilibration procedure as described above, 
approximately 24 h before use. 
** Control reactions showed that no detectable ester (as judged by HPLC) 
was formed in the absence of enzyme, either with or without Et 3N, over a 
48 h analysis period. 
ft Other organic bases give very similar results to Et 3N, e.g. DABCO and 
lutidine. Insoluble inorganic bases, e.g. KHCO3 and K2CO3,  had no effect 
and did not result in the high catalytic rate and enantioselectivity observed 
with the soluble organic bases. 
l Electrospray ionisation mass spectrometry (ESI-MS) and atmospheric 
chemical ionisation (APCI) were performed on a Micromass Platform II 
spectrometer (cone voltage 20 V). 
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